nct_id,brief_title,official_title,overall_status,start_date,completion_date,last_update,study_type,phase,enrollment,enrollment_type,allocation,intervention_model,primary_purpose,masking,condition,intervention_name,intervention_type,primary_outcome_count,secondary_outcome_count,min_age,max_age,sex,healthy_volunteers,lead_sponsor_name,lead_sponsor_class,collaborator_count,location_count,countries
NCT02137239,Regimen Optimization Study,"Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression",COMPLETED,2015-12-31,2019-05-02,2021-06-22,INTERVENTIONAL,PHASE2,58.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Kidney Transplantation,Thymoglobulin|Belatacept|mycophenolate mofetil(MMF)|Corticosteroids|Everolimus(EVL)|Tacrolimus(TAC),DRUG,1,27,18 Years,75 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,20,United States|Argentina
NCT04427072,Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation,"A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (METΔex14).",TERMINATED,2020-09-25,2023-11-06,2025-05-16,INTERVENTIONAL,PHASE3,22.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Capmatinib|Docetaxel,DRUG,1,20,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,43,Spain|Italy|Belgium|South Korea|Russia|France|Hungary|Lithuania|Thailand|Portugal|Germany|Netherlands|South Africa|Vietnam|Brazil|India|Malaysia|Bulgaria
NCT02593175,Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC,"Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",COMPLETED,2016-11-03,2025-04-03,2025-11-06,INTERVENTIONAL,PHASE2,43.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma,Carboplatin|Paclitaxel|Panitumumab,DRUG|BIOLOGICAL,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States
NCT03019575,Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043),"A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (Corifollitropin Alfa) in Combination With Human Chorionic Gonadotropin (hCG) for Initiation or Restoration of Puberty as Assessed by Increased Testicular Volume in Adolescent Males 14 to <18 Years Old With Hypogonadotropic Hypogonadism (MK-8962-043)",COMPLETED,2017-02-02,2020-05-05,2024-05-23,INTERVENTIONAL,PHASE3,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hypogonadotropic Hypogonadism,Corifollitropin alfa|hCG,DRUG,4,13,14 Years,17 Years,MALE,False,Organon and Co,INDUSTRY,0,15,Denmark|Italy|Russia|South Africa|Mexico|Brazil
NCT04779957,Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy,Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy ; a Pilot Phase II Study.,COMPLETED,2021-10-01,2024-08-09,2025-12-31,INTERVENTIONAL,PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Transplantation|Graft Failure,Tocilizumab,DRUG,1,2,18 Years,,ALL,False,"University Hospital, Toulouse",OTHER,0,1,France
NCT02465801,Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein,Efficacy and Safety Phase II Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients,COMPLETED,2014-12-16,2016-04-26,2017-07-18,INTERVENTIONAL,PHASE2,216.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Chemotherapy-induced Neutropenia,HSA-GCSF 1.2 mg|HSA-GCSF 1.5 mg|GCSF,DRUG,1,5,18 Years,65 Years,FEMALE,False,Tianjin SinoBiotech Ltd.,INDUSTRY,0,1,China
NCT03802201,Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia,A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects With Chronic Anemia,COMPLETED,2018-12-19,2020-07-31,2021-07-16,INTERVENTIONAL,PHASE2,63.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,β-thalassemia|Ineffective Erythropoiesis|Chronic Anemia,PTG-300,DRUG,2,0,12 Years,65 Years,ALL,False,"Protagonist Therapeutics, Inc.",INDUSTRY,0,33,United States|Italy|United Kingdom|Tunisia|Lebanon|Thailand|Turkey (Türkiye)|Greece|Malaysia
NCT03401112,A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia),"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)",COMPLETED,2018-01-26,2020-08-28,2025-05-15,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Sickle Cell Disease,IMR-687|Placebo,DRUG,1,6,18 Years,55 Years,ALL,False,"Cardurion Pharmaceuticals, Inc.",INDUSTRY,1,13,United States|United Kingdom
NCT01511081,Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT),"Randomized Phase II Study Comparing Stereotactic Body Radiotherapy (SBRT) With Stereotactic Body Proton Therapy (SBPT) for Centrally Located Stage I, Selected Stage II and Recurrent Non-Small Cell Lung Cancer",TERMINATED,2012-08,2016-10,2017-12-07,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Non-small-cell Lung Cancer,SBRT (stereotactic body radiotherapy)|SBPT (stereotactic body proton therapy),RADIATION,1,1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,1,United States
NCT04592419,"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)","A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)",COMPLETED,2020-09-25,2023-01-19,2024-06-26,INTERVENTIONAL,PHASE3,568.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Macular Edema|Retinal Vein Occlusion,KSI-301|Aflibercept|Sham Procedure,DRUG|OTHER,2,8,18 Years,,ALL,False,Kodiak Sciences Inc,INDUSTRY,0,141,Puerto Rico|United States|Italy|Spain|Slovakia|France|Hungary|Poland|Germany|Israel|Czechia|Latvia
NCT02353728,Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy,"Detection, Monitoring, and Molecular Characterization of Leukemic Stem Cells From Patients With Chronic Myeloid Leukemia (CML) Undergoing Therapy With Nilotinib",COMPLETED,2015-01,2021-02,2022-03-25,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Chronic Myeloid Leukemia,Nilotinib,DRUG,1,0,18 Years,,ALL,False,Weill Medical College of Cornell University,OTHER,1,1,United States
NCT03513328,Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation,"PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders",COMPLETED,2018-06-15,2023-02-19,2023-09-15,INTERVENTIONAL,PHASE1|PHASE2,6.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Bone Marrow Failure Syndrome|Thalassemia|Sickle Cell Disease|Diamond Blackfan Anemia|Acquired Neutropenia in Newborn|Acquired Anemia Hemolytic|Acquired Thrombocytopenia|Hemophagocytic Lymphohistiocytoses|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|Common Variable Immunodeficiency|X-linked Lymphoproliferative Disease|Severe Combined Immunodeficiency|Hurler Syndrome|Mannosidosis|Adrenoleukodystrophy,Thiotepa--single daily dose|Thiotepa--escalated dose,DRUG,1,7,3 Months,39 Years,ALL,False,University of Florida,OTHER,1,1,United States
NCT02239692,A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy,"A Randomised, Assessor-blinded, Multi-centre Trial Comparing the Efficacy, Safety and Tolerability of the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy",COMPLETED,2014-11,2015-06,2016-06-23,INTERVENTIONAL,PHASE3,204.0,ACTUAL,RANDOMIZED,PARALLEL,,SINGLE,Bowel Cleansing,PICOPREP,DRUG,2,4,18 Years,,ALL,False,Ferring Pharmaceuticals,INDUSTRY,0,3,Germany|France|Netherlands
NCT03101111,Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area,Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area,COMPLETED,2017-08-09,2019-04-02,2021-07-19,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Chikungunya,MV-CHIK|MMR-vaccine,BIOLOGICAL,1,1,21 Years,50 Years,ALL,True,Themis Bioscience GmbH,INDUSTRY,1,1,Puerto Rico
NCT04765371,"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, with CoViD-19","Comparison Between Prednisolone and Dexamethasone on D28 Mortality in Patients on Oxygen Therapy, with CoViD-19: Multicenter, Randomized, Open-label Non-inferiority Study",COMPLETED,2021-03-03,2022-02-10,2024-09-19,INTERVENTIONAL,PHASE3,89.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Coronavirus Infection,DEXAMETHASONE|PREDNISOLONE,DRUG,1,5,18 Years,,ALL,False,Hôpital NOVO,OTHER,0,8,France
NCT04756271,Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection,Safety and Immunogenicity of Oxford AstraZeneca Vaccine in Zagazig University Hospital Health-care Workers,COMPLETED,2021-02-11,2021-12-22,2022-02-09,INTERVENTIONAL,PHASE3,246.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Vaccine Adverse Reaction|Seroconversion,SARS-Cov-2 neutralizing antibody titer,BIOLOGICAL,2,0,18 Years,,ALL,True,Zagazig University,OTHER_GOV,0,1,Egypt
NCT01828034,"First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma","A Phase I/II Study of First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",COMPLETED,2013-04,2019-05-30,2020-11-17,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Biliary Tract Carcinoma,Gemcitabine|Cisplatin|MEK162,DRUG,3,3,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States
NCT04618744,A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH),"A Double-Blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)",COMPLETED,2020-11-24,2022-06-27,2024-08-07,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2|NASH - Nonalcoholic Steatohepatitis",ORMD-0801 (Insulin) capsule 8 mg BD|Placebo,DRUG|OTHER,1,20,18 Years,70 Years,ALL,False,"Oramed, Ltd.",INDUSTRY,1,3,United States|Israel
NCT03031444,Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis,A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis,COMPLETED,2016-01,2020-12-30,2021-02-01,INTERVENTIONAL,PHASE2|PHASE3,135.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer Stage IV|Metastasis,Cetuximab plus FOLFIRI/FOLFOX|FOLFIRI/FOLFOX/CapeOX,DRUG,1,2,18 Years,80 Years,ALL,False,Peking University Cancer Hospital & Institute,OTHER,4,4,China
NCT03830164,"Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer","Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction",COMPLETED,2019-11-20,2022-11-02,2023-10-17,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Male Erectile Disorder|Prostate Adenocarcinoma|Erectile Dysfunction, CTCAE|Impotence",Atorvastatin|Pentoxifylline|Vitamin E Compound,DRUG|DIETARY_SUPPLEMENT,1,2,18 Years,,MALE,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT03970109,HLAB-002 of ANS-6637 for Alcohol Use Disorder,Human Laboratory Study of ANS-6637 for Alcohol Use Disorder,TERMINATED,2019-10-08,2020-05-22,2024-10-29,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alcohol Use Disorder,ANS-6637|Placebo oral tablet,DRUG,1,16,21 Years,,ALL,False,National Institute on Alcohol Abuse and Alcoholism (NIAAA),NIH,0,3,United States
NCT01276509,Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease,"A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera)",COMPLETED,2011-04-06,2015-10-09,2021-06-03,INTERVENTIONAL,PHASE2,265.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Crohn's Disease,PF-00547659 SC injection|PF-00547659 SC injection|PF-00547659 SC injection|PF-00547659 SC injection,DRUG,1,12,18 Years,75 Years,ALL,False,Shire,INDUSTRY,0,137,Canada|United States|Japan|Belgium|Spain|Norway|South Korea|Slovakia|France|Poland|Austria|Germany|Netherlands|Serbia|South Africa|Bulgaria
NCT03199963,Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue,"A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D",TERMINATED,2017-08-21,2019-04-23,2022-07-26,INTERVENTIONAL,PHASE3,223.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Mammographic Breast Density,4-OH tamoxifen|Placebo,DRUG,1,6,35 Years,75 Years,FEMALE,False,"BHR Pharma, LLC",INDUSTRY,0,19,Germany|United States|Spain
NCT00737893,Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy,Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: a Prospective Randomized Controlled Trial (ERECT),COMPLETED,2017-07-01,2019-12-31,2021-04-08,INTERVENTIONAL,PHASE2,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Prostate Cancer|Erectile Dysfunction,Placebo|Erythropoietin (EPO),DRUG,1,21,40 Years,65 Years,MALE,False,Johns Hopkins University,OTHER,0,1,United States
NCT05008393,Efficacy of PJS-539 for Adult Patients With COVID-19.,"Efficacy of PJS-539 for Adult Patients With SARS-CoV-2: Multicentre, Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial.",COMPLETED,2021-09-25,2022-03-04,2022-04-12,INTERVENTIONAL,PHASE2,153.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Covid19|COVID-19 Pneumonia,PJS-539 Dose 1|PJS-539 Dose 2|Placebo,DRUG,1,6,18 Years,,ALL,False,Hospital do Coracao,OTHER,1,1,Brazil
NCT01762904,Residual Effect of Chlorhexidine-alcohol Compared to Triclosan-alcohol,Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Compared to Triclosan 1% / Isopropyl Alcohol 70%,COMPLETED,2013-01,2013-10,2014-07-02,INTERVENTIONAL,PHASE3,135.0,ACTUAL,,SINGLE_GROUP,PREVENTION,SINGLE,Infectious Diseases,Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Preparing skin's areas to be tested with two antiseptics and two controls,OTHER,3,1,18 Years,,ALL,True,Universidad de Guanajuato,OTHER,1,1,Mexico
NCT03136484,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,COMPLETED,2017-03-15,2018-11-16,2020-01-21,INTERVENTIONAL,PHASE3,788.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes|Diabetes Mellitus, Type 2",Semaglutide|Canagliflozin|Placebo (canagliflozin)|Placebo (semaglutide),DRUG,1,60,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,119,Canada|United States|Italy|United Kingdom|Ireland|Argentina|Lebanon|Sweden|Mexico|India|Malaysia|Brazil
NCT04224584,A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain,A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain,COMPLETED,2020-01-01,2021-07-01,2022-02-16,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,"Osteoarthritis, Knee",Duloxetine|Placebo oral tablet,DRUG,1,0,40 Years,75 Years,ALL,False,Kristian Kjær Petersen,OTHER,2,1,Denmark
NCT02542514,Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma,Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma,COMPLETED,2015-09,2021-12-01,2022-04-14,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Central Nervous Lymphoma|Intraocular Lymphoma,Ibrutinib,DRUG,1,7,18 Years,,ALL,False,The Lymphoma Academic Research Organisation,OTHER,0,10,France
NCT01839916,Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies,Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies,COMPLETED,2013-04-04,2018-08,2019-08-07,INTERVENTIONAL,PHASE2,77.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,therapeutic allogeneic lymphocytes|laboratory biomarker analysis,OTHER|BIOLOGICAL,1,5,14 Years,75 Years,ALL,False,University of Chicago,OTHER,1,1,United States
NCT02379806,The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study,Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study,COMPLETED,2015-09-03,2020-12-29,2022-07-05,INTERVENTIONAL,PHASE3,2560.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Venous Thromboembolism,Enoxaparin|Placebo,DRUG,1,1,70 Years,,ALL,False,"University Hospital, Brest",OTHER,0,46,Switzerland|France
NCT06022406,Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study,Fecal Microbiota Transplantation to Reduce Immune Activation in ART-treated People Living With HIV With Low CD4/CD8 Ratio: The Gutsy Study,COMPLETED,2024-07-31,2025-08-13,2025-09-03,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,HIV-1-infection,FMT capsules|Placebo capsules,BIOLOGICAL,1,17,18 Years,,ALL,False,Jean-Pierre Routy,OTHER,1,1,Canada
NCT02639533,Brain Response to Single Dose of Pregabalin in Fibromyalgia,"Pregabalin Acute Effects on Cortical Excitability, Psychophysical Parameters, and Serum Markers of Neuroplastic Processes in Fibromyalgia: a Placebo Controlled, Double Blinded, Randomized, Crossover Clinical Trial",COMPLETED,2014-12,2017-01,2018-02-08,INTERVENTIONAL,PHASE2|PHASE3,27.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,QUADRUPLE,Fibromyalgia,Pregabalin|Placebo,DRUG|OTHER,2,7,18 Years,65 Years,FEMALE,True,Hospital de Clinicas de Porto Alegre,OTHER,3,0,
NCT02834052,Pembrolizumab + Poly-ICLC in MRP Colon Cancer,A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer,COMPLETED,2018-01-10,2022-07-29,2024-06-07,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Metastatic Colon Cancer|Solid Tumor,pembrolizumab|Poly-ICLC,DRUG,3,3,18 Years,,ALL,False,Asha Nayak,OTHER,2,1,United States
NCT02931175,ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study),"An Open-label, Multi-center, Randomized, Phase II Study of the Safety,Efficacy and Bioactivity of Two Dose Regimens of Subcutaneous Injections of ACTH Gel in Patients With Non-infectious Uveitis",COMPLETED,2017-11-10,2021-10-28,2025-12-17,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Uveitis,ACTH gel,DRUG,2,16,18 Years,,ALL,False,Quan Dong Nguyen,OTHER,1,7,United States
NCT02581657,"Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM","Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus",COMPLETED,2015-10,2016-11,2018-04-10,INTERVENTIONAL,PHASE2,37.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,PE0139 Injection|Placebo Injection,DRUG,1,14,18 Years,80 Years,ALL,False,PhaseBio Pharmaceuticals Inc.,INDUSTRY,0,6,United States
NCT04601857,Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma,A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma,TERMINATED,2021-01-07,2025-09-16,2025-12-31,INTERVENTIONAL,PHASE2,43.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced and Metastatic Urothelial Cancer,Futibatinib|Pembrolizumab,DRUG,1,5,18 Years,,ALL,False,"Taiho Oncology, Inc.",INDUSTRY,1,18,Spain|United States|France
NCT05746481,Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases,A Phase II Clinical Trial of Tiragolumab in Combination With Atezolizumab in Patients With Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases.,TERMINATED,2023-08-10,2025-11-08,2026-01-22,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer,Tiragolumab|Atezolizumab|Pemetrexed|Carboplatin,DRUG,1,10,18 Years,,ALL,False,"Liza Villaruz, MD",OTHER,1,1,United States
NCT01323400,Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST),"A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib",COMPLETED,2011-03,2016-02,2016-02-25,INTERVENTIONAL,PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,GIST,Pazopanib|Best supportive care,DRUG|OTHER,1,8,18 Years,90 Years,ALL,False,Centre Leon Berard,OTHER,1,13,France
NCT02949700,Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,A Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,COMPLETED,2017-01-26,2022-07-07,2023-06-29,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Squamous Cell Carcinoma,Metformin,DRUG,2,2,18 Years,,ALL,False,Baylor College of Medicine,OTHER,0,3,United States
NCT01994707,Remote Ischemic Preconditioning of Human Myocardium,Remote Ischemic Preconditioning of Human Myocardium,COMPLETED,2013-08,2016-04-27,2018-01-12,INTERVENTIONAL,PHASE2,134.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Coronary Artery Bypass Graft Triple Vessel|Apoptotic DNA Damage,Remote ischemic preconditioning|Placebo,PROCEDURE,1,5,18 Years,80 Years,ALL,False,Medical University of Silesia,OTHER,1,1,Poland
NCT02592707,Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs,"An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)",TERMINATED,2017-03-06,2022-02-22,2023-07-19,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Neuroendocrine Tumors,Satoreotide tetraxetan|Amino acid solution|Antiemetic,DRUG|OTHER,2,23,18 Years,,ALL,False,Ipsen,INDUSTRY,0,9,Canada|Denmark|United States|Australia|United Kingdom|France|Austria|Switzerland
NCT03108911,Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy,Gluten Free Diet for AML Patients Undergoing Induction Chemotherapy,TERMINATED,2017-07-27,2017-11-14,2017-11-17,INTERVENTIONAL,PHASE2,1.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Acute Myeloid Leukemia,Best Practice|Biospecimen Collection|Dietary Intervention|Laboratory Biomarker Analysis,PROCEDURE|OTHER,3,0,18 Years,,ALL,False,"Rutgers, The State University of New Jersey",OTHER,1,1,United States
NCT03569371,A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa,"A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",COMPLETED,2018-07-17,2019-04-22,2022-09-26,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hidradenitis Suppurativa,INCB054707,DRUG,1,15,18 Years,75 Years,ALL,False,Incyte Corporation,INDUSTRY,0,4,United States
NCT02409264,The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females,The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females,COMPLETED,2015-01,2015-08,2016-05-17,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Insomnia Disorder,Individualised Homeopathic Remedy,OTHER,1,1,18 Years,45 Years,FEMALE,True,University of Johannesburg,OTHER,0,1,South Africa
NCT02131064,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,"A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer",COMPLETED,2014-06-25,2018-05-29,2019-07-02,INTERVENTIONAL,PHASE3,444.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Neoplasms,Carboplatin|Docetaxel|Pertuzumab|Trastuzumab|Trastuzumab Emtansine,DRUG,1,21,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,79,Canada|United States|Spain|Belgium|Ukraine|South Korea|Russia|France|Taiwan|Germany
NCT04336332,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,TERMINATED,2020-04-01,2020-10-14,2023-02-28,INTERVENTIONAL,PHASE2,75.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,SARS-CoV-2|COVID-19,Hydroxychloroquine Sulfate + Azithromycin|Hydroxychloroquine Sulfate,DRUG|COMBINATION_PRODUCT,1,0,18 Years,,ALL,False,"Rutgers, The State University of New Jersey",OTHER,0,5,United States
NCT01309932,Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin,"A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects",COMPLETED,2011-03,2014-09,2015-10-09,INTERVENTIONAL,PHASE2,165.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hepatitis C,Pegylated Interferon Lambda (pegIFNλ)|BMS-790052 (NS5A Inhibitor)|Ribavirin (RBV)|BMS-650032 (NS3 Protease Inhibitor)|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Pegylated Interferon Lambda (pegIFNλ)|Ribavirin (RBV)|Pegylated Interferon Lambda (pegIFNλ)|Ribavirin (RBV)|BMS-790052 (NS5A Inhibitor)|BMS-650032 (NS3 Protease Inhibitor)|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Placebo for Ribavirin (RBV)|Placebo for Ribavirin (RBV),DRUG|BIOLOGICAL,3,14,18 Years,70 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,40,Japan|United States|Australia|Italy|Puerto Rico|Spain|France|Germany|New Zealand
NCT04666298,Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C,"A Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effect of Different Doses of Inclisiran Given as Subcutaneous Injections in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C",COMPLETED,2021-01-29,2022-10-19,2024-06-20,INTERVENTIONAL,PHASE2,312.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypercholesterolemia|Heterozygous Familial Hypercholesterolemia,Inclisiran sodium|Placebo,DRUG,1,15,20 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,42,Japan
NCT02276898,A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index,A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index as a Short-term Pharmacodynamic Biomarker in Patients With Cystic Fibrosis.,COMPLETED,2011-11,2014-09,2015-05-22,INTERVENTIONAL,PHASE2,24.0,ESTIMATED,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Cystic Fibrosis,Hypertonic Saline 7%|Isotonic Saline 0.9% (Placebo),DRUG,1,3,6 Years,18 Years,ALL,False,The Hospital for Sick Children,OTHER,0,2,Canada
NCT01200498,Study of SB939 in Subjects With Myelofibrosis,"A Phase 2, Prospective, Open-Label Study to Determine the Safety and Efficacy of SB939, A Histone Deacetylase Inhibitor, in Subjects With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (PMF; Post-Polycythemia Vera (PV) Myelofibrosis (MF), Or Post- Essential Thrombosis (ET) MF",COMPLETED,2010-11,2012-11,2014-01-30,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Myeloproliferative Disorders,SB939,DRUG,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT03518398,Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction,Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction,COMPLETED,2018-07-03,2019-04-02,2019-06-19,INTERVENTIONAL,PHASE3,114.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Meibomian Gland Dysfunction (Disorder)|Dry Eye Syndromes,Intense Pulsed Light|Standard treatment,DEVICE|COMBINATION_PRODUCT,1,10,18 Years,80 Years,ALL,True,Chulalongkorn University,OTHER,0,1,Thailand
NCT01210898,Immunogenicity and Safety of V70P5 Revaccination Subjects,"A Phase IIIB, Observer-Blind, Randomized, Parallel Groups, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of a Sub-unit Adjuvanted or a Non-adjuvanted Influenza Vaccines in Healthy Children Previously Vaccinated in the V70P5 Study",COMPLETED,2010-09,2011-12,2016-12-01,INTERVENTIONAL,PHASE3,197.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Influenza,Adjuvanted seasonal influenza vaccine,BIOLOGICAL,4,2,18 Months,96 Months,ALL,True,Novartis Vaccines,INDUSTRY,0,16,Finland
NCT01821963,Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC),Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation,TERMINATED,2013-04,2014-02,2020-09-24,INTERVENTIONAL,PHASE3,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Infection,Pegylated Interferon Alfa 2a|Ribavirin|Telaprevir,DRUG,1,1,18 Years,69 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT04261387,LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients,"A Two-Part (Open-Label Followed by Randomized, Double-Blind, Placebo-Controlled) Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of Topically Administered LUT014 for the Treatment of Radiation-Induced Dermatitis in Breast Cancer Patients",COMPLETED,2021-01-30,2022-07-15,2022-07-27,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Radiation Dermatitis,LUT014 Gel|Placebo for LUT014 Gel,DRUG,2,4,18 Years,,FEMALE,False,Lutris Pharma Ltd.,INDUSTRY,0,2,United States
NCT01113593,A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease,"A Randomized, Multiple-Dose, Crossover Study Characterizing the Pharmacodynamic Profiles of Formoterol Fumarate Inhalation Solution and Formoterol Dry Powder Inhaler in Subjects With Stable Chronic Obstructive Pulmonary Disease",COMPLETED,2010-05,,2013-05-27,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Chronic Obstructive Pulmonary Disease (COPD),Formoterol Fumarate|Formoterol Fumarate|Formoterol Fumarate|Foradil Aerolizer|Foradil Aerolizer,DRUG,1,0,40 Years,,ALL,False,Dey,INDUSTRY,0,4,United States
NCT03795116,Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention,Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention,COMPLETED,2019-03-18,2020-10-26,2022-06-01,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Fibrosis|Skin Scarring|Skin Wound|Hypertrophic Scar|Scar|Keloid,LED-RL phototherapy|Mock irradiation,DEVICE,2,10,,,ALL,True,State University of New York - Downstate Medical Center,OTHER,0,1,United States
NCT03081416,"""THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department""","""THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department""",COMPLETED,2016-05,2017-10,2018-01-18,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Headache|Intranasal Ketamine,Ketamine|Normal saline|Metoclopramide|Ketorolac|Dexamethasone|Benadryl,DRUG,1,6,18 Years,65 Years,ALL,True,Brooke Army Medical Center,FED,0,1,United States
NCT01652716,Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes,"A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-Controlled, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Exenatide Twice Daily in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2013-01,2014-08,2018-07-03,INTERVENTIONAL,PHASE3,377.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",Exenatide once weekly suspension|Exenatide twice daily,DRUG,1,4,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,58,United States
NCT02394106,Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome,"Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial",TERMINATED,2015-07,2019-06,2020-07-29,INTERVENTIONAL,PHASE2,13.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Nephrotic Syndrome,Ofatumumab|Placebo,DRUG|OTHER,1,3,2 Years,18 Years,ALL,False,Istituto Giannina Gaslini,OTHER,0,1,Italy
NCT06428084,Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV,Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Controlled Trial,COMPLETED,2023-11-01,2024-02-28,2024-05-24,INTERVENTIONAL,PHASE2,38.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Laparoscopic Cholecystectomy,Ondansetron|Haloperidol,DRUG,1,0,18 Years,65 Years,ALL,False,Universitas Padjadjaran,OTHER,0,1,Indonesia
NCT01052077,Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPDC-34712 (1 to 3 mg/Day) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder.",COMPLETED,2010-03,2011-11,2015-11-02,INTERVENTIONAL,PHASE2,773.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Major Depressive Disorder,OPC-34712|Placebo|ADT,DRUG,1,9,18 Years,65 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,0,43,United States
NCT01072175,"Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212","An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma",COMPLETED,2010-03-26,2018-02-27,2019-07-05,INTERVENTIONAL,PHASE2,430.0,ACTUAL,NON_RANDOMIZED,,TREATMENT,NONE,Cancer,GSK2118436|GSK1120212,DRUG,30,27,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,15,United States|Australia
NCT01402401,Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients,"An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer",TERMINATED,2011-11,2013-06,2020-12-10,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Gastric Cancer,AUY922|Trastuzumab,DRUG,1,0,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,15,Japan|United States|Italy|Belgium|Spain|South Korea|France|Germany
NCT01189812,Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders",COMPLETED,2010-03,2011-01,2011-08-24,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Major Depressive Disorder|Dysthymia|Depression Not Otherwise Specified|Borderline Personality Disorder,Lithium Carbonate|Placebo|Citalopram,DRUG,1,2,18 Years,75 Years,ALL,False,Columbia Northwest Pharmaceuticals,INDUSTRY,0,2,United States
NCT01775930,Carfilzomib in Refractory Renal Cell Carcinoma (RCC),Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma,COMPLETED,2013-10,2019-01-18,2020-03-04,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Cancer,Carfilzomib,DRUG,1,4,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT03071965,Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel),Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel),COMPLETED,2017-05-12,2021-05-11,2025-05-09,INTERVENTIONAL,PHASE2,70.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,SINGLE,MacTel (Macular Telangiectasia) Type 2,Ciliary neurotrophic factor (CNTF)|Surgery|Surgery,PROCEDURE|BIOLOGICAL,2,4,21 Years,80 Years,ALL,False,Neurotech Pharmaceuticals,INDUSTRY,0,11,United States|Australia
NCT01621867,Repeated Application of Gene Therapy in CF Patients,"A Randomised, Double-blind, Placebo-controlled Phase 2B Clinical Trial of Repeated Application of Gene Therapy in Patients With Cystic Fibrosis",COMPLETED,2012-05,2014-05,2015-10-22,INTERVENTIONAL,PHASE2,130.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Cystic Fibrosis,pGM169/GL67A|Placebo,DRUG,1,3,12 Years,,ALL,False,Imperial College London,OTHER,3,3,United Kingdom
NCT01657292,Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Healing of Grade 2a Partial-Thickness Burn Wounds",COMPLETED,2012-08,2014-07,2015-09-28,INTERVENTIONAL,PHASE3,61.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Burns,Oleogel-S10 ointment|Octenilin® wound gel,DRUG|DEVICE,1,10,18 Years,,ALL,False,Birken AG,INDUSTRY,0,9,Switzerland|Germany|Sweden|United Kingdom
NCT05397171,A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours,"A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours",TERMINATED,2022-06-07,2023-06-06,2024-10-01,INTERVENTIONAL,PHASE1|PHASE2,17.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Urinary Bladder Neoplasms|Colorectal Cancer|Carcinoma, Non-Small-Cell Lung",AZD8853|Zirconium-89 crefmirlimab berdoxam,DRUG,2,13,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,1,6,Canada|United States
NCT01628471,"MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer",A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects,COMPLETED,2012-11,2015-09,2015-09-23,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non Small Cell Lung Cancer,decitabine in combination with genistein,DRUG,1,2,18 Years,75 Years,ALL,False,Uman Pharma,INDUSTRY,3,1,Canada
NCT02874144,Anti-Inflammatory Agent in Sinusitis,"A Phase 2A, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of an Anti-Inflammatory Agent in Patients With Sinusitis",COMPLETED,2016-06-20,2020-08-10,2022-05-25,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Nasal Polyps,AZ compound|Collection of Biological Specimens|Intranasal corticosteroid|Placebo,DRUG|OTHER,3,2,18 Years,70 Years,ALL,False,Northwestern University,OTHER,0,0,
NCT02362464,Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139,A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139.,COMPLETED,2015-05-12,2022-03-25,2024-12-10,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostatic Neoplasms|Neoplasms of Prostate|Prostate Cancer|Cancer Of Prostate|Stage D0 Prostate Cancer,Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine,BIOLOGICAL,1,4,18 Years,,MALE,False,National Cancer Institute (NCI),NIH,0,1,United States
NCT05263999,A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease",TERMINATED,2022-04-29,2025-05-12,2025-06-17,INTERVENTIONAL,PHASE3,158.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Graft Versus Host Disease|GVHD|Acute-graft-versus-host Disease|Acute GVHD|aGVHD,Itolizumab|EQ001 Placebo,DRUG|BIOLOGICAL,1,2,12 Years,,ALL,False,Equillium,INDUSTRY,1,118,Canada|United States|Australia|Belgium|Italy|Spain|South Korea|France|Portugal|Germany|Israel|New Zealand
NCT04346199,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",COMPLETED,2020-06-12,2020-11-17,2021-09-17,INTERVENTIONAL,PHASE2,177.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID-19,Acalabrutinib,DRUG,1,18,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,1,50,Japan|Italy|Argentina|France|Russia|Poland|Germany|South Africa|Peru|Turkey (Türkiye)|Chile|Mexico|India|Brazil
NCT03100032,Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis,"A Prospective Multi-centre, Randomised, Controlled Study to Evaluate the Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Fusion (L1 - S1)",COMPLETED,2017-01,2021-06,2021-08-13,INTERVENTIONAL,PHASE1|PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Spondylolisthesis,NVD-001|Standard of Care,PROCEDURE|BIOLOGICAL,8,8,18 Years,,ALL,False,Novadip Biosciences,INDUSTRY,0,12,Czechia|Poland|Belgium
NCT03172598,"Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy","A Phase IIa, Multi-Centre, Randomised, Double-Blind, Cross-Over, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy Incorporating an Open Label Pilot Arm",COMPLETED,2017-07-25,2018-08-08,2025-12-22,INTERVENTIONAL,PHASE2,61.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Painful Diabetic Peripheral Neuropathy,MT-8554 low dose|MT-8554 middle dose|MT-8554 high dose|Placebo,DRUG,2,2,18 Years,,ALL,False,Tanabe Pharma Corporation,INDUSTRY,0,3,Poland|Germany|Hungary
NCT02740387,Open Label Study of OTO-104 in Subjects With Meniere's Disease,"A 1-Year, Phase 2, Open-Label Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease",TERMINATED,2016-06,2017-09,2017-09-15,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Meniere's Disease,OTO-104,DRUG,1,3,18 Years,80 Years,ALL,False,"Otonomy, Inc.",INDUSTRY,0,1,Canada
NCT01952314,Medical Expulsive Therapy for Ureter Stone Using Naftopidil,"Medical Expulsive Therapy for Ureter Stone Using Naftopidil: Multicenter, Randomized, Double-blind, Placebo Controlled Study",COMPLETED,2014-05,2015-08,2015-12-10,INTERVENTIONAL,PHASE3,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ureter Stones,Naftopidil 75mg|Placebo for Naftopidil|Standard treatment,DRUG,1,4,20 Years,,ALL,False,Seoul National University Hospital,OTHER,1,6,South Korea
NCT01767116,A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection,"A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)",COMPLETED,2012-12,2014-08,2021-07-12,INTERVENTIONAL,PHASE3,419.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Hepatitis C Infection,"ABT-450/r/ABT-267, ABT-333|Ribavirin|Placebo for ribavirin",DRUG,1,5,18 Years,70 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,0,
NCT02976116,A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer,"Fruquintinib in Combination With Gefitinib as First-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring Activating EGFR Mutations : a Single-arm, Multicenter, Phase II Study",COMPLETED,2016-12,2019-06-28,2019-11-15,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,NSCLC,Fruquintinib|Gefitinib,DRUG,2,4,18 Years,,ALL,False,Hutchison Medipharma Limited,INDUSTRY,0,2,China
NCT02678533,Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor,Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy,COMPLETED,2017-02-10,2019-05-03,2025-09-11,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fanconi Anemia,G-CSF|Plerixafor,DRUG,1,1,2 Years,17 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France
NCT04633447,A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis,"A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis",TERMINATED,2020-12-10,2024-05-22,2025-07-01,INTERVENTIONAL,PHASE2,53.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Giant Cell Arteritis,Guselkumab|Placebo,DRUG,1,14,50 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,30,Canada|United States|Italy|Belgium|Spain|France|Poland|Germany|Israel
NCT01230138,Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis,"A Randomised, Double Blind, Placebo Controlled Efficacy and Safety Trial of Different Doses/Dose Regimens of FP187 Compared to Placebo in Moderate to Severe Plaque Psoriasis (Pivotal Registration Study)",COMPLETED,2010-09,2012-05,2012-12-11,INTERVENTIONAL,PHASE2,252.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plaque Psoriasis,Placebo|FP187|FP187|FP187|FP187,DRUG,1,9,18 Years,90 Years,ALL,False,Forward-Pharma GmbH,INDUSTRY,0,2,Germany
NCT01716377,Healing With Venlafaxine After Injury (HELP),Healing With Venlafaxine After Injury: A Randomized Clinical Trial of Venlafaxine Following Motor Vehicle Collision,COMPLETED,2012-10,2016-09,2017-04-13,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Neck Pain,Venlafaxine,DRUG,1,1,18 Years,50 Years,ALL,False,Rhode Island Hospital,OTHER,4,3,United States
NCT03189745,A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).,"A PHASE IIIB, OPEN STUDY TO EVALUATE THE IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER HEALTHY SUBJECTS AGED 11-17 YEARS RECEIVED EITHER MENACWY-TT VACCINE (NIMENRIX(REGISTERED)) OR MENCEVAX ACWY(REGISTERED).",COMPLETED,2017-08-01,2018-04-11,2020-10-12,INTERVENTIONAL,PHASE3,229.0,ACTUAL,,PARALLEL,PREVENTION,NONE,Meningococcal ACWY Disease,MenACWY-TT,BIOLOGICAL,1,8,20 Years,28 Years,ALL,True,Pfizer,INDUSTRY,0,1,Philippines
NCT01809977,Comparison of Partial Removal and Total Removal of the Corneal Epithelium on Keratoconus,Study of Surgical Methods for Keratoconus,COMPLETED,2012-07,2012-12,2013-03-13,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Keratoconus,collagen cross-linking procedure (total removal)|collagen cross-linking procedure (partial removal),PROCEDURE,1,1,16 Years,40 Years,ALL,True,Isfahan University of Medical Sciences,OTHER,0,1,Iran
NCT02785172,Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis,"A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis",COMPLETED,2016-04,2017-01,2020-08-20,INTERVENTIONAL,PHASE2,154.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis,IDP-118 Vehicle Lotion|IDP-118 Vehicle Cream|IDP-118 Lotion|Ultravate Cream,DRUG,1,0,18 Years,,ALL,True,"Bausch Health Americas, Inc.",INDUSTRY,0,14,United States
NCT01256372,An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery,"An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery",COMPLETED,2010-10,2011-08,2012-03-15,INTERVENTIONAL,PHASE2,77.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Cardiac Surgery|Coronary Artery Bypass|Aortic Aneurysm|Valve Surgery|Kidney Diseases,AP214|Placebo,DRUG,2,1,18 Years,,ALL,False,Action Pharma A/S,INDUSTRY,0,1,Denmark
NCT01213095,Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL),R-CVP Followed by Rituximab Maintenance Therapy for Patients With Advanced Marginal Zone B-cell Lymphoma,COMPLETED,2010-09,2015-09,2016-04-11,INTERVENTIONAL,PHASE2,48.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lymphoma,rituximab,DRUG,1,2,20 Years,,ALL,False,Dong-A University Hospital,OTHER,0,1,South Korea
NCT03876795,Evaluation of Effectiveness of Combined Intra-articular and Intra-osseus Injection VS a Single Intra-articular Injection of Bone Marrow Concentrate,"Evaluation of Effectiveness of Combined Intra-articular and Intra-osseus Injection VS a Single Intra-articular Injection of Bone Marrow Concentrate for the Treatment of Osteoarthritis in the Knee. (INTERFACE) Double Blind, Randomized Clinical Trial",COMPLETED,2019-11-08,2023-03-01,2023-04-19,INTERVENTIONAL,PHASE3,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Osteoarthritis, Knee",Bone Marrow Concentrate,BIOLOGICAL,1,1,40 Years,70 Years,ALL,False,Istituto Ortopedico Rizzoli,OTHER,0,1,Italy
NCT06002295,A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns,A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns,COMPLETED,2020-09-12,2021-11-19,2023-08-23,INTERVENTIONAL,PHASE2,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Neonatal Sepsis|Omphalitis,Chlorhexidine Topical Cream|Methylated Spirit,DRUG,1,1,1 Day,10 Days,ALL,True,Sheikh Zayed Federal Postgraduate Medical Institute,OTHER,0,1,Pakistan
NCT02645175,Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue,"A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety Profile and Ability of TW1025 to Decrease Fatigue",TERMINATED,2016-01,2018-12,2016-10-21,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Metastatic Breast Cancer|Fatigue,TW1025|Placebo,DIETARY_SUPPLEMENT,1,1,18 Years,80 Years,FEMALE,False,Meriyana Bio Inc.,INDUSTRY,1,0,
NCT02975557,Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD),"A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)",TERMINATED,2016-05,2017-04-13,2019-11-08,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dry Eye|Ocular Graft vs Host Disease|Meibomian Gland Dysfunction,Brimonidine 0.15%|Brimonidine 0.075%|Placebo,DRUG,1,0,18 Years,,ALL,False,"Sandeep Jain, MD",OTHER,1,2,United States
NCT02767557,Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients,"A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.",COMPLETED,2017-01-26,2023-01-01,2023-09-22,INTERVENTIONAL,PHASE2,147.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Unresectable Pancreatic Carcinoma,Tocilizumab|Gemcitabine|nab-Paclitaxel,DRUG,1,8,18 Years,,ALL,False,Herlev Hospital,OTHER,1,2,Denmark|Norway
NCT03170401,Supplemental Enteral Protein in Critical Illness,Protein-enhanced Enteral Nutrition and Metabolomics in Critically Ill Trauma and Surgical Patients,COMPLETED,2016-11,2022-12,2024-06-05,INTERVENTIONAL,PHASE3,500.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Nutrition Disorder|Trauma|Critical Illness,Protein supplementation|Standard enteral nutrition,DIETARY_SUPPLEMENT|OTHER,1,2,18 Years,,ALL,False,University of Washington,OTHER,1,1,United States
NCT02485301,A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults,Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa,COMPLETED,2015-07-15,2016-12-23,2018-01-04,INTERVENTIONAL,PHASE2,3024.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Virus Diseases,GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|Placebo,DRUG|BIOLOGICAL,21,2,18 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,0,5,Mali|Senegal|Nigeria|Cameroon
NCT06414512,Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis,Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis,COMPLETED,2024-04-09,2024-10-02,2025-08-27,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cryptococcal Meningitis,AMBITION trial control|Flucytosine,DRUG,1,2,18 Years,,ALL,False,University of Minnesota,OTHER,3,2,Uganda
NCT04461119,"Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia","A Phase II, Randomized, 4-Week, Double-Blind, Placebo-Controlled, Multiple-Dose Study, Designed to Determine the Safety, Tolerability, EEG Effects and Preliminary Efficacy of Fixed Oral Doses of 7.5 and 15 MG BID of Evenamide in Patients With Chronic Schizophrenia Who Are Symptomatic on Their Current Second-Generation Antipsychotic Medication",COMPLETED,2020-06-16,2021-03-13,2021-05-20,INTERVENTIONAL,PHASE2,138.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,Evenamide|Placebo,DRUG,2,6,18 Years,,ALL,False,Newron Pharmaceuticals SPA,INDUSTRY,0,14,United States|India
NCT02137330,Obalon in Children With Severe Obesity,Tolerance and Efficacy of the Swallowable Obalon® Gastric Balloons System in Children With Severe Obesity,COMPLETED,2014-01,2014-06,2015-07-22,INTERVENTIONAL,PHASE3,10.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Severe Pediatric Obesity (BMI > 97° pc -According to Centers for Disease Control and Prevention BMI Charts-)|Altered Liver Function Tests|Glycemic Intolerance,Swallowable Obalon® Gastric Balloon,DEVICE,1,1,9 Years,17 Years,ALL,False,Bambino Gesù Hospital and Research Institute,OTHER,0,1,Italy
NCT05508867,"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","A Phase 2 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)",COMPLETED,2022-10-18,2026-01-08,2026-01-20,INTERVENTIONAL,PHASE2,203.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hodgkin Lymphoma,favezelimab/pembrolizumab|bendamustine|gemcitabine,DRUG|BIOLOGICAL,1,5,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,105,Canada|United States|Spain|Australia|China|France|United Kingdom|South Korea|Argentina|Poland|Germany|Israel|Switzerland|Chile|Czechia|Sweden|Belgium|Turkey (Türkiye)|Mexico|Brazil
NCT02230800,PPALM-Palm Oil and Pentoxifylline Against Late Morbidity,Randomised Double-blind Placebo Controlled Phase II Trial of Tocovid SupraBio in Combination With Pentoxifylline (PTX) in Patients Suffering Long-term Adverse Effects of Radiotherapy for Pelvic Cancer,COMPLETED,2014-11-25,2019-12-20,2019-12-23,INTERVENTIONAL,PHASE2,62.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Long-term Adverse Effects of Radiotherapy for Pelvic Cancer,Tocovid SupraBio plus pentoxifylline|Matching placebos,DRUG,1,7,18 Years,,ALL,False,Royal Marsden NHS Foundation Trust,OTHER,1,1,United Kingdom
NCT03338400,Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role?,Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Reconstructive Surgery: Is There A Role?,COMPLETED,2017-05-01,2018-08-21,2021-04-14,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Quality of Recovery|Same Day Surgery|Nausea and Vomiting, Postoperative|Vaginal Prolapse",Dexamethasone|Normal saline,DRUG,1,4,18 Years,,FEMALE,False,The Cleveland Clinic,OTHER,0,1,United States
NCT01540292,Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders,Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders,TERMINATED,2013-02-01,2015-12-31,2021-05-12,INTERVENTIONAL,PHASE1|PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Crohn's Disease,Mesenchymal Stem Cells (MSC),BIOLOGICAL,1,7,18 Years,75 Years,ALL,False,University of Liege,OTHER,0,1,Belgium
NCT02131636,Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea,,COMPLETED,2014-05,2014-12,2019-11-18,INTERVENTIONAL,PHASE3,440.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Erythema|Rosacea,AGN-199201|Vehicle to AGN-199201,DRUG,1,5,18 Years,,ALL,False,Allergan,INDUSTRY,0,1,United States
NCT01122511,Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration,,TERMINATED,2010-08,2011-05,2012-09-05,INTERVENTIONAL,PHASE2,4.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Subfoveal Choroidal Neovascularization|Age-Related Maculopathy,700 ug dexamethasone|ranibizumab|sham,DRUG|OTHER|BIOLOGICAL,1,3,50 Years,,ALL,False,Allergan,INDUSTRY,0,2,United States
NCT01573871,Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula,Tolerance and Compliance of Infants Fed an Extensively Hydrolyzed Infant Formula,COMPLETED,2012-02,2012-09,2013-02-15,INTERVENTIONAL,PHASE3,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Infant|Gastrointestinal Intolerance,Experimental Hydrolyzed infant formula,OTHER,1,1,,180 Days,ALL,False,Abbott Nutrition,INDUSTRY,0,3,United States
NCT04762771,Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19),Open-label (Unblinded) Randomization to Treatment of Colchicine Plus Current Care Per Institution Treating Physicians vs. Current Care Per Institution Treating Physicians (Control Arm),TERMINATED,2020-12-23,2021-09-20,2022-07-25,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Covid19,Colchicine,DRUG,3,7,18 Years,99 Years,ALL,False,Baptist Health South Florida,OTHER,1,1,United States
NCT03089944,A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis,"A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis",COMPLETED,2017-04-28,2019-11-08,2020-07-13,INTERVENTIONAL,PHASE3,343.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatitis C Virus (HCV),Glecaprevir/Pibrentasvir,DRUG,2,6,18 Years,,ALL,False,AbbVie,INDUSTRY,0,113,Canada|United States|Spain|Russia|Hungary|Italy|France|Romania|United Kingdom|Ireland|Taiwan|Poland|Israel|Czechia|Bulgaria|Puerto Rico|Portugal|Vietnam|Greece
NCT05466344,the Condylar Response of Mini-plate Anchored Rigid Fixed Functional Appliance Versus Dentally Anchored Semi-rigid One,Assessment of the Condylar Response of Mini-plate Anchored Rigid Fixed Functional Appliance Versus Dentally Anchored Semi-rigid One; A Randomized Clinical Trial,COMPLETED,2020-06-15,2022-04-15,2022-07-21,INTERVENTIONAL,PHASE2|PHASE3,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Class II Malocclusion,Herbst Group|TFBC Group,DEVICE,1,1,18 Years,20 Years,ALL,True,Al-Azhar University,OTHER,0,1,Egypt
NCT02111044,Phase II Study With ITF2984 in Acromegalic Patients,"A Randomized, Multicenter, Phase II Study to Investigate Efficacy and Safety of ITF2984 in Acromegalic Patients",COMPLETED,2014-04,2016-02,2016-06-16,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Acromegaly,Octreotide|ITF2984 500 mcg|ITF2984 1000 mcg|ITF2984 2000 mcg,DRUG,1,6,18 Years,80 Years,ALL,False,Italfarmaco,INDUSTRY,0,26,Romania|Spain|Italy|France|Hungary|Poland|Netherlands|Serbia|Czechia
NCT01891864,Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel,"A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Etanercept (GP2015) and Enbrel® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis",COMPLETED,2013-06,2015-03,2017-03-27,INTERVENTIONAL,PHASE3,531.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Stable Plaque Psoriasis,GP2015 Etanercept|Enbrel,DRUG,1,4,18 Years,,ALL,False,Sandoz,INDUSTRY,1,74,Romania|Ukraine|United Kingdom|Slovakia|Russia|Hungary|Poland|Germany|South Africa|Czechia|Estonia|Bulgaria
NCT04417699,SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer,"SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial",COMPLETED,2022-07-05,2024-02-21,2025-12-10,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rectal Cancer,TAS 102|Oxaliplatin,DRUG,1,1,18 Years,,ALL,False,Providence Health & Services,OTHER,1,4,United States
NCT01335932,Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure,A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study),COMPLETED,2011-03-10,2016-10-28,2018-08-21,INTERVENTIONAL,PHASE2,160.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Failure,IV Ganciclovir|Placebo,DRUG,1,66,18 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,2,14,United States
NCT00984763,"A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria","A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",COMPLETED,2010-01,2010-09,2015-05-28,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Malaria,AMA1-C1/Alhydrogel® + CPG 7909,BIOLOGICAL,1,1,18 Years,50 Years,ALL,True,University of Oxford,OTHER,1,1,United Kingdom
NCT01385293,BKM120 in Metastatic Castration-resistant Prostate Cancer,Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer,TERMINATED,2011-08,2016-02,2017-05-19,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer|Metastatic (Spread to Other Areas of the Body),BKM120,DRUG,1,6,18 Years,,MALE,False,"Andrew J. Armstrong, MD",OTHER,1,3,United States
NCT02325414,Prevention of Bone Loss After Acute SCI by Zoledronic Acid,"Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy",COMPLETED,2015-02,2020-08-25,2025-12-02,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Spinal Cord Injury|Acute Spinal Cord Injury|Bone Loss|Osteoporosis,Zoledronic acid|Placebo,DRUG,2,2,18 Years,,ALL,False,Northwestern University,OTHER,1,2,United States
NCT01527006,"Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs","An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy",COMPLETED,2012-01,2015-04,2016-07-12,INTERVENTIONAL,PHASE2,63.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Central Nervous System,perampanel,DRUG,2,13,2 Years,11 Years,ALL,False,Eisai Inc.,INDUSTRY,0,23,United States
NCT01621633,A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers,"A Single-dose, Open-label Parallel-group Study to Assess the Pharmacokinetics of LCZ696 in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects",COMPLETED,2012-09,2013-01,2015-08-10,INTERVENTIONAL,PHASE2,32.0,ACTUAL,NON_RANDOMIZED,PARALLEL,,NONE,Hepatic Impairment,LCZ696,DRUG,3,1,18 Years,75 Years,ALL,True,Novartis Pharmaceuticals,INDUSTRY,0,1,Germany
NCT01997333,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer","A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)",COMPLETED,2013-11,2018-08-07,2019-03-08,INTERVENTIONAL,PHASE2,327.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic gpNMB Over-expressing Triple Negative Breast Cancer,CDX-011|Capecitabine,DRUG,1,5,18 Years,,ALL,False,Celldex Therapeutics,INDUSTRY,0,140,Canada|United States|Australia|Belgium|Italy|Spain|United Kingdom|France|Germany
NCT01605747,Study of Culturelle in the Prophylaxis of Infection and Diarrhea,A Blinded Placebo Controlled Clinical Outcomes Study of Culturelle® in the Prophylaxis of Infection and Diarrhea,TERMINATED,2011-01,2015-12,2013-11-13,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Pediatric Burns,Culturelle|Placebo,DIETARY_SUPPLEMENT,1,1,6 Months,18 Years,ALL,False,Shriners Hospitals for Children,OTHER,0,1,United States
NCT05925647,The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients,The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients,COMPLETED,2022-08-01,2023-03-09,2023-06-29,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,Messenchymal stem cell secretome|Placebo,DRUG,1,0,18 Years,60 Years,ALL,False,Universitas Sebelas Maret,OTHER,0,1,Indonesia
NCT01151449,"Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer","A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma",TERMINATED,2010-06,2015-08,2017-04-11,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer,gamma-secretase/Notch signalling pathway inhibitor RO4929097|laboratory biomarker analysis,DRUG|OTHER,2,3,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,2,Canada
NCT01231438,Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.,"An Open, Randomized, Crossover Phase 2 Pilot Study of Treatment of Stage 3B Renal Failure With Active Vitamin D or a Phosphate Binder to Evaluate the Effect on the FGF23 and PTH Levels.",COMPLETED,2010-10,2011-03,2012-11-09,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Kidney Failure,Renvela|Etalpha,DRUG,1,5,18 Years,,ALL,False,Helse Stavanger HF,OTHER_GOV,1,2,Norway
NCT01955512,Effect of Clopidogrel on Allergen Challenge in Asthma,Effect of Clopidogrel on Allergen Challenge in Asthma,COMPLETED,2013-05,2014-05,2023-05-22,INTERVENTIONAL,PHASE2,24.0,ESTIMATED,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Asthma,Clopidogrel|Placebo,DRUG,1,7,18 Years,50 Years,ALL,False,University of Southampton,OTHER,0,1,United Kingdom
NCT02630381,Shock Wave Therapy for Osteoporosis,Treatment of Osteoporosis With Unfocused Extracorporeal Shock Wave Therapy: Pilot Study,COMPLETED,2015-05-18,2016-09-19,2017-10-12,INTERVENTIONAL,PHASE2,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Osteoporosis,Unfocused extracoporeal shock wave therapy,DEVICE,2,2,50 Years,80 Years,FEMALE,False,UMC Utrecht,OTHER,0,0,
NCT02648581,"Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease","A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease",COMPLETED,2017-06-14,2019-11-19,2025-09-08,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Behçet Disease,Subcutaneous Ustekinumab,DRUG,2,40,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,1,France
NCT05376930,Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.,"A Multi-center, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2021-09-16,2022-05-31,2022-10-25,INTERVENTIONAL,PHASE3,63.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,T2DM (Type 2 Diabetes Mellitus),DWP16001 Amg,DRUG,1,3,19 Years,80 Years,ALL,False,Daewoong Pharmaceutical Co. LTD.,INDUSTRY,0,1,South Korea
NCT01688128,Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART),"An Open-label, Controlled, Cross-over Trial of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART) in Mild Cognitive Impairment",COMPLETED,2012-08,2015-12,2016-04-20,INTERVENTIONAL,PHASE3,50.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Mild Cognitive Impairment,Phase I U-SMART (4 wks)|Washout (2 wks)|Phase II U-SMART (4 wks),OTHER|DEVICE,1,3,55 Years,90 Years,ALL,False,Seoul National University Bundang Hospital,OTHER,1,1,South Korea
NCT02945800,Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma,Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults,COMPLETED,2016-10-25,2025-02-17,2026-01-26,INTERVENTIONAL,PHASE2,59.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Soft Tissue Sarcoma,nab-Paclitaxel|Gemcitabine,DRUG,2,1,3 Years,30 Years,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,14,United States
NCT02834936,A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation,A Phase 2 Clinica Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation,COMPLETED,2016-10-20,2019-06-20,2025-08-28,INTERVENTIONAL,PHASE2,60.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non Small Cell Lung,pyrotinib,DRUG,1,2,18 Years,75 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,11,China
NCT04004611,A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC),"A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis",COMPLETED,2020-05-18,2023-03-15,2024-03-26,INTERVENTIONAL,PHASE2,26.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Ulcerative Colitis,Mirikizumab,DRUG,1,12,2 Years,17 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,37,Canada|United States|Japan|South Korea|Israel
NCT05277571,"A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)","A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)",COMPLETED,2022-03-07,2025-09-19,2025-10-20,INTERVENTIONAL,PHASE1|PHASE2,273.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Atopic Dermatitis,UCB1381|Placebo,DRUG|BIOLOGICAL,5,12,18 Years,65 Years,ALL,True,UCB Biopharma SRL,INDUSTRY,0,16,United States
NCT03302871,Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A,Integrated Management With Brain Stimulation and Hybrid Training Enhances Functional Gains in Children With Cerebral Palsy Treated by Botulinum Toxin A,COMPLETED,2016-01-18,2020-01-30,2020-04-24,INTERVENTIONAL,PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Cerebral Palsy,Botulinum toxin type A|transcranial direct current stimulation|hybrid training model of CIMT and BIT|usual care,OTHER|DRUG|DEVICE,1,1,5 Years,16 Years,ALL,False,Kocaeli University,OTHER,0,1,Turkey (Türkiye)
NCT03151434,Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.,"Randomized Prospective Study Comparing Paravertebral Catheters, Single Shot Paravertebral Block, Thoracic Epidural, for Postoperative Analgesia Following Video-assisted Thoracoscopic Surgery",COMPLETED,2017-02-07,2018-07-30,2021-01-27,INTERVENTIONAL,PHASE3,147.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Video Assisted Thoracoscopic Surgery|Pain, Postoperative|Pain, Acute",US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)|US Guided Paravertebral Catheter (0.2% ropivicaine bolus)|Thoracic Epidural (0.125% bupivicaine/hydromorphone),DRUG,2,1,18 Years,,ALL,False,Indiana University,OTHER,0,1,United States
NCT05178134,A Phase 2 Bridging Study to Assess the New Formulation of ETVAX,"A Phase 2 Immunological Bridging Study Assessing the Non-inferiority of a New Formulation of ETVAX®. A Prospective Double-blind, Randomized Study in Healthy Volunteers.",COMPLETED,2021-11-08,2022-10-20,2025-08-19,INTERVENTIONAL,PHASE2,280.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,"Healty Volunteers|Preventable Disease, Vaccine",Etvax|Etvax,BIOLOGICAL,1,1,18 Years,50 Years,ALL,True,Scandinavian Biopharma AB,INDUSTRY,3,1,Sweden
NCT03616964,A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus",COMPLETED,2018-08-02,2021-10-20,2022-11-23,INTERVENTIONAL,PHASE3,778.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Systemic Lupus Erythematosus,Baricitinib|Placebo,DRUG,1,11,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,1,159,Romania|Japan|United States|Colombia|Italy|Spain|South Korea|Argentina|France|Philippines|Poland|South Africa|Serbia|Chile|India
NCT01258309,Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis,,COMPLETED,2010-12,2011-01,2012-01-25,INTERVENTIONAL,PHASE3,129.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Rhinitis, Allergic, Seasonal|Conjunctivitis, Allergic",olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|olopatadine hydrochloride 0.1% ophthalmic solution,DRUG,1,3,18 Years,,ALL,False,Allergan,INDUSTRY,0,1,India
NCT01621399,Safety and Efficacy Study to Treat Bacterial Vaginosis,"A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis",COMPLETED,2012-05,2012-12,2013-08-21,INTERVENTIONAL,PHASE3,651.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Bacterial Vaginosis,Product 55394|Placebo Vehicle (non-treatment),DRUG,1,1,18 Years,,FEMALE,False,Medicis Global Service Corporation,INDUSTRY,0,37,United States
NCT02739698,Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia,Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia,COMPLETED,2012-07,2017-03,2017-08-01,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Peritoneal Carcinomatosis,Paclitaxel|Radical surgery-peritonectomy,PROCEDURE|DRUG,1,0,18 Years,75 Years,FEMALE,False,Maimónides Biomedical Research Institute of Córdoba,OTHER,0,0,
NCT05516498,"Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)","A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension",TERMINATED,2022-10-31,2025-07-17,2025-08-15,INTERVENTIONAL,PHASE2,205.0,ACTUAL,RANDOMIZED,PARALLEL,SCREENING,TRIPLE,Liver Cirrhosis,Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|Part A: zibotentan (dose B) + dapagliflozin|Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|Part B: placebo (matching zibotentan capsule) + dapagliflozin|Part B: zibotentan (dose A) + dapagliflozin|Part B: zibotentan (dose B) + dapagliflozin|Part B: zibotentan (dose C) + dapagliflozin,DRUG,2,12,18 Years,80 Years,ALL,False,AstraZeneca,INDUSTRY,0,50,Romania|Spain|United States|Australia|Belgium|China|Denmark|United Kingdom|France|Taiwan|Austria|Germany|Netherlands|Switzerland|Czechia
NCT02039063,A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease,A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease,COMPLETED,2014-04-05,2017-11-27,2023-01-30,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,,Crohn's Disease,E6011 2 mg/kg|E6011 5 mg/kg|E6011 10 mg/kg|E6011 15 mg/kg,DRUG,6,2,20 Years,64 Years,ALL,False,"EA Pharma Co., Ltd.",INDUSTRY,0,17,Japan
NCT02247193,Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair,Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair,COMPLETED,2015-12,2020-01-13,2021-11-03,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cleft Lip|Scarring|Cleft Palate,Botulinum Toxin Type A|Normal Saline Injection,DRUG,8,0,,6 Months,ALL,True,"The University of Texas Health Science Center, Houston",OTHER,0,1,United States
NCT03318614,Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster,Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster,COMPLETED,2015-09,2015-12,2017-10-24,INTERVENTIONAL,PHASE2|PHASE3,53.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Irritable Bowel Syndrome|Abdominal Pain|Small Intestinal Bacterial Overgrowth,Probiotics M-63|Control group,DIETARY_SUPPLEMENT|OTHER,1,4,18 Years,,ALL,True,Universiti Sains Malaysia,OTHER,1,0,
NCT02473016,Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia,"A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia",COMPLETED,2015-09,2017-04,2017-11-17,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,CROSSOVER,TREATMENT,SINGLE,Trigeminal Neuralgia,Carbon Dioxide Drug Delivery System (CDDS),DRUG,1,10,18 Years,,ALL,False,"Capnia, Inc.",INDUSTRY,0,6,United States
NCT03959384,Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age,"Efficacy and Safety of Curosurf® in Patients Under 12 Months of Age Requiring Invasive Mechanical Ventilation for Acute Respiratory Distress Syndrome in the Course of Bronchiolitis: A Randomized, Double-blind, Placebo-controlled Trial",TERMINATED,2019-01-09,2021-04-09,2021-04-15,INTERVENTIONAL,PHASE3,9.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Bronchiolitis, Viral",Curosurf 80Mg/Ml Intratracheal Suspension|Ambient Air,DRUG|OTHER,1,11,40 Weeks,12 Months,ALL,False,Azienda Ospedaliera Universitaria Integrata Verona,OTHER,0,1,Italy
NCT02960204,"Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension",COMPLETED,2016-10-17,2019-04-08,2022-02-11,INTERVENTIONAL,PHASE2,263.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Cirrhosis|Portal Hypertension|Non-alcoholic Steatohepatitis,Emricasan|Placebo,DRUG,1,3,18 Years,,ALL,False,Histogen,INDUSTRY,0,37,Germany|United States|Spain
NCT01693484,Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures,Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures Requiring Extensile Lateral Incision,TERMINATED,2013-04,2015-03,2017-06-20,INTERVENTIONAL,PHASE2|PHASE3,13.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,"Fractures, Comminuted|Surgical Wound Dehiscence|Necrosis",ICG (Indocyanine Green),DRUG,1,0,18 Years,65 Years,ALL,False,Louisiana State University Health Sciences Center Shreveport,OTHER,0,1,United States
NCT03806933,Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines,"A Prospective, Randomized, Double-blind, Multicenter Study to Investigate the Safety and Duration of Effect of Different NT 201 Dose Groups Following the Treatment of Glabellar Frown Lines",COMPLETED,2019-01-23,2020-10-08,2023-11-15,INTERVENTIONAL,PHASE2,241.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Moderate to Severe Glabellar Frown Lines,NT 201,DRUG,6,6,18 Years,,ALL,False,Merz Aesthetics GmbH,INDUSTRY,1,9,Germany|United States
NCT02757352,A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis,"A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis",COMPLETED,2016-08-02,2019-05-07,2020-03-13,INTERVENTIONAL,PHASE3,303.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Axial Spondyloarthritis,Ixekizumab|Placebo,DRUG,2,27,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,109,Romania|Canada|United States|Japan|Puerto Rico|South Korea|Finland|Argentina|Russia|Poland|Austria|Germany|Netherlands|Czechia|Mexico|Brazil
NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),"Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects",COMPLETED,2014-08-12,2022-12-27,2023-11-28,INTERVENTIONAL,PHASE2,294.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hodgkin Disease,Nivolumab|Doxorubicin|Vinblastine|Dacarbazine,DRUG,2,19,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,38,Canada|United States|Italy|Belgium|Spain|United Kingdom|Austria|Germany|Netherlands|Czechia
NCT02193958,Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies,"A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies",COMPLETED,2014-07,2019-10-15,2025-03-19,INTERVENTIONAL,PHASE1|PHASE2,55.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,AML|CMML|MDS,FF-10501-01,DRUG,1,1,18 Years,,ALL,False,"Fujifilm Pharmaceuticals U.S.A., Inc.",INDUSTRY,0,2,United States
NCT03685448,ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB),A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802),COMPLETED,2019-04-11,2025-06-04,2025-08-08,INTERVENTIONAL,PHASE2,35.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Renal Cell Carcinoma|Papillary Renal Cell Carcinoma Type 1|Papillary Renal Cell Carcinoma Type 2|Chromophobe Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Xp11.2 Translocation-Related Renal Cell Carcinoma,Cabozantinib,DRUG,1,3,18 Years,,ALL,False,Australian and New Zealand Urogenital and Prostate Cancer Trials Group,OTHER,0,11,Australia
NCT03379675,"A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus","A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Subjects Infected With Respiratory Syncytial Virus",COMPLETED,2018-02-06,2019-12-26,2025-02-04,INTERVENTIONAL,PHASE2,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Respiratory Syncytial Virus Infections,JNJ-53718678 500 mg|JNJ-53718678 80 mg|Placebo,DRUG,21,19,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,124,Canada|United States|Spain|Ukraine|Russia|Australia|France|South Korea|Argentina|Taiwan|Poland|Germany|South Africa|Sweden|Bulgaria|Japan|Belgium|Mexico|Brazil
NCT02049957,Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer,A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant,COMPLETED,2014-02-13,2018-06-29,2023-02-08,INTERVENTIONAL,PHASE2,118.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Sapanisertib|Fulvestrant|Exemestane,DRUG,2,10,18 Years,,FEMALE,False,"Calithera Biosciences, Inc",INDUSTRY,0,40,United States|France|Belgium
NCT03403712,A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer,"A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination (Akynzeo®) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Initial and Repeated Cycles of Anthracycline-cyclophosphamide (AC) Chemotherapy in Women With Breast Cancer",COMPLETED,2018-03-16,2018-09-19,2020-06-01,INTERVENTIONAL,PHASE3,404.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Chemotherapy-induced Nausea and Vomiting,fosnetupitant/ palonosetron|netupitant/palonosetron|dexamethasone,DRUG,4,4,18 Years,,FEMALE,False,Helsinn Healthcare SA,INDUSTRY,2,40,Georgia|United States
NCT04856865,ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults,"A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Harmony Study)",COMPLETED,2021-04-20,2022-12-13,2024-05-16,INTERVENTIONAL,PHASE1|PHASE2,73.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Food Allergy,Low dose ADP101|High dose ADP101|Pooled Placebo,BIOLOGICAL,1,3,4 Years,55 Years,ALL,False,"Alladapt Immunotherapeutics, Inc.",INDUSTRY,0,15,United States
NCT02694328,A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study),A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia,COMPLETED,2016-03-02,2018-11-07,2020-02-10,INTERVENTIONAL,PHASE3,561.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,ALKS 3831|Olanzapine,DRUG,2,2,18 Years,55 Years,ALL,False,"Alkermes, Inc.",INDUSTRY,0,54,Puerto Rico|United States
NCT02316028,Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC),A Phase I Clinical Trial on Decitabine (5-aza-2'-Deoxycytidine) Administered by Hepatic Arterial Infusion in Patients With Unresectable Liver-predominant Metastases From Colorectal Cancer,COMPLETED,2014-03,2017-07,2017-10-27,INTERVENTIONAL,PHASE1|PHASE2,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Liver Metastasis|Colorectal Cancer,Decitabine,DRUG,1,5,18 Years,,ALL,False,Universitair Ziekenhuis Brussel,OTHER,1,2,Belgium
NCT04140292,Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses,Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses,COMPLETED,2020-01-13,2021-05-27,2022-06-24,INTERVENTIONAL,PHASE2,75.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Actinic Keratosis,Photodynamic therapy (PDT)|Vitamin D3,DRUG,1,4,18 Years,,ALL,False,Case Comprehensive Cancer Center,OTHER,0,1,United States
NCT03938792,Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B,An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis,COMPLETED,2020-03-09,2025-04-29,2025-06-10,INTERVENTIONAL,PHASE3,189.0,ACTUAL,,CROSSOVER,TREATMENT,NONE,Hemophilia A|Hemophilia B,PF-06741086,DRUG,12,11,12 Years,74 Years,MALE,False,Pfizer,INDUSTRY,0,62,Canada|United States|Oman|Spain|Russia|Saudi Arabia|Italy|China|France|South Korea|Taiwan|South Africa|Serbia|Croatia|Bulgaria|Japan|Hong Kong|Turkey (Türkiye)|Mexico|India
NCT02188771,"A Phase I, Prospective, Randomized, Open-label, Active-Controlled Clinical Trial for Safety Evaluation of Intra-articular Injection of RegenoGel-SP for the Treatment of Moderate to Severe Osteoarthritis",,COMPLETED,2014-02,2015-10,2017-04-27,INTERVENTIONAL,PHASE1|PHASE2,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Osteoarthritis,intra-articular administration of RegenoGel-SP or hyaluronic acid (HA),DEVICE,1,1,45 Years,75 Years,ALL,False,ProCore Ltd.,INDUSTRY,0,1,Israel
NCT02169271,Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules,A Randomized Phase II Trial of Low Dose Aspirin Versus Placebo in High-Risk Individuals With CT-Detected Subsolid Lung Nodules,COMPLETED,2014-11-21,2020-02-14,2020-05-21,INTERVENTIONAL,PHASE2,109.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Current Smoker|Former Smoker|Multiple Pulmonary Nodules|Tobacco Use Disorder,Aspirin|Laboratory Biomarker Analysis|Placebo,DRUG|OTHER,1,8,50 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,2,United States|Italy
NCT02101034,PD 0332991 and Cetuximab in Patients With Incurable SCCHN,Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN,COMPLETED,2014-06-17,2023-11-10,2023-12-21,INTERVENTIONAL,PHASE1|PHASE2,96.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Carcinoma, Squamous Cell of Head and Neck",Cetuximab|PD 0332991,DRUG|BIOLOGICAL,2,7,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,5,United States
NCT01328444,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,COMPLETED,2011-03-01,2012-06-14,2017-10-11,INTERVENTIONAL,PHASE3,349.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",GSK 573719 +GW642444 125/25|GSK573719 + GW642444 62.5/25|GSK 573719 125|GSK 573719 62.5|GW642444 25|Plb,DRUG,2,4,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,31,United States|United Kingdom|Russia|Germany|Estonia|Bulgaria
NCT01648634,Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy,"A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Examine the Effect of Nebivolol, a Beta-Blockade Drug, for the Prevention of Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy",COMPLETED,2012-02-13,2021-07-20,2025-11-20,INTERVENTIONAL,PHASE3,51.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Duchenne Muscular Dystrophy|Cardiomyopathy|Heart Failure,Nebivolol|Placebo,DRUG,1,5,10 Years,15 Years,MALE,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France
NCT02534909,"Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria","An Open-label Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316, an Anti-C5 Monoclonal Antibody in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",COMPLETED,2015-09-09,2022-05-24,2025-05-16,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Paroxysmal Nocturnal Hemoglobinuria,LFG316|LNP023,DRUG|BIOLOGICAL,2,4,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,7,Czechia|Japan|Lithuania
NCT03961009,"Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients","A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients",COMPLETED,2019-04-30,2020-12-21,2025-04-13,INTERVENTIONAL,PHASE3,47.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Immunodeficiency Disease,Kedrion IVIG 10%,BIOLOGICAL,1,78,2 Years,70 Years,ALL,False,Kedrion S.p.A.,INDUSTRY,0,11,United States
NCT04052932,A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout,"A Phase3, Multicentre, Randomized, Double-Blind, Allopurinol and Placebo-Controlled Study to Evaluate the Efficacy and Safety of SHR4640 Monotherapy in Subjects With Gout",COMPLETED,2019-07-16,2021-07-14,2022-06-13,INTERVENTIONAL,PHASE3,594.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Gout,SHR4640 dose1|SHR4640 dose2|Placebo oral tablet|Allopurinol 300 MG,DRUG,1,4,18 Years,75 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,1,China
NCT02820987,"PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock","Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock",COMPLETED,2016-09-27,2018-10-04,2025-01-16,INTERVENTIONAL,PHASE3,119.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Septic Shock,MEROPENEM|PIPERACILLIN-TAZOBACTAM|CEFEPIME,DRUG,1,1,18 Years,,ALL,False,Centre Hospitalier Universitaire de Besancon,OTHER,0,1,France
NCT02163187,Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation,Randomized Crossover Study of the Efficacy of Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation,TERMINATED,2014-06-10,2016-12-19,2018-02-05,INTERVENTIONAL,PHASE2|PHASE3,4.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Rectal Cancer|for Bowel Dysfunction Following Surgery for Rectal Cancers,Implantation of the InterStimTM|MSK BFI questionnaires|The Low Anterior Resection Score (LARS) questionnaires|The EuroQOL5D questionnaires|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires,DEVICE|BEHAVIORAL,1,1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,2,United States
NCT01536314,Prophylaxis of Neuropathic Pain by mémantine,Preventing the Development of Neuropathic Pain Post-mastectomy/Tumorectomy by Pre-emptive or Post-operative Memantine Administration,COMPLETED,2012-02,2013-11,2014-07-01,INTERVENTIONAL,PHASE3,43.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Neuropathic Pain,Memantine EBIXA®|Placebo : lactose,DRUG,1,3,18 Years,,FEMALE,False,"University Hospital, Clermont-Ferrand",OTHER,0,1,France
NCT01332916,Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging,Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging,TERMINATED,2010-12,2014-04,2014-04-25,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,,NONE,Breast Cancer|Healthy,cognitive tests and cerebral IRM|cognitive tests and cerebral IRM,PROCEDURE,1,1,45 Years,,FEMALE,True,Centre Francois Baclesse,OTHER,0,2,France
NCT02164916,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,COMPLETED,2014-11,2020-11-19,2020-12-30,INTERVENTIONAL,PHASE2,106.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Colorectal Cancer,cetuximab|irinotecan hydrochloride|vemurafenib,DRUG|BIOLOGICAL,1,1,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,2,763,United States
NCT01970306,Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material,A Prospective Phase II Trial to Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material,COMPLETED,2013-10-18,2023-02-24,2023-11-03,INTERVENTIONAL,PHASE2,78.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Esophageal Adenocarcinoma,MatriStem PSM,DEVICE,1,2,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,4,United States
NCT01240304,A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas,A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemotherapy With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas,TERMINATED,2010-11,2019-10,2019-12-10,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Cancer,Gemcitabine|Radiation therapy|pancreaticoduodenectomy,RADIATION|PROCEDURE|DRUG,1,0,18 Years,,ALL,False,University of Arkansas,OTHER,0,1,United States
NCT02412852,A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain,"A Randomized, Double-blinded, Phase 2a Study to Assess the Safety and Pharmacokinetics of a Sustained Release Formulation of Sodium Nitrite (TV1001sr) in Patients With Diabetic Neuropathic Pain (DNP)",COMPLETED,2015-04-28,2017-04-03,2020-04-24,INTERVENTIONAL,PHASE2,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes,Sodium nitrite|Placebo,DRUG,1,6,18 Years,,ALL,False,TheraVasc Inc.,INDUSTRY,1,1,United States
NCT03039049,GNRH Agonist Trigger and Modified Luteal Phase Adding a Bolus of GnRHa at the Time of Implantation: a RCT,"GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Mid-luteal Bolus of GnRHa: a Randomised Controlled Trial.",COMPLETED,2014-03,2017-03,2017-07-07,INTERVENTIONAL,PHASE3,328.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Infertility,Triptorelin 0.1 mg,DRUG,1,4,18 Years,40 Years,FEMALE,False,Centre Hospitalier Universitaire Ibn Rochd,OTHER,0,2,Algeria
NCT01594749,Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031),"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy",COMPLETED,2012-09-24,2014-11-03,2018-09-04,INTERVENTIONAL,PHASE3,1015.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Chemotherapy-Induced Nausea and Vomiting (CINV),Fosaprepitant dimeglumine|Fosaprepitant Placebo|Dexamethasone|Ondansetron|Dexamethasone Placebo|Ondansetron Placebo|Rescue Therapy,DRUG,3,3,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,
NCT05087849,Intralesional HPV Vaccine for Condylomata,Therapeutic Intralesional Nonavalent HPV Vaccine for Genital Condylomata in Adults: an Open Label Pilot Study,COMPLETED,2022-04-15,2024-07-01,2025-10-02,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Human Papilloma Virus|Warts|Warts, Genital|Condyloma|Condylomata Acuminata",nonavalent human papillomavirus vaccine,BIOLOGICAL,2,2,18 Years,,ALL,False,"University of California, San Francisco",OTHER,0,1,United States
NCT05991349,"A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","A Phase 1/2 Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors",COMPLETED,2024-03-12,2025-05-31,2025-11-25,INTERVENTIONAL,PHASE1|PHASE2,180.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Solid Tumor,IBI129,DRUG,4,13,18 Years,,ALL,False,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,0,7,Australia|China
NCT03613571,"A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis","A Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral Sclerosis",TERMINATED,2018-08-15,2019-08-20,2023-06-12,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Amyotrophic Lateral Sclerosis,ILB,DRUG,17,9,18 Years,80 Years,ALL,False,TikoMed AB,INDUSTRY,0,1,Sweden
NCT03503344,Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer,"A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging",COMPLETED,2019-12-17,2025-10-31,2026-01-21,INTERVENTIONAL,PHASE2,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|PSA Progression|Stage IV Prostate Adenocarcinoma AJCC v7,Apalutamide|Stereotactic Body Radiation Therapy,RADIATION|DRUG,1,2,18 Years,,MALE,False,"University of California, San Francisco",OTHER,1,1,United States
NCT03169244,Buproprion for Binge Drinking,Efficacy and Safety of the Melanocortin Activator Bupropion in Treating Binge Drinking,COMPLETED,2017-09-04,2019-09-17,2020-08-26,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alcohol Abuse,Bupropion|Placebo Oral Tablet,DRUG,2,1,21 Years,44 Years,ALL,False,"University of North Carolina, Chapel Hill",OTHER,1,1,United States
NCT01829464,TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes",TERMINATED,2013-05,2014-03,2016-06-01,INTERVENTIONAL,PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes,Placebo|TAK-875|TAK-875,DRUG,1,2,18 Years,,ALL,False,Takeda,INDUSTRY,0,86,United States|Peru|Argentina
NCT01426698,18 Month Follow Up of Preterm Infants Enrolled in the Cord Clamping Study,18 Month Follow Up of Preterm Infants Enrolled in the Cord Clamping Study,COMPLETED,2011-08,2014-12,2014-12-05,INTERVENTIONAL,PHASE2,208.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,Developmental Delay,delayed cord clamping,PROCEDURE,1,1,24 Weeks,31 Weeks,ALL,False,University of Rhode Island,OTHER,1,1,United States
NCT05383898,Study to Evaluate D-1553 in Subjects With Lung Cancer,"A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors",COMPLETED,2021-03-16,2024-05-17,2024-10-15,INTERVENTIONAL,PHASE1|PHASE2,225.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,NSCLC,D-1553,DRUG,3,1,18 Years,,ALL,False,"InventisBio Co., Ltd",INDUSTRY,0,2,China
NCT03701763,Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis,"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN PEDIATRIC SUBJECTS FROM 6 THROUGH 17 YEARS WITH MODERATE TO SEVERE PLAQUE PSORIASIS",COMPLETED,2018-12-19,2023-03-27,2024-12-16,INTERVENTIONAL,PHASE3,245.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis,Apremilast (CC-10004)|Placebo,DRUG|OTHER,1,29,6 Years,17 Years,ALL,False,Amgen,INDUSTRY,0,99,Canada|United States|Italy|Belgium|Spain|Russia|France|Israel|Netherlands|Czechia
NCT04717193,Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis,Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis - a Randomized Control Trial,COMPLETED,2021-05-28,2023-04-17,2024-03-12,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Appendicitis Acute,Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine,PROCEDURE|DRUG,1,4,8 Years,17 Years,ALL,False,University of Alberta,OTHER,0,1,Canada
NCT01807221,Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone,"A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone",COMPLETED,2013-06-17,2014-12-09,2021-07-06,INTERVENTIONAL,PHASE2,1066.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Heart Failure,Finerenone (BAY94-8862)|Placebo|Inspra (eplerenone),DRUG,1,7,18 Years,,ALL,False,Bayer,INDUSTRY,0,172,Canada|United States|Spain|Hungary|Lithuania|Finland|Italy|Australia|France|Austria|Norway|South Korea|Taiwan|Poland|Germany|Israel|South Africa|Czechia|Sweden|Bulgaria|Denmark|Portugal|Netherlands|Turkey (Türkiye)|Greece
NCT02093221,Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus,"A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus",TERMINATED,2014-03,2017-06,2018-09-05,INTERVENTIONAL,PHASE2,76.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 1 Diabetes Mellitus,180 mg/kg Alpha1-PI|90 mg/kg Alpha1-PI|Placebo,BIOLOGICAL,1,5,6 Years,35 Years,ALL,False,Grifols Therapeutics LLC,INDUSTRY,0,36,United States
NCT05370521,A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens,"A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens",TERMINATED,2022-05-15,2023-08-31,2025-10-09,INTERVENTIONAL,PHASE2,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Polycystic Ovary Syndrome,Tildacerfont|Placebo,DRUG,1,3,18 Years,40 Years,FEMALE,False,Spruce Biosciences,INDUSTRY,0,21,United States
NCT04046614,Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology,Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology - An AIO Phase Ib Trial,COMPLETED,2018-05-25,2023-09-15,2024-02-06,INTERVENTIONAL,PHASE1|PHASE2,56.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adenocarcinoma of the Lung,nintedanib-nivolumab combination therapy,DRUG,3,7,18 Years,,ALL,False,AIO-Studien-gGmbH,OTHER,0,1,Germany
NCT07186114,A Prospective Study on the Therapeutic Outcomes of Mebo and Tantum Verde in Patients With Oral Mucositis,A Prospective Study on the Therapeutic Outcomes of Mebo and Tantum Verde in Patients With Oral Mucositis,COMPLETED,2023-03-01,2024-12-14,2025-09-22,INTERVENTIONAL,PHASE3,36.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Oral Mucositis (Ulcerative) Due to Radiation,MEBO Wound Ointment (MEBO)|Tantum Verde® mouthwash,DRUG,1,0,18 Years,,ALL,False,Cairo University,OTHER,0,2,Egypt
NCT03345914,Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD),"A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis",COMPLETED,2017-11-17,2019-09-10,2020-08-13,INTERVENTIONAL,PHASE3,367.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Dermatitis, Atopic",Dupilumab|Matching Placebo|Background Treatment: Topical Corticosteroids|Background Treatment: Moisturizers,DRUG|OTHER,1,21,6 Years,11 Years,ALL,False,Regeneron Pharmaceuticals,INDUSTRY,1,61,Canada|United States|United Kingdom|Poland|Germany|Czechia
NCT02157506,A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure,"A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure",COMPLETED,2014-06-30,2015-07-31,2019-07-31,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Heart Failure|Decompensated Heart Failure|Acute Heart Failure,CXL-1427|Placebo,DRUG,4,6,18 Years,85 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,1,35,United States|Russia|Poland|Germany|Jordan
NCT04229706,A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation),"A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)",COMPLETED,2019-12-31,2022-01-15,2024-09-05,INTERVENTIONAL,PHASE2,180.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hyperplasia of Breast,High dose Xiang Ju Ru Pi Ning capsule|Low dose Xiang Ju Ru Pi Ning capsule|Xiang Ju Ru Pi Ning capsule placebo,DRUG,5,0,18 Years,50 Years,FEMALE,False,"Tasly Pharmaceutical Group Co., Ltd",INDUSTRY,0,8,China
NCT02647684,Triple P for Parents of Children With a Diagnosis of Cancer,Triple P for Parents of Children With a Diagnosis of Cancer,COMPLETED,2016-01,2016-08,2016-10-25,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Cancer,Self-Directed Triple P,BEHAVIORAL,1,4,18 Years,100 Years,ALL,False,University of Manchester,OTHER,1,1,United Kingdom
NCT05351684,Effect of Dolutegravir Intensification on HIV-1 Reservoirs,Effect of Dolutegravir Intensification on Blood and Tissue Latent HIV-1 Reservoirs and on Residual Viremia Despite ART,COMPLETED,2019-01-01,2022-12-13,2022-12-15,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV-1-infection,Dolutegravir 50 MG,DRUG,1,5,18 Years,,ALL,False,University of Liege,OTHER,0,1,Belgium
NCT07235033,Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2),"A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria",COMPLETED,2024-01-23,2025-03-19,2025-11-19,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Uncomplicated Plasmodium Falciparum Malaria,Cipargamin|SoC (Coartem)|KLU156,DRUG,1,10,12 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,6,Gabon|Burkina Faso|Ghana|Kenya|Uganda|Côte d’Ivoire
NCT01220752,Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12),Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12),COMPLETED,2011-06-17,2021-12-19,2022-09-01,INTERVENTIONAL,PHASE2,36.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Sinonasal Malignancies|Adenocarcinoma and Squamous Cell Carcinoma of the Paranasal Sinuses,carbon ion boost,RADIATION,1,5,18 Years,80 Years,ALL,False,Heidelberg University,OTHER,0,1,Germany
NCT01180647,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,COMPLETED,2010-05,2013-07,2016-04-07,INTERVENTIONAL,PHASE3,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Opiate Dependence,Extended-Release Naltrexone|Motivational Enhancement Counseling,DRUG|BEHAVIORAL,1,5,18 Years,60 Years,ALL,False,NYU Langone Health,OTHER,2,2,United States
NCT01965158,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy",COMPLETED,2013-08-29,2015-01-22,2017-05-30,INTERVENTIONAL,PHASE3,547.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Opioid-induced Constipation,Naldemedine|Placebo,DRUG,1,4,18 Years,80 Years,ALL,False,Shionogi,INDUSTRY,0,65,Spain|United States|United Kingdom|Poland|Germany|Austria|Czechia
NCT02375048,Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI,Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation (WBI) Versus Accelerated Partial Breast Irradiation (APBI),TERMINATED,2015-01-19,2018-02-01,2018-10-24,INTERVENTIONAL,PHASE2,179.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cancer of Breast,Hypofractionated WBI|Accelerated Partial Breast Irradiation,RADIATION,2,4,55 Years,70 Years,FEMALE,False,Istituto Clinico Humanitas,OTHER,0,1,Italy
NCT02559648,Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis,"Evaluation of Efficacy of Denosumab in Patients With Thalassemia Major and Osteoporosis: A Randomized, Placebo-controlled, Single-site, Double Blind Phase 2b Clinical Trial",COMPLETED,2014-09,2017-12,2019-08-26,INTERVENTIONAL,PHASE2,63.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Thalassemia Major|Osteoporosis,Denosumab|Placebo,DRUG,1,3,30 Years,,ALL,False,Ersi Voskaridou,OTHER,0,1,Greece
NCT02458248,Sodium Intake in Chronic Kidney Disease (STICK),Sodium Intake in Chronic Kidney Disease (STICK): A Randomised Controlled Trial,COMPLETED,2016-03,2020-08,2021-04-28,INTERVENTIONAL,PHASE2,105.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Kidney Diseases|Renal Insufficiency, Chronic|Renal Insufficiency",Sodium Reduction,BEHAVIORAL,1,9,18 Years,,ALL,False,University College Hospital Galway,OTHER,2,1,Ireland
NCT05454358,Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP,Letrozole as Maintenance Therapy Versus Observation After Adjuvant Treatment on the Prognosis for Post-surgical Endometrial Cancer Patients With Non-specific Molecular Profile: a Superiority Randomized Controlled Trial,TERMINATED,2022-08-02,2025-12-01,2025-12-15,INTERVENTIONAL,PHASE2|PHASE3,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Endometrial Cancer,Letrozole 2.5mg,DRUG,1,5,18 Years,80 Years,FEMALE,False,Fudan University,OTHER,1,1,China
NCT06949358,A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France,A Long-Term Follow-up Study to Evaluate Safety and Tolerability of Olipudase Alfa in Patients Who Completed the DFI12712 or the LTS13632 Study in France,COMPLETED,2021-11-18,2025-04-08,2025-04-29,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Niemann-Pick Disease,Olipudase alfa,DRUG,1,0,,,ALL,False,Sanofi,INDUSTRY,0,2,France
NCT02037555,Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass,"A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery With Cardiopulmonary Bypass",COMPLETED,2014-06-26,2018-01-25,2019-03-15,INTERVENTIONAL,PHASE2,425.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cardiac Surgery|Cardiopulmonary Bypass,AT-III (Human)|Placebo,OTHER|BIOLOGICAL,1,0,18 Years,,ALL,False,Grifols Therapeutics LLC,INDUSTRY,2,41,United States
NCT06684626,The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment,The Role of Butirprost® as an Adjuvant in Enhancing the Effect of Antibiotics in Patients Affected by Chronic Bacterial Prostatitis: A Randomized Prospective Trial,COMPLETED,2024-03-01,2024-09-01,2024-11-18,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Prostate Inflammation|Prostate Disease|Chronic Bacterial Prostatitis,Sodium Hyaluronate|Levofloxacin 500mg,DRUG,4,0,18 Years,50 Years,MALE,False,Federico II University,OTHER,0,1,Italy
NCT01773109,Etirinotecan Pegol (NKTR-102) in NSCLC,Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment,COMPLETED,2013-01,2017-03-15,2020-04-03,INTERVENTIONAL,PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Non Small Cell Lung Cancer|Recurrent Non Small Cell Lung Cancer,Etirinotecan pegol (NKTR-102),DRUG,1,0,18 Years,,ALL,False,Abramson Cancer Center at Penn Medicine,OTHER,0,1,United States
NCT01979393,"IRCI Gynae Sarcomas, High Grade Uterine Sarcoma",A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment,COMPLETED,2015-02-02,2024-01-15,2025-08-01,INTERVENTIONAL,PHASE2,58.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Uterine Sarcoma,Cabozantinib|Placebo,DRUG,1,7,18 Years,,FEMALE,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,2,15,Spain|Italy|United Kingdom|France|Netherlands
NCT01950221,Pomegranate Extract and Memory,"12-Month, Double-blind, Placebo-Controlled Study of Pomegranate Extract",COMPLETED,2011-10,2015-10,2020-03-02,INTERVENTIONAL,PHASE2,212.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Healthy Volunteers,POMx|Placebo,DIETARY_SUPPLEMENT|OTHER,1,1,50 Years,75 Years,ALL,True,"University of California, Los Angeles",OTHER,1,1,United States
NCT02090621,Extracorporeal Photopheresis After Liver Transplant,Extracorporeal Photopheresis After Liver Transplant. Phase II Clinical Trial on Safety and Efficacy in Patients With Progressive Withdrawal of Immunosuppression,COMPLETED,2012-10,2015-03,2015-03-12,INTERVENTIONAL,PHASE2,10.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Hepatic Insufficiency,Extracorporeal photopheresis,PROCEDURE,3,5,18 Years,,ALL,False,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,OTHER,0,1,Spain
NCT03063606,Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment,Behavioral and Pharmacologic Treatment of Binge Eating and Obesity,COMPLETED,2017-09-05,2022-12-16,2024-02-01,INTERVENTIONAL,PHASE2|PHASE3,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Binge-Eating Disorder|Obesity,Cognitive-Behavioral Therapy (CBT)|NB Medication (on-going from acute treatment),DRUG|BEHAVIORAL,2,2,18 Years,70 Years,ALL,False,Yale University,OTHER,1,1,United States
NCT02141204,"Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants","Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants",COMPLETED,2019-02-20,2019-12-28,2020-12-09,INTERVENTIONAL,PHASE3,451.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Rotavirus,HRV Liquid|HRV Lyophilized,BIOLOGICAL,1,4,6 Weeks,10 Weeks,ALL,True,GlaxoSmithKline,INDUSTRY,0,8,India
NCT02762084,"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients","Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients",COMPLETED,2016-06-06,2017-04-24,2020-07-23,INTERVENTIONAL,PHASE2,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Basal Cell Nevus Syndrome,Patidegib|Vehicle gel,DRUG,4,7,18 Years,85 Years,ALL,False,"PellePharm, Inc.",INDUSTRY,0,2,United Kingdom
NCT02255552,Study of Eteplirsen in DMD Patients,"An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy",COMPLETED,2014-11-17,2019-06-14,2021-01-25,INTERVENTIONAL,PHASE3,109.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Duchenne Muscular Dystrophy (DMD),eteplirsen,DRUG,1,6,7 Years,16 Years,MALE,False,"Sarepta Therapeutics, Inc.",INDUSTRY,0,37,United States
NCT03343652,A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma,A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma,COMPLETED,2017-05-27,2020-03-27,2020-05-28,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hodgkin's Lymphoma,Nivolumab|Bendamustine Hydrochloride,DRUG,1,5,18 Years,70 Years,ALL,False,St. Petersburg State Pavlov Medical University,OTHER,0,1,Russia
NCT01583738,Effect of V0251 in Acute Vertigo,,COMPLETED,2012-04,2013-04,2014-10-30,INTERVENTIONAL,PHASE2,132.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Vertigo,V0251|placebo,DRUG,1,2,18 Years,70 Years,ALL,False,Pierre Fabre Medicament,INDUSTRY,0,40,Spain|France|Hungary|Germany|Czechia
NCT01728558,Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients,Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients: a Prospective Multicentre Randomised Controlled Trial,COMPLETED,2013-11,2018-12,2019-08-20,INTERVENTIONAL,PHASE3,4000.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Critical Illness and Mechanical Ventilation,Early goal Directed Sedation|Standard care sedation,OTHER,1,15,18 Years,,ALL,False,Australian and New Zealand Intensive Care Research Centre,OTHER,1,74,Italy|Australia|United Kingdom|Ireland|Saudi Arabia|Switzerland|Malaysia|New Zealand
NCT02380755,Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism,Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism: Metabolic and Cardiovascular Effects.,COMPLETED,2015-04,2017-01,2017-12-27,INTERVENTIONAL,PHASE2,78.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Obesity|Hypoandrogenism,Clomiphene Citrate|Placebo,DRUG,2,0,18 Years,50 Years,MALE,False,University of Sao Paulo,OTHER,1,1,Brazil
NCT01543555,Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose,Multicenter Randomized Controlled Trial of Loading Dose Statins for the Prevention of Cardiovascular Complications in High-Risk Non-Cardiac Surgery,COMPLETED,2012-11,2015-06,2015-12-31,INTERVENTIONAL,PHASE3,648.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Myocardial Infarction|Peripheral Vascular Disease|Aortic Aneurism,Atorvastatin|Placebo,DRUG,1,9,40 Years,,ALL,False,Hospital do Coracao,OTHER,0,1,Brazil
NCT01437878,Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD),"A Phase 2, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Inhaled Iloprost on Endurance Time During Cardiopulmonary Exercise Testing in Patients With Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease",TERMINATED,2012-03,2012-11,2015-11-20,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Obstructive Pulmonary Disease|Pulmonary Hypertension,Iloprost|Placebo,DRUG,1,17,40 Years,75 Years,ALL,False,Actelion,INDUSTRY,0,11,Spain|United States|France
NCT05331885,A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial Pneumonia",TERMINATED,2022-09-02,2024-07-08,2025-03-24,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ventilator Associated Pneumonia|Staphylococcus Aureus,Suvratoxumab|Placebo,DRUG|BIOLOGICAL,1,9,12 Years,65 Years,ALL,False,"Aridis Pharmaceuticals, Inc.",INDUSTRY,0,27,Spain|Belgium|France|Israel|Netherlands|Greece
NCT02872285,An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis,"A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis",COMPLETED,2016-12-05,2017-06-22,2019-04-10,INTERVENTIONAL,PHASE2,33.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Psoriasis,Drug: LYC-30937-EC|Placebo,DRUG,1,4,18 Years,75 Years,ALL,False,Lycera Corp.,INDUSTRY,0,7,United States
NCT02545036,Combined Western and Traditional Chinese Medicine Daycare for CKD Patients,Clinical Study of Combined Western Medicine and Traditional Chinese Medicine Daycare Model for Chronic Kidney Disease Patients,COMPLETED,2015-06,2017-09-20,2021-08-02,INTERVENTIONAL,PHASE3,58.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Kidney Disease,Traditional Chinese Medicine (TCM) daycare model,OTHER,2,9,20 Years,,ALL,False,China Medical University Hospital,OTHER,1,1,Taiwan
NCT01103271,Pilot Study of Open-label Placebo to Treat Major Depressive Disorder,Harnessing the Placebo Effect in Major Depressive Disorder,COMPLETED,2010-05,2011-05,2013-01-14,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Major Depressive Disorder,Open-label Placebo,OTHER,1,1,18 Years,60 Years,ALL,False,Massachusetts General Hospital,OTHER,2,1,United States
NCT01288534,Hypofractionated Stereotactic Body Radiation Therapy (SBRT),A Study of Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Using Continuous Real-time Evaluation of Prostate Motion,COMPLETED,2011-01,2016-01,2017-10-24,INTERVENTIONAL,PHASE2,68.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Radiation Therapy,RADIATION,1,4,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,3,2,United States
NCT01540864,A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects,"A 26 Week Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Various Doses of HPP404 on Weight Loss in Overweight or Obese Subjects",TERMINATED,2012-05,2013-05,2015-09-04,INTERVENTIONAL,PHASE2,126.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Obesity|Overweight,HPP404|Placebo,DRUG,1,2,18 Years,65 Years,ALL,False,"High Point Pharmaceuticals, LLC.",INDUSTRY,0,10,United States
NCT04880109,A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.,"A Phase 2, Double-blind, Placebo-controlled, Efficacy, and Safety Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.",TERMINATED,2021-10-20,2022-04-28,2024-01-18,INTERVENTIONAL,PHASE2,16.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,COVID-19,APX-115|Placebo,DRUG,1,15,18 Years,80 Years,ALL,False,"Aptabio Therapeutics, Inc.",INDIV,1,3,United States
NCT04669132,"Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer","Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer",COMPLETED,2020-12-17,2022-01-17,2022-02-23,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Nausea Post Chemotherapy,Olanzapine|Netupitant|Palonesetron,DRUG,1,2,18 Years,,FEMALE,False,Instituto Brasileiro de Controle do Cancer,OTHER,0,1,Brazil
NCT05239598,Povidone-Iodine Oral Rinse Study,"A Phase II, Randomized Trial to Test the Effect of Povidone-iodine 0.5% as Mouthwash/Gargle on SARS-CoV-2 Load (COVID 19) as an Adjuvant Infection Control Measure in Dental Practice",COMPLETED,2022-02-07,2022-07-13,2023-08-14,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,COVID-19,Mouth rinse,DRUG,1,1,18 Years,,ALL,False,University of Pennsylvania,OTHER,1,1,United States
NCT02058563,"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762),COMPLETED,2014-07-01,2015-09-17,2018-06-06,INTERVENTIONAL,PHASE3,996.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Rubella|Mumps|Measles,"Priorix®|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine",BIOLOGICAL,3,13,7 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,1,17,Slovakia|United States|Estonia
NCT04544787,A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates,"A Phase 2, Partial Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of Two Novel Live Attenuated Serotype 2 Oral Poliovirus Vaccines Candidates, in Healthy Adults Previously Vaccinated With Oral Polio Vaccine (OPV) or Inactivated Polio Vaccine (IPV), Compared With Historical Controls Given Sabin OPV2 or Placebo",COMPLETED,2018-10-22,2019-05-08,2021-10-15,INTERVENTIONAL,PHASE2,250.0,ACTUAL,RANDOMIZED,SEQUENTIAL,PREVENTION,QUADRUPLE,Poliomyelitis,Novel OPV2 candidate 1|Novel OPV2 candidate 2|Placebo,BIOLOGICAL,2,11,18 Years,50 Years,ALL,True,Pierre Van Damme,OTHER,4,2,Belgium
NCT02370121,Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin,"Effect of Gymnema Sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion",COMPLETED,2013-02,2015-01,2019-06-18,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Metabolic Syndrome,Placebo|Gymnema Sylvestre,DRUG,9,8,30 Years,60 Years,ALL,False,University of Guadalajara,OTHER,0,0,
NCT01219816,Multi-centric Study,"Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study.",COMPLETED,2010-11,2016-11,2018-02-27,INTERVENTIONAL,PHASE2,57.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,B ALL|CD22+ Expression|Refractory B-ALL,Epratuzumab|Epratuzumab,DRUG,1,5,18 Years,,ALL,False,Nantes University Hospital,OTHER,0,11,France
NCT03297216,Improving Pregnancy Outcomes With Progesterone,Z 31702 - Improving Pregnancy Outcomes With Progesterone (IPOP): a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy,COMPLETED,2018-02-07,2020-08-06,2021-07-22,INTERVENTIONAL,PHASE3,800.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Pre-term Birth|HIV-1-infection,17P|Placebo,DRUG|OTHER,1,13,18 Years,,FEMALE,False,"University of North Carolina, Chapel Hill",OTHER,3,2,Zambia
NCT03494504,ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis,"A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis",COMPLETED,2018-03-30,2018-11-05,2025-02-11,INTERVENTIONAL,PHASE3,318.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Allergic Conjunctivitis,Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.5%)|Vehicle Ophthalmic Solution,DRUG,1,1,18 Years,,ALL,False,"Aldeyra Therapeutics, Inc.",INDUSTRY,0,7,United States
NCT04539938,A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer,"A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer",COMPLETED,2020-12-01,2025-03-07,2025-09-30,INTERVENTIONAL,PHASE2,70.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,HER2 Positive Breast Cancer,tucatinib|trastuzumab deruxtecan,DRUG,1,13,18 Years,,ALL,False,"Seagen, a wholly owned subsidiary of Pfizer",INDUSTRY,0,140,United States
NCT01222338,Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients,"Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients",COMPLETED,2010-01,2011-01,2012-08-03,INTERVENTIONAL,PHASE2,123.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Tuberculosis,V-5 immunitor,BIOLOGICAL,1,4,18 Years,70 Years,ALL,False,Lisichansk Regional Tuberculosis Dispensary,OTHER,2,1,Ukraine
NCT04147858,Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia",COMPLETED,2019-11-12,2022-06-16,2023-04-28,INTERVENTIONAL,PHASE2,310.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Fibromyalgia,NYX-2925|Placebo,DRUG,1,9,18 Years,75 Years,ALL,False,Aptinyx,INDUSTRY,1,42,United States
NCT04896658,"Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma","Belantamab Mafodotin, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma",TERMINATED,2021-12-03,2024-12-01,2025-04-03,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Relapsed/Refractory Multiple Myeloma,"Belantamab Mafodotin, Cyclophosphamide and Dexamethasone",DRUG,2,3,18 Years,,ALL,False,"University of Maryland, Baltimore",OTHER,0,1,United States
NCT01833455,Premature Ventricular Contractions (PVCs) and Blood Pressure Control,The Effects of PVC Suppression on Blood Pressure Control in Patients With Frequent PVCs,TERMINATED,2013-02,2016-06,2019-02-22,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,QUADRUPLE,Ventricular Premature Complexes|Blood Pressure,PVC Suppression using Flecainide|No PVC Suppression using Placebo,DRUG,1,1,18 Years,65 Years,ALL,False,"University of Wisconsin, Madison",OTHER,0,1,United States
NCT04442048,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,"COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure",COMPLETED,2020-10-01,2025-12-22,2025-12-30,INTERVENTIONAL,PHASE3,195.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cancer|Covid-19,IMM-101|Observation,OTHER|BIOLOGICAL,1,10,18 Years,,ALL,False,Canadian Cancer Trials Group,NETWORK,6,8,Canada
NCT01739348,An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738),"A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)",TERMINATED,2012-11-30,2017-04-14,2018-10-24,INTERVENTIONAL,PHASE2|PHASE3,2211.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alzheimer's Disease,Verubecestat (Part I and Part II)|Verubecestat (Part I and Part II)|Verubecestat (Part I and Part II)|Placebo (Part I)|Verubecestat (Part II),DRUG,8,7,55 Years,85 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,
NCT01305226,A Trial Using Double-Bolus THR-100 Versus Streptokinase,"A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction",COMPLETED,2010-10,2011-08,2021-02-23,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myocardial Infarction,THR-100|Streptokinase,DRUG,1,1,30 Years,75 Years,ALL,False,Bharat Biotech International Limited,INDUSTRY,0,4,India
NCT04527471,Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19",COMPLETED,2020-09-04,2021-05-01,2022-09-22,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Coronavirus Infection|Covid-19|SARS-CoV-2,Ensifentrine Dose 1|Placebo pMDI,DRUG,1,0,18 Years,80 Years,ALL,False,Verona Pharma Inc,INDUSTRY,0,1,United States
NCT02906644,Combination Nicotine Patch / Lorcaserin for Smoking Cessation,Combination Nicotine Patch / Lorcaserin for Smoking Cessation,COMPLETED,2016-11-08,2018-10-18,2019-05-07,INTERVENTIONAL,PHASE2,97.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Nicotine Dependence,lorcaserin|nicotine patch|placebo lorcaserin,DRUG,2,6,18 Years,65 Years,ALL,False,Duke University,OTHER,1,1,United States
NCT01212744,"Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)","A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Dose Levels of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria",COMPLETED,2011-03,2015-04,2019-02-26,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Phenylketonuria,rAvPAL-PEG,DRUG,1,9,16 Years,70 Years,ALL,False,BioMarin Pharmaceutical,INDUSTRY,0,9,United States
NCT04381234,Strategies for Asymmetrical Triacetate Dialyzer Heparin-Free Effective Hemodialysis,Strategies for Asymmetrical Triacetate Dialyzer,COMPLETED,2018-01-06,2020-05-05,2020-05-21,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Hemodialysis Complication,dialyzer|hemodialysis with citrate-containing dialysate|predilution hemodiafiltration,OTHER|DEVICE|COMBINATION_PRODUCT,1,3,18 Years,,ALL,False,Universitaire Ziekenhuizen KU Leuven,OTHER,1,1,Belgium
NCT01570764,Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease,Intravenous Cyclophosphamide for the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease,COMPLETED,2013-01-14,2018-02-22,2025-09-12,INTERVENTIONAL,PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Systemic Sclerosis|Scleroderma|Interstitial Lung Disease|Lung Fibrosis,Cyclophosphamide|Placebo,DRUG,1,9,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France
NCT02914509,Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT,"A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3A Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension",COMPLETED,2016-11-07,2019-03-30,2021-10-11,INTERVENTIONAL,PHASE3,565.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Open Angle Glaucoma|Ocular Hypertension,Travoprost|Placebo Vehicle,DRUG|OTHER,3,0,18 Years,,ALL,False,"Ocular Therapeutix, Inc.",INDUSTRY,0,10,United States
NCT03492099,Assessing the Safety of Buprenorphine in People With Sickle Cell Disease,Assessing the Safety of Buprenorphine in People With Sickle Cell Disease,COMPLETED,2018-08-01,2022-02-28,2022-04-25,INTERVENTIONAL,PHASE2,47.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sickle Cell Disease,buprenorphine,DRUG,1,3,18 Years,,ALL,False,Johns Hopkins University,OTHER,0,1,United States
NCT03323398,Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies,"A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination With Durvalumab for Patients With Advanced Malignancies",TERMINATED,2017-08-15,2021-08-18,2024-07-31,INTERVENTIONAL,PHASE1|PHASE2,79.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Relapsed/Refractory Solid Tumor Malignancies or Lymphoma|Ovarian Cancer,mRNA-2416|Durvalumab,BIOLOGICAL,3,3,18 Years,,ALL,False,"ModernaTX, Inc.",INDUSTRY,0,9,United States
NCT03645863,Effects of Iron Supplements on the Pharmacokinetics of MT-6548,A Clinical Pharmacological Study to Evaluate the Effects of Iron Supplements on the Pharmacokinetics of MT-6548 in Healthy Male Volunteers,COMPLETED,2018-08-27,2018-09-30,2026-01-07,INTERVENTIONAL,PHASE3,61.0,ACTUAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Healthy,MT-6548|Iron supplement A|Iron supplement B|Iron supplement C|Iron supplement D,DRUG,7,0,20 Years,45 Years,MALE,True,Tanabe Pharma Corporation,INDUSTRY,0,1,Japan
NCT03298087,Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,COMPLETED,2018-07-01,2024-03-31,2025-08-01,INTERVENTIONAL,PHASE2,28.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Newly Diagnosed Oligometastatic Prostate Cancer,radical prostatectomy|stereotactic body radiotherapy|Leuprolide|apalutamide|abiraterone,RADIATION|PROCEDURE|DRUG,1,6,18 Years,,MALE,False,VA Office of Research and Development,FED,0,3,United States
NCT01620593,Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer,"Phase II, Randomized, Placebo Controlled, Double Blind, Prospective Study of Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer.",COMPLETED,2011-04,2016-09,2018-05-23,INTERVENTIONAL,PHASE2,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Prostate Cancer,Placebo|Metformin,DRUG,2,3,18 Years,,MALE,False,The University of Texas Health Science Center at San Antonio,OTHER,0,1,United States
NCT01827293,Promethazine vs. Lorazepam for Treatment of Vertigo,Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial,COMPLETED,2013-04,2013-06,2013-06-14,INTERVENTIONAL,PHASE3,210.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Peripheral Vertigo.,Promethazine|Lorazepam,DRUG,1,1,18 Years,65 Years,ALL,False,Shahid Beheshti University of Medical Sciences,OTHER,0,1,Iran
NCT01421121,Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants,,COMPLETED,2011-06,2011-12,2012-11-27,INTERVENTIONAL,PHASE2,540.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,"Infection, Viral, Enterovirus",100U EV71 vaccine with adjuvant|200 U EV71 vaccine with adjuvant|400U EV71 vaccine with adjuvant|200U EV71 vaccine without adjuvant|Placebo,BIOLOGICAL,1,1,6 Months,35 Months,ALL,True,"Sinovac Biotech Co., Ltd",INDUSTRY,0,1,China
NCT02275806,Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC,A Phase II Study of Definitive Concurrent Radiation Therapy With Cisplatin and Irinotecan Chemotherapy in Locally Advanced In-operable Non-Small Cell Lung Cancer,TERMINATED,2014-10,2017-09-27,2019-08-21,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lung Neoplasms, Non-Small Cell Lung Cancer",Irinotecan|Cisplatin,DRUG,2,2,18 Years,,ALL,False,Leo W. Jenkins Cancer Center,OTHER,0,1,United States
NCT01987804,Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women,"A Double-blind, Placebo Controlled Single Centre Trial to Evaluate the Dose-relationship of the Effects of Vaginally Administered Oxytocin on the Vaginal Mucosal Membrane in Postmenopausal Women With Vaginal Atrophy",COMPLETED,2012-01,2013-01,2020-11-13,INTERVENTIONAL,PHASE2,64.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Vaginal Atrophy,Oxytocin 100 i.u.|Oxytocin 400 i.u.|Placebo,DRUG,1,1,40 Years,,FEMALE,False,PepTonic Medical AB,INDUSTRY,1,1,Sweden
NCT04968184,Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD),A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD,TERMINATED,2021-11-05,2024-07-10,2025-09-03,INTERVENTIONAL,PHASE3,652.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Kidney Diseases,Placebo|KBP-5074,DRUG,2,11,18 Years,,ALL,False,KBP Biosciences,INDUSTRY,0,215,Canada|United States|Spain|Hungary|Lithuania|Australia|China|Malaysia|Georgia|South Korea|Taiwan|Poland|Bosnia and Herzegovina|Germany|Israel|Serbia|South Africa|Czechia|Croatia|Latvia|Bulgaria|Hong Kong
NCT01876433,Beta 3 Agonist Treatment in Heart Failure,Beta 3 Agonist Treatment in Heart Failure,COMPLETED,2013-09-30,2015-09-30,2020-10-19,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Heart Failure With Reduced Ejection Fraction (HFrEF),Mirabegron|Placebo,DRUG,1,10,18 Years,,ALL,False,Henning Bundgaard,OTHER,0,3,Denmark|Australia
NCT01468233,Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa,A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II,COMPLETED,2011-11,2014-04,2021-07-12,INTERVENTIONAL,PHASE3,326.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hidradenitis Suppurativa (HS),adalimumab|placebo,BIOLOGICAL,1,3,18 Years,99 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,0,
NCT05324852,AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine,"AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine, a Randomized Non Inferiority Trial",TERMINATED,2023-04-09,2024-04-23,2024-05-28,INTERVENTIONAL,PHASE3,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Emergence Delirium,Intranasal midazolam|Intramuscular loxapine,DRUG,1,7,18 Years,60 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,1,France
NCT01416155,Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis,"A Long-Term, Open-Label, Multicenter, Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2010-10,2014-12,2016-01-14,INTERVENTIONAL,PHASE2,97.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,natalizumab,DRUG,2,2,18 Years,65 Years,ALL,False,Biogen,INDUSTRY,0,22,Japan
NCT02114255,Effects of BCG on Influenza Induced Immune Response,The Effects of BCG-vaccination on the Immune Response Induced by Influenza-vaccination in Healthy Volunteers. A Pilot Proof-of-principle Study.,COMPLETED,2014-05,2014-09,2015-11-10,INTERVENTIONAL,PHASE2|PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Influenza Virus Infection|Trained Immunity,Placebo|BCG,OTHER|BIOLOGICAL,2,7,18 Years,35 Years,MALE,True,Radboud University Medical Center,OTHER,0,1,Netherlands
NCT01339455,Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica,Autologous Hematopoietic Stem Cell Transplant in Patients With Neuromyelitis Optica,TERMINATED,2011-03,2017-03,2018-05-02,INTERVENTIONAL,PHASE1|PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Neuromyelitis Optica,AHSCT,PROCEDURE,1,9,18 Years,65 Years,ALL,False,University of Calgary,OTHER,0,1,Canada
NCT00957346,Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP),Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP): A Randomized-controlled Double-blinded Trial,TERMINATED,2011-02,2012-01,2011-11-08,INTERVENTIONAL,PHASE3,20.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Abortion, Induced",Mifepristone+misoprostol|Placebo+Misoprostol,DRUG,2,5,,,FEMALE,True,Gynuity Health Projects,OTHER,1,1,Puerto Rico
NCT01023061,Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer,"Phase II Trial of Radiation With Androgen Deprivation: Abiraterone Acetate, Prednisone and Luteinizing Hormone Releasing Hormone Agonist Prior to Radiation Therapy",COMPLETED,2010-03,2015-09,2017-06-06,INTERVENTIONAL,PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adenocarcinoma of the Prostate|Stage II Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer,abiraterone acetate|prednisone|leuprolide acetate|laboratory biomarker analysis|external beam radiation therapy|goserelin acetate,RADIATION|DRUG|OTHER,2,1,18 Years,,MALE,False,University of Washington,OTHER,1,2,United States
NCT01641042,Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered to at Risk Subjects From 1 to Less Than 18 Years,COMPLETED,2012-09-10,2015-03-03,2017-10-18,INTERVENTIONAL,PHASE3,86.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,"Infections, Meningococcal",Meningococcal vaccine GSK134612,BIOLOGICAL,2,19,1 Year,17 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,16,Czechia|United States
NCT01124370,Chronic Evaluation of Respicardia Therapy,Safety and Efficacy Evaluation of Respicardia Therapy for Central Sleep Apnea,COMPLETED,2010-05,2014-08,2016-05-16,INTERVENTIONAL,PHASE2,57.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sleep Disordered Breathing|Cheyne Stokes Respiration|Periodic Breathing|Sleep Apnea|Central Sleep Apnea,remedē (TM) system,DEVICE,1,6,18 Years,,ALL,False,"Respicardia, Inc.",INDUSTRY,0,13,Poland|Germany|United States|Italy
NCT02968173,A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus,"A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus",COMPLETED,2016-11-09,2017-07-13,2018-03-13,INTERVENTIONAL,PHASE3,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Respiratory Syncytial Virus (RSV),Palivizumab,DRUG,1,7,,24 Months,ALL,False,AbbVie,INDUSTRY,0,0,
NCT04951869,: Protescal: Prevention of Hypertrophic Scar and Keloid Formation Post Caesarean Section,Assessing the Effectiveness of Protescal In Preventing Post Caesarean Section Hypertrophic Scar and Keloid,COMPLETED,2017-04-26,2017-11-16,2021-07-07,INTERVENTIONAL,PHASE2|PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Caesarean Wound|Hypertrophic Surgical Scar|Keloid Scar Following Surgery,Protescal gel,DRUG,3,1,18 Years,,FEMALE,True,Universiti Kebangsaan Malaysia Medical Centre,OTHER,0,1,Malaysia
NCT06128369,Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery,"A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 Ophthalmic Suspension in the Treatment of Inflammation and Pain Following Cataract Surgery",TERMINATED,2023-12-18,2024-05-09,2024-12-10,INTERVENTIONAL,PHASE3,117.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Inflammation Eye|Pain, Postoperative|Cataract",Dexamethasone Ophthalmic Suspension|Vehicle of OCS-01,DRUG|OTHER,2,0,18 Years,,ALL,False,Oculis,INDUSTRY,1,12,United States
NCT02980341,Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer,"Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer",COMPLETED,2016-11-28,2023-09-07,2024-10-30,INTERVENTIONAL,PHASE1|PHASE2,182.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Metastatic Breast Cancer,Patritumab Deruxtecan,DRUG,2,18,18 Years,,ALL,False,"Daiichi Sankyo Co., Ltd.",INDUSTRY,2,26,Japan|United States
NCT04158141,Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma,Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM),TERMINATED,2020-01-29,2023-11-20,2025-02-19,INTERVENTIONAL,PHASE3,16.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pleural Biphasic Mesothelioma|Pleural Epithelioid Mesothelioma|Stage I Pleural Malignant Mesothelioma AJCC v8|Stage IA Pleural Malignant Mesothelioma AJCC v8|Stage IB Pleural Malignant Mesothelioma AJCC v8|Stage II Pleural Malignant Mesothelioma AJCC v8|Stage IIIA Pleural Malignant Mesothelioma AJCC v8,Carboplatin|Cisplatin|Decortication|Intensity-Modulated Radiation Therapy|Pemetrexed|Pemetrexed Disodium|Pencil beam scanning proton therapy|Pleurectomy,RADIATION|PROCEDURE|DRUG,1,5,18 Years,80 Years,ALL,False,NRG Oncology,OTHER,1,27,Canada|United States
NCT01526694,Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM,"Phase II Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in R/R MM Pts After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs",COMPLETED,2012-07,2017-04-08,2018-07-03,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,Bendamustine|Thalidomide|Dexamethasone,DRUG,2,3,18 Years,,ALL,False,Azienda Ospedaliera di Bolzano,OTHER,1,19,Italy
NCT02976766,Gypenosides Treatment for Optic Neuritis,"Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial",TERMINATED,2017-02-04,2020-12-31,2025-12-19,INTERVENTIONAL,PHASE2,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Optic Neuritis,Gypenosides|Placebo,DRUG,1,5,18 Years,60 Years,ALL,False,First Affiliated Hospital of Guangxi Medical University,OTHER,0,1,China
NCT03517566,A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis,"A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)",TERMINATED,2018-11-14,2020-08-06,2021-10-08,INTERVENTIONAL,PHASE2,293.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Atopic Dermatitis,Placebo|ZPL389 3mg|ZPL389 10mg|ZPL389 30mg|ZPL389 50mg,DRUG,1,6,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,89,Canada|United States|Japan|Belgium|Iceland|United Kingdom|Finland|Russia|Slovakia|Hungary|Taiwan|Poland|Austria|Germany|Netherlands|Czechia
NCT05591222,Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus",TERMINATED,2022-12-29,2025-05-08,2025-10-21,INTERVENTIONAL,PHASE2,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Discoid Lupus Erythematosus,Placebo|Daxdilimab,DRUG,1,6,18 Years,75 Years,ALL,False,Amgen,INDUSTRY,0,68,Canada|United States|Denmark|Argentina|Czechia|France|Poland|Germany|Greece|Brazil|Bulgaria
NCT02300922,Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer,Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer : A Multicentric Phase I/II Study of Fractionated TF2 Plus 90Y-IMP288 (RITCOLON),TERMINATED,2015-01-27,2017-12-20,2022-08-01,INTERVENTIONAL,PHASE1|PHASE2,7.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Metastatic Colorectal Cancer,Antibody TF2|90-Y-IMP-288|111-In-IMP-288,DRUG,1,0,18 Years,,ALL,False,Nantes University Hospital,OTHER,0,1,France
NCT02092922,A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM),,COMPLETED,2014-05,2017-09-05,2020-10-19,INTERVENTIONAL,PHASE2,154.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Multiple Myeloma,"Filanesib, KSP (Eg5) inhibitor; intravenous|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous",DRUG,1,7,18 Years,,ALL,False,Pfizer,INDUSTRY,0,60,Canada|United States|Spain|Belgium|United Kingdom|France|Germany|Greece
NCT01321151,Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers,"Use of Resveratrol to Decrease Secondary Brain Injury Following Sports-Related Concussions: a Double-Blind, Placebo-Controlled Study",COMPLETED,2011-03,2011-11,2021-02-11,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Sports Concussion,Resveratrol|Placebo,DRUG,2,4,18 Years,35 Years,ALL,True,University of Texas Southwestern Medical Center,OTHER,0,1,United States
NCT01703351,Prospective Randomized Trial Comparing the Effectiveness of Continuous Paravertebral Infusion of Local Anesthetics Versus Intravenous Patient-controlled Analgesia on Acute and Chronic Neuropathic Pain After VATS Lobectomy,,COMPLETED,2012-10-04,2015-11-06,2019-01-31,INTERVENTIONAL,PHASE2,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Lung Neoplasms|Postoperative Pain,0.5% ropivacaine|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg,DRUG,1,1,18 Years,78 Years,ALL,False,Yonsei University,OTHER,0,1,South Korea
NCT01135329,"Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers","Reduced-intensity, Related-donor Allogeneic BMT With Fludarabine, Busulfan, and High-dose Posttransplantation Cyclophosphamide for Hematologic Malignancies",TERMINATED,2010-08,2012-05,2018-07-03,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lymphoma|Leukemia|Myelodysplastic Syndrome,Fludarabine|Busulfan|Cyclophosphamide|Mycophenolate Mofetil|Tacrolimus,DRUG,2,6,6 Months,75 Years,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,0,1,United States
NCT01466231,Everolimus in Refractory Testicular Germ Cell Cancer,Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.,COMPLETED,2011-11,2015-06,2016-01-12,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Germ Cell Tumor,Everolimus,DRUG,1,7,18 Years,,MALE,False,"National Cancer Institute, Slovakia",OTHER_GOV,0,1,Slovakia
NCT05809453,Intranasal Cocaine and Temperature Regulation During Exercise,Intranasal Cocaine and Temperature Regulation During Exercise,COMPLETED,2023-09-01,2024-08-01,2025-07-14,INTERVENTIONAL,PHASE1|PHASE2,27.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,Hyperthermia|Cocaine Use|Exercise,Cocaine|Lidocaine,DRUG,1,5,18 Years,50 Years,ALL,True,University of Texas Southwestern Medical Center,OTHER,0,1,United States
NCT01685853,Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One,"Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One. A Randomized, Observer-blind, Parallel Group, Comparative Study.",COMPLETED,2011-04,2012-03,2012-09-19,INTERVENTIONAL,PHASE3,164.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Colonoscopy,Bisacodyl plus PEG-CS|PEG 4 litres split,DRUG,1,6,18 Years,85 Years,ALL,False,European Institute of Oncology,OTHER,0,1,Italy
NCT02205372,"Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy","A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 (Low Dose) in Subjects With Diabetic Nephropathy",COMPLETED,2014-07,2015-08,2015-09-16,INTERVENTIONAL,PHASE1|PHASE2,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetic Nephropathy,MT-3995|Placebo,DRUG,1,4,20 Years,75 Years,ALL,False,Tanabe Pharma Corporation,INDUSTRY,0,1,Japan
NCT03678545,Dupilumab in Eosinophilic Gastritis,"A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis",COMPLETED,2021-05-15,2024-11-13,2025-11-04,INTERVENTIONAL,PHASE2,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Eosinophilic Gastritis|Eosinophilic Gastroenteritis,Dupilumab (blinded)|Placebo (blinded),DRUG,1,0,12 Years,70 Years,ALL,False,"Children's Hospital Medical Center, Cincinnati",OTHER,2,12,United States
NCT04356495,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France),COMPLETED,2020-07-29,2021-10-22,2022-02-04,INTERVENTIONAL,PHASE2|PHASE3,412.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Corona Virus Infection|Sars-CoV2,Vitamins|Telmisartan|Ciclesonide|interferon β-1b,DRUG|DIETARY_SUPPLEMENT,4,12,50 Years,,ALL,False,"University Hospital, Bordeaux",OTHER,1,7,France
NCT01447212,Study to Assess Longer-term Opioid Medication Effectiveness (SALOME),"SALOME: Multi-Centre, Double Blind Randomized Controlled Trial Comparing The Effectiveness Of Diacetylmorphine Vs. Hydromorphone For The Treatment Of Long-Term Injection Opioid Users Who Do Not Benefit From Available Therapies",COMPLETED,2011-12,2016-02,2016-06-07,INTERVENTIONAL,PHASE3,202.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Opioid Dependence|Heroin Dependence,"Hydromorphone, Injectable|Diacetylmorphine, injectable|Hydromorphone, liquid oral|Diacetylmorphine, liquid oral",DRUG,1,0,19 Years,,ALL,False,University of British Columbia,OTHER,3,1,Canada
NCT02045212,Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).,"A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).",COMPLETED,2014-02,2016-12,2020-03-19,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Non-arteritic Ischemic Optic Neuropathy|Optic Nerve Injuries,RPh201|Placebo,DRUG,3,1,18 Years,,ALL,False,Regenera Pharma Ltd,INDUSTRY,0,1,Israel
NCT05585112,Articaine 4% Versus Lidocaine 2% for Local Anesthesia of MIH-affected Maxillary Molars,Comparative Study of Articaine 4% Versus Lidocaine 2% in Local Anesthesia and Permanent Maxillary First Molars Affected by MIH.,COMPLETED,2022-10-17,2022-12-25,2023-05-03,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Molar Incisor Hypomineralisation,Lidocaine 2%|Articaine 4%,DRUG,4,0,6 Years,12 Years,ALL,True,Tishreen University,OTHER,0,1,Syria
NCT01754181,Initial Testing of the Diabeloop Algorithm in T1D Patients on Pump Therapy Over the Prandial Period and Physical Activity.,"Development of the Glycemic Control Algorithm, in Prandial and Physical Effort Situations.",COMPLETED,2013-03,2013-07,2014-10-27,INTERVENTIONAL,PHASE3,18.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,HEALTH_SERVICES_RESEARCH,NONE,Type 1 Diabetes,Insulin,DRUG,1,1,18 Years,,ALL,False,Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète,OTHER,0,3,France
NCT02652130,Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD,Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD,COMPLETED,2015-10-28,2018-06-15,2022-03-16,INTERVENTIONAL,PHASE3,32.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Grade B Acute Graft Versus Host Disease|Grade C Acute Graft Versus Host Disease|Grade D Acute Graft Versus Host Disease,Remestemcel-L,BIOLOGICAL,1,1,2 Months,17 Years,ALL,False,"Mesoblast, Inc.",INDUSTRY,1,20,United States
NCT01185028,A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures,"An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders",COMPLETED,2010-08,2011-10,2021-10-05,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatitis C Infection|HIV Infection,Nitazoxanide With Pegylated Interferon And Ribavirin,DRUG,1,2,18 Years,99 Years,ALL,False,National Institutes of Health Clinical Center (CC),NIH,0,4,United States
NCT01032200,Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors,A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue,COMPLETED,2010-08-01,2013-01-08,2021-09-28,INTERVENTIONAL,PHASE2,54.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,QUADRUPLE,Brain Tumors|Nervous System Tumors|Cognition Disorders|Fatigue,Armodafinil|placebo,DRUG|OTHER,2,3,18 Years,,ALL,False,Wake Forest University Health Sciences,OTHER,1,1,United States
NCT01454531,An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy,An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy,COMPLETED,2011-06,2012-04,2015-03-06,INTERVENTIONAL,PHASE2|PHASE3,199.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Allergic Rhinoconjunctivitis,AVANZ Phleum pratense,DRUG,1,5,18 Years,65 Years,ALL,False,ALK-Abelló A/S,INDUSTRY,0,20,Spain
NCT02287831,Umbilical Cord Mesenchymal Stem Cells Injection for Peripheral Arterial Disease,Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection for Peripheral Arterial Disease,COMPLETED,2014-02,2022-12-26,2023-02-08,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Peripheral Arterial Disease,umbilical cord mesenchymal stem cells,BIOLOGICAL,1,1,18 Years,75 Years,ALL,False,"Institute of Hematology & Blood Diseases Hospital, China",OTHER,0,0,
NCT01138722,Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial,Pathologic Effects of Neoadjuvant Radiation Therapy in Operable Early Stage Lung Cancer,TERMINATED,2010-05,2011-08,2021-07-08,INTERVENTIONAL,PHASE2,1.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Early Stage Non-small Cell Lung Cancer,hypofractionated radiation therapy followed by surgery,RADIATION,1,7,18 Years,,ALL,False,"University Hospital, Ghent",OTHER,1,2,Belgium
NCT01613651,Robotic Assisted Laparoscopic Prostatectomy With or Without Pelvic Drain Placement in Reducing Adverse Events After Surgery in Patients With Prostate Cancer,A Prospective Randomized Trial of Pelvic Drain Placement Versus no Pelvic Drain Placement After Robotic Assisted Laparoscopic Prostatectomy (RALP) in Patients With Prostate Cancer,COMPLETED,2012-08-24,2017-09-11,2017-09-14,INTERVENTIONAL,PHASE3,191.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,SINGLE,Perioperative/Postoperative Complications|Prostate Cancer,robot-assisted laparoscopic surgery|questionnaire administration|intraoperative complication management/prevention,PROCEDURE|OTHER,1,3,18 Years,,MALE,False,City of Hope Medical Center,OTHER,1,1,United States
NCT01825551,The Effect of GCSF in the Treatment of ALS Patients,The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013,COMPLETED,2012-11,2013-11,2013-11-13,INTERVENTIONAL,PHASE2|PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Amyotrophic Lateral Sclerosis,Granulocyte Colony Stimulating Factor|Placebo,DRUG,1,4,18 Years,85 Years,ALL,False,Tehran University of Medical Sciences,OTHER,0,1,Iran
NCT02033629,Low Remifentanil Target Controlled Infusions for Cardiac Surgery,Early Extubation After Cardiac Surgery: What Is the Appropriate Target Remifentanil Effect-Site Concentration?,COMPLETED,2014-05,2019-05-15,2019-07-18,INTERVENTIONAL,PHASE3,75.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Cardiac Surgery,Ce 1 ng/ml|Ce 2 ng/ml|Ce 3 ng/ml,DRUG,1,7,18 Years,,ALL,False,Imam Abdulrahman Bin Faisal University,OTHER,0,1,Saudi Arabia
NCT02740231,A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis,"A Two-stage 6-month Multicentre, Randomised, Double-blind, Controlled Study on the Safety and Efficacy Intra-articular Administration of JTA-004 in Patients With Symptomatic Knee Osteoarthritis",COMPLETED,2016-02,2018-04-27,2021-12-06,INTERVENTIONAL,PHASE2|PHASE3,173.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Knee Osteoarthritis,JTA-004 intra-articular injection|Reference product intra-articular injection,DRUG|DEVICE,1,4,50 Years,79 Years,ALL,False,Bone Therapeutics S.A,INDUSTRY,0,0,
NCT01762202,"Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.","Phase 2 Multicenter, Study to Assess the Efficacy and the Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab (FCO2) Chemoimmunotherapy in Young (≤65 Yrs) Patients With Chronic Lymphocytic Leukemia (CLL).",COMPLETED,2013-11-05,2018-10,2020-10-14,INTERVENTIONAL,PHASE2,80.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,B-cell Lymphoid Leukemia|Young Patients,Cyclophosphamide|Fludarabine|Ofatumumab,DRUG,1,6,18 Years,65 Years,ALL,False,Gruppo Italiano Malattie EMatologiche dell'Adulto,OTHER,0,22,Italy
NCT02652702,Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients,Randomized Clinical Trial Comparing the Safety and Efficiency of Circular Stapler-assisted Colostomy With Hand-stitching Colostomy for Colorectal Cancer Patients,TERMINATED,2016-12,2020-01,2020-07-07,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Carcinoma,circular stapler-assisted colostomy|conventional hand-stitching colostomy,PROCEDURE,1,0,18 Years,80 Years,ALL,False,Zhejiang University,OTHER,0,1,China
NCT05799053,Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study,Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study,COMPLETED,2022-05-12,2024-11-30,2025-05-30,INTERVENTIONAL,PHASE3,228.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Irritable Bowel Syndrome|Functional Abdominal Pain Syndrome|Child|Adolescent|Therapeutics|Adverse Drug Event,Small intestinal release peppermint oil|Peppermint sweets|Placebo,DRUG,1,17,8 Years,17 Years,ALL,False,St. Antonius Hospital,OTHER,0,3,Netherlands
NCT01817153,Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.,Effect of Intravenous Hydrocortison on Post-ischemic Brachial Artery Dilation and on Thenar Oxygen Saturation in Adult Septic Shock. A Human Placebo-controlled Randomized Study.,TERMINATED,2013-11-05,2019-11-05,2020-02-11,INTERVENTIONAL,PHASE2|PHASE3,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Septic Shock|Adult,hydrocortison hemisuccinate|placebo followed by hydrocortisone hemisuccinate,DRUG,1,0,18 Years,,ALL,False,Centre Hospitalier Régional d'Orléans,OTHER,0,1,France
NCT03054337,Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD),"Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)",COMPLETED,2016-10,2017-08-28,2021-04-08,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Anemia|Non-dialysis Dependent Chronic Kidney Disease,Vadadustat|Placebo,DRUG,1,25,20 Years,,ALL,False,Akebia Therapeutics,INDUSTRY,0,18,Japan
NCT04359095,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial,COMPLETED,2020-08-18,2021-06-30,2021-08-12,INTERVENTIONAL,PHASE2|PHASE3,650.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID-19,Emtricitabine/tenofovir|Colchicine Pill|Rosuvastatin|Standard treatment,DRUG|OTHER,2,7,18 Years,,ALL,False,Universidad Nacional de Colombia,OTHER,6,6,Colombia
NCT01124695,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen,COMPLETED,2011-01-07,2022-12,2023-06-29,INTERVENTIONAL,PHASE2,124.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer|Stage IV Breast Cancer,tamoxifen,DRUG,1,5,18 Years,,ALL,False,ECOG-ACRIN Cancer Research Group,NETWORK,1,294,Canada|United States|Peru
NCT03110575,12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients,A 12-Week Open-Label Extension Study to Evaluate TNX-102 SL Taken Daily at Bedtime in Patients With PTSD,TERMINATED,2017-06-20,2018-07-27,2025-02-06,INTERVENTIONAL,PHASE3,190.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,PTSD,TNX-102 SL,DRUG,1,1,18 Years,75 Years,ALL,False,"Tonix Pharmaceuticals, Inc.",INDUSTRY,1,32,United States
NCT02571777,Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma,"A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma",COMPLETED,2015-12-08,2019-06-14,2020-07-22,INTERVENTIONAL,PHASE3,3092.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Asthma,QVM149 150/50/160|QVM149 150/50/80|QMF149 150/320|QMF149 150/160|salmeterol/fluticasone,DRUG,1,23,18 Years,75 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,403,Canada|Spain|Russia|Lebanon|Hungary|Lithuania|Finland|Italy|China|France|Thailand|Austria|Jordan|Estonia|Romania|United Kingdom|Ireland|Slovakia|Argentina|Poland|Germany|Israel|Peru|South Africa|Chile|Switzerland|Croatia|Sweden|Latvia|Bulgaria|Japan|Denmark|Colombia|Belgium|Philippines|Portugal|Vietnam|Netherlands|Greece|Mexico|India
NCT02175381,Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC,A Phase I/II Trial of the Carboplatin/Gemcitabine Combination as First Line Treatment for Elderly Patients With Stage IV NSCLC.,COMPLETED,2011-02,2014-04,2015-05-15,INTERVENTIONAL,PHASE1|PHASE2,69.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,NSCLC,Carboplatin|Gemcitabine,DRUG,1,4,70 Years,,ALL,False,Hellenic Oncology Research Group,OTHER,0,5,Greece
NCT05348681,A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS),"A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa",TERMINATED,2022-07-18,2023-02-28,2023-06-13,INTERVENTIONAL,PHASE2,25.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hidradenitis Suppurativa,RIST4721|Placebo,DRUG,2,1,18 Years,,ALL,False,"Aristea Therapeutics, Inc.",INDUSTRY,0,12,Canada|United States
NCT01660581,Intracardiac CD133+ Cells in Patients With No-option Resistant Angina,"A Randomized,Prospective,Double-blind Study to Evaluate Intracardiac Injections of Bone Marrow,Autologous CD133+Cells(Electromechanical Mapping Based)in Patients With Resistant Angina and no Effective Revascularization Option. RegentVsel",COMPLETED,2012-06,2016-09,2017-09-28,INTERVENTIONAL,PHASE2,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Stable Angina,intramyocardial injection (electromechanical mapping based)|Placebo,BIOLOGICAL,1,6,18 Years,75 Years,ALL,False,Medical University of Silesia,OTHER,0,1,Poland
NCT02143219,Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer,"Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of ""FOLFIRINOX "" Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.",COMPLETED,2014-07-31,2020-11-25,2022-07-28,INTERVENTIONAL,PHASE2,72.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Metastatic Cancer|Toxicity,Oxaliplatine|Folinic acid|Irinotecan|5-FU,DRUG,1,1,70 Years,,ALL,False,Institut Cancerologie de l'Ouest,OTHER,0,6,France
NCT01844830,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients","A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients",COMPLETED,2013-05,2013-07,2017-08-30,INTERVENTIONAL,PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Anesthesia,Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Placebo,DRUG,1,11,3 Years,17 Years,ALL,False,"St. Renatus, LLC",INDUSTRY,2,2,United States
NCT02191930,Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma,Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II Trial -,COMPLETED,2015-09,2022-03-16,2024-08-23,INTERVENTIONAL,PHASE2,70.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hodgkin Lymphoma,B-CAP|Brentuximab Vedotin,DRUG,1,0,60 Years,99 Years,ALL,False,University of Cologne,OTHER,0,1,Germany
NCT04842565,cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria,Phase II Trial of cTACE Plus Sintilimab for Treatment of Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria,COMPLETED,2021-05-01,2023-05-01,2024-05-22,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma,Sintilimab|TACE,DRUG|DEVICE,1,5,20 Years,75 Years,ALL,False,Fudan University,OTHER,0,1,China
NCT05107765,Effects of Pioglitazone on Stress Reactivity and Alcohol Craving,Effects of Pioglitazone on Stress Reactivity and Alcohol Craving,COMPLETED,2022-05-12,2024-08-16,2025-08-27,INTERVENTIONAL,PHASE1|PHASE2,67.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alcohol Use Disorder,Pioglitazone|Placebo,DRUG,10,22,18 Years,,ALL,False,"The University of Texas Health Science Center, Houston",OTHER,1,1,United States
NCT01443728,Vitamin D for Sickle-cell Respiratory Complications,Vitamin D for Sickle-cell Respiratory Complications,COMPLETED,2011-12-13,2015-02-15,2024-08-09,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sickle Cell Disease|Vitamin D Deficiency|Acute Chest Syndrome|Asthma|Respiratory Infections,"Experimental: Vitamin D3 100,000 IU|Active Comparator: Vitamin D3 12,000 IU",DRUG,1,13,3 Years,20 Years,ALL,False,"Gary M Brittenham, MD",OTHER,0,1,United States
NCT02210065,Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation,The Pre-Emptive Use of Recipient-Derived Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation After Allogeneic Stem Cell Transplantation,COMPLETED,2015-03-03,2019-05-13,2020-03-17,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia|Lymphoma,Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs),BIOLOGICAL,2,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT06353165,"Anti-bacterial Clinical Study on Teeth, Tongue, Cheek, Gum, and Saliva",A Clinical Study to Investigate Stannous Fluoride Toothpaste on Antibacterial Effects in the Different Regions of the Mouth as Compared to Colgate Cavity Protection Toothpaste,COMPLETED,2023-03-08,2023-04-12,2024-04-15,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,"Plaque, Dental",Stannous fluoride toothpaste|Colgate Dental Cream,DRUG,5,0,18 Years,70 Years,ALL,True,Colgate Palmolive,INDUSTRY,0,1,Thailand
NCT02953665,Safety and Efficacy of Liraglutide in Parkinson's Disease,"A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease",COMPLETED,2017-04-03,2022-08-03,2024-03-07,INTERVENTIONAL,PHASE2,63.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson Disease,Liraglutide|Placebo,DRUG,3,3,25 Years,85 Years,ALL,False,Cedars-Sinai Medical Center,OTHER,2,1,United States
NCT02807428,Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery,"A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty",COMPLETED,2017-02-20,2017-12-19,2018-10-17,INTERVENTIONAL,PHASE2,210.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Post-surgical Pain,AYX1 Injection 660 mg/6 mL|Placebo Injection 6 mL,DRUG,1,3,40 Years,,ALL,False,"Adynxx, Inc.",INDUSTRY,0,9,United States
NCT02219165,Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study,Efficacy of IntraVenous ImmunoGlobulins (IVIG) in Toxic Shock Syndromes (Staphylococcal and Streptococcal): a Paediatric Pilot Study.,COMPLETED,2015-01-08,2019-04-19,2025-09-04,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,QUADRUPLE,Toxic Shock Syndrome,Intravenous human immunoglobulin|Albumin,DRUG,4,7,1 Month,17 Years,ALL,False,Hospices Civils de Lyon,OTHER,0,1,France
NCT01936896,Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction,Alpha-1 Anti-Trypsin (AAT) to Quench the Acute Inflammatory Response in ST-segment Elevation Acute Myocardial Infarction,COMPLETED,2013-12,2014-07,2016-02-12,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myocardial Infarction,Alpha 1-Antitrypsin,DRUG,1,1,21 Years,99 Years,ALL,False,Virginia Commonwealth University,OTHER,0,1,United States
NCT01673646,Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism,"A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism",COMPLETED,2012-10-16,2017-04-10,2019-09-16,INTERVENTIONAL,PHASE2,33.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acromegaly|Pituitary Gigantism,Pasireotide LAR,DRUG,1,17,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,27,Japan
NCT02109146,Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma,"A Randomized, Open-label, Phase 3 Trial Evaluating Adjuvant Transarterial Chemoembolization for TNM Stage I and II Hepatocellular Carcinoma Recurrence After Curative Resection",COMPLETED,2014-03-26,2023-05-13,2024-05-29,INTERVENTIONAL,PHASE3,332.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatocellular Carcinoma|Transcatheter Arterial Chemoembolization,Prophylactic Transcatheter Arterial Chemoembolization|Observation,DRUG|OTHER,1,3,18 Years,80 Years,ALL,False,Zhejiang University,OTHER,0,1,China
NCT03119961,Blood Brain Barrier Opening in Alzheimer' Disease,Phase 1/2 Open Single-arm Monocentric Study Evaluating the Tolerance and Interest of Transient Opening of the Blood-Brain Barrier by Low Intensity Pulsed Ultrasound With the SONOCLOUD® Implantable Medical Device in Mild Alzheimer's Disease Patients (MMSE 20-26),COMPLETED,2017-06-26,2020-10-07,2022-04-12,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Alzheimer Disease,SONOCLOUD®,DEVICE,1,1,50 Years,85 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France
NCT01578642,Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease,A Feasibility Study: An Evaluation of the Effect of Long-Term Electrical Stimulation on Lower Esophageal Sphincter (LES) Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD),COMPLETED,2010-09,2013-05,2014-02-12,INTERVENTIONAL,PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastroesophageal Reflux Disease,EndoStim LES Stimulation System,DEVICE,2,4,21 Years,65 Years,ALL,False,EndoStim Inc.,INDUSTRY,0,1,Chile
NCT01899742,The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium,"DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a Fixed Combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects With COPD Who Continue To Have Symptoms on Tiotropium",COMPLETED,2014-09-15,2015-07-22,2018-01-24,INTERVENTIONAL,PHASE3,497.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",Umeclidinium/Vilanterol 62.5/25 mcg|Tiotropium 18 mcg,DRUG,1,1,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,64,United States|Ukraine|Norway|South Korea|Argentina|Russia|Germany|South Africa|Sweden|Estonia
NCT02176369,Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial,Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase II Study - MA.NI.LA. Trial,COMPLETED,2013-02,2018-10-27,2019-04-22,INTERVENTIONAL,PHASE2,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV,Vinorelbine,DRUG,1,6,18 Years,,ALL,False,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",OTHER,1,20,Italy
NCT02628769,A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease,"A Single-center, Double-blind, Randomised, Placebo-controlled Crossover Study to Evaluate the Effect of Solithromycin on Airway Inflammation in Male and Female Patients With Chronic Obstructive Pulmonary Disease",TERMINATED,2015-07,2017-01-05,2019-12-30,INTERVENTIONAL,PHASE2,6.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Pulmonary Disease, Chronic Obstructive",Solithromycin|Placebo,DRUG,1,11,45 Years,,ALL,False,Imperial College London,OTHER,1,1,United Kingdom
NCT01911169,Vitamin D to Improve Endothelial Function in SLE,Vitamin D Repletion to Improve Endothelial Function in Lupus Patients,COMPLETED,2011-06,2014-01,2017-10-27,INTERVENTIONAL,PHASE2,9.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,QUADRUPLE,Atherosclerosis|Systemic Lupus Erythematosus,Cholecalciferol,DRUG,1,1,18 Years,80 Years,ALL,False,Medical University of South Carolina,OTHER,0,1,United States
NCT03271541,A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia,"A Phase II, Single Arm, Multicenter, Proof-of-Mechanism Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Βeta-Thalassemia",COMPLETED,2017-10-26,2018-06-29,2018-10-05,INTERVENTIONAL,PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Beta-Thalassemia,Bitopertin,DRUG,3,12,18 Years,55 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,4,Italy|Lebanon|Thailand
NCT01856283,Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells,"An Open Label, Single Arm, Phase II Study of Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients, in Order to Verify Disappearance of CD34+/Lin-Ph+ Cells From Bone Marrow During Treatment",COMPLETED,2013-03,2021-01,2021-01-13,INTERVENTIONAL,PHASE2,87.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Leukemia, Myeloid, Chronic-Phase",Nilotinib 300mg BID,DRUG,1,1,18 Years,,ALL,False,Niguarda Hospital,OTHER,0,17,Italy
NCT01270841,Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism,"A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism",COMPLETED,2011-01,2011-12,2014-07-28,INTERVENTIONAL,PHASE2,83.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Secondary Hypogonadism,Placebo|topical testosterone|Androxal,DRUG,1,3,21 Years,65 Years,MALE,False,Repros Therapeutics Inc.,INDUSTRY,0,18,United States
NCT04065841,"Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.","A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis.(ELIVATE)",TERMINATED,2019-12-30,2022-10-27,2025-01-28,INTERVENTIONAL,PHASE2,234.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Non Alcoholic Steatohepatitis (NASH),Tropifexor|Licogliflozin|Placebo,DRUG|OTHER,2,8,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,80,Canada|United States|Spain|Russia|Italy|Estonia|United Kingdom|South Korea|Argentina|Taiwan|Germany|South Africa|Chile|Bulgaria|Japan|Denmark|Colombia|Belgium|Puerto Rico|Turkey (Türkiye)|Mexico|India|Brazil|Singapore
NCT01225094,Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair,Curcumin to Prevent Perioperative Complications After Elective Abdominal Aortic Aneurysm Repair: a Randomized Controlled Trial,COMPLETED,2011-11,2016-08,2017-03-07,INTERVENTIONAL,PHASE2|PHASE3,606.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Acute Kidney Injury|Abdominal Aortic Aneurysm,curcumin|placebo,DRUG|OTHER,4,3,18 Years,,ALL,False,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,1,10,Canada
NCT01436266,Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester Dilation and Evacuation Abortion,Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester,TERMINATED,2011-07,2012-08,2017-05-30,INTERVENTIONAL,PHASE3,3.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Abortion|Blood Loss,Misoprostol|Folic acid,DRUG|OTHER,1,0,18 Years,50 Years,FEMALE,False,Boston University,OTHER,0,1,United States
NCT01914666,An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain,Phase 3 Clinical Study of Duloxetine Hydrochloride in Patients With CLBP - Open Label Long Term Extension Study,COMPLETED,2013-09,2014-12,2016-01-27,INTERVENTIONAL,PHASE3,151.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Back Pain Lower Back Chronic,Duloxetine,DRUG,1,9,20 Years,79 Years,ALL,False,Eli Lilly and Company,INDUSTRY,1,1,Japan
NCT05089656,Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA),"A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Type 2 Spinal Muscular Atrophy (SMA) Patients Who Are ≥ 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory",COMPLETED,2022-02-01,2025-04-29,2026-01-13,INTERVENTIONAL,PHASE3,126.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 2 Spinal Muscular Atrophy,OAV101|Sham control,PROCEDURE|GENETIC,1,9,2 Years,17 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,42,Denmark|United States|China|Taiwan|Thailand|Saudi Arabia|South Africa|Vietnam|Mexico|India|Malaysia|Brazil|Singapore
NCT01842594,A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma,A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma,TERMINATED,2012-08,2015-01,2015-11-03,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sarcoma,Sirolimus and hydroxychloroquine,DRUG,1,1,21 Years,75 Years,ALL,False,Shin Kong Wu Ho-Su Memorial Hospital,OTHER,0,1,Taiwan
NCT02308956,Task Sharing for the Care of Severe Mental Disorders in a Low-income Country,"Task Sharing for the Care of Severe Mental Disorders in a Low-income Country: a Randomised, Controlled Non-inferiority Trial",COMPLETED,2015-03,2017-11-16,2017-11-29,INTERVENTIONAL,PHASE3,324.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,SINGLE,Schizophrenia|Bipolar Disorder|Major Depressive Disorder|Schizoaffective Disorder,Integrated mental health in primary care|Psychiatric nurse-led specialist care,BEHAVIORAL,1,13,25 Years,,ALL,False,University of Cape Town,OTHER,5,1,Ethiopia
NCT01608022,A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus,,COMPLETED,2012-07,2015-10,2016-09-07,INTERVENTIONAL,PHASE2,48.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Esophageal Squamous Cell Carcinoma,PF804,DRUG,1,0,20 Years,,ALL,False,Yonsei University,OTHER,0,1,South Korea
NCT03135522,Pilot of Zinc Acetate to Improve Chronic Cough,Pilot of Zinc Acetate to Improve Chronic Cough,COMPLETED,2018-02-14,2019-12-11,2021-01-20,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cough,Zinc Acetate 50 Mg Oral Capsule|Placebo oral capsule,DRUG,1,3,18 Years,,ALL,False,Johns Hopkins University,OTHER,2,5,United States
NCT02157922,A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis,"A Double-blind, Randomized, Placebo-controlled Cross Over Study of Inhaled Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis",COMPLETED,2014-10,2017-09,2018-04-19,INTERVENTIONAL,PHASE2,65.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Cystic Fibrosis,alginate oligosaccharide,DRUG,1,1,18 Years,,ALL,False,AlgiPharma AS,INDUSTRY,2,18,Denmark|Norway|United Kingdom|Germany|Sweden
NCT01889251,A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion,A Phase III Study of A01016 125μg Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection,COMPLETED,2013-07,2014-09,2015-11-30,INTERVENTIONAL,PHASE3,251.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Symptomatic Vitreomacular Adhesion,Ocriplasmin|Sham injection,DRUG,1,0,20 Years,,ALL,False,Alcon Research,INDUSTRY,0,1,Japan
NCT05230251,Radioligand fOr locAl raDiorecurrent proStaTe cancER,Radioligand fOr locAl raDiorecurrent proStaTe cancER,COMPLETED,2022-03-17,2024-12-31,2025-09-12,INTERVENTIONAL,PHASE1|PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,177Lu-PNT2002|High Dose Radiation,RADIATION|DRUG,1,1,18 Years,,MALE,False,Glenn Bauman,OTHER,1,1,Canada
NCT05101629,Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy,A Phase-II Open-label Study of Pembrolizumab and Lenvatinib in Patients With Advanced Stage Hepatocellular Carcinoma Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy,COMPLETED,2022-05-11,2025-06-30,2025-07-23,INTERVENTIONAL,PHASE2,32.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma,Pembrolizumab|Lenvatinib Capsules,DRUG,1,3,18 Years,,ALL,False,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,OTHER,2,12,Germany
NCT05290545,Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT,A Comparative Study of Haploidentical Transplantation Supported by Third-party Cord Blood and Haploidentical Transplantation in Hematological Malignancies,COMPLETED,2022-02-15,2024-03-30,2024-08-13,INTERVENTIONAL,PHASE3,314.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hematological Malignancies|Hematopoietic Stem Cell Transplantation,PBSCs|Cord|BMSCs,OTHER,1,5,18 Years,65 Years,ALL,False,"Nanfang Hospital, Southern Medical University",OTHER,6,1,China
NCT05119972,"Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）","A Multi-center, Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, PK and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis",COMPLETED,2021-10-21,2023-12-21,2025-03-19,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Idiopathic Pulmonary Fibrosis (IPF),ZSP1603|Placebo,DRUG,2,2,40 Years,,ALL,False,"Guangdong Raynovent Biotech Co., Ltd",INDUSTRY,0,1,China
NCT04442295,An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome,An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome,COMPLETED,2020-06-29,2023-11-14,2025-05-18,INTERVENTIONAL,PHASE1|PHASE2,62.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Dravet Syndrome,STK-001 - Single Ascending Doses|STK-001 - Multiple Ascending Doses,DRUG,3,4,2 Years,18 Years,ALL,False,"Stoke Therapeutics, Inc",INDUSTRY,0,18,United States
NCT01255475,Blood Pressure Reduction in Heart Failure,"Effect of Blood Pressure Reduction in Patients With Chronic Heart Failure - Randomized, Double-blind, Placebo-controlled Trial",COMPLETED,2011-01,2013-01,2014-06-10,INTERVENTIONAL,PHASE2|PHASE3,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Heart Failure|Cardiac Failure|Congestive Heart Failure,Hydralazine/amlodipine|Placebo,DRUG,2,7,18 Years,,ALL,False,University of Sao Paulo,OTHER,1,1,Brazil
NCT04858139,Exploring the Effect of Lactate Administration After Ischemic Stroke on Brain Metabolism,"""Exploration de l'Effet Sur le métabolisme cérébral de l'Administration de Lactate après Accident Vasculaire cérébral Chez l'Homme"" (French Title)",TERMINATED,2021-08-05,2025-03-27,2025-04-17,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Stroke, Acute",Lactate|Placebo,DRUG,2,7,18 Years,,ALL,False,Centre Hospitalier Universitaire Vaudois,OTHER,0,1,Switzerland
NCT01574612,Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old,An Open Label Multi Center Phase III Subject/Caregiver Initiated Safety Study of Xerese(Acyclovir and Hydrocortisone)Cream 5%/1% in the Treatment of Recurrent Herpes Labialis in Children,COMPLETED,2012-03,2013-02,2014-05-22,INTERVENTIONAL,PHASE3,54.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Herpes Labialis,acyclovir/hydrocortisone cream,DRUG,1,0,6 Years,11 Years,ALL,False,Meda Pharmaceuticals,INDUSTRY,1,10,United States
NCT02755246,Polyamine-enriched Diet in Healthy Older Adults With Subjective Cognitive Decline,Effect of Polyamine-enriched Dietary Supplementation on Cognitive Function in Healthy Older Adults With Subjective Cognitive Decline,COMPLETED,2016-04,2016-09,2021-04-26,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Subjective Cognitive Decline,Polyamine supplementation|Placebo supplementation,DIETARY_SUPPLEMENT,1,2,60 Years,80 Years,ALL,True,"Charite University, Berlin, Germany",OTHER,2,1,Germany
NCT07212946,Ayahuasca and Esketamine for Major Depression,Four Doses of Ayahuasca or Esketamine in Major Depressive Disorder: a Double-blind Randomized Trial,COMPLETED,2022-10-30,2025-10-01,2025-12-29,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Major Depression Severe,Ayahuasca|Esketamine,DRUG,1,0,18 Years,65 Years,ALL,False,University of Sao Paulo,OTHER,0,1,Brazil
NCT02395627,Reversing Therapy Resistance With Epigenetic-Immune Modification,"Reversing Therapy Resistance With Epigenetic-immune Modification: Phase II Trial of Vorinostat, Tamoxifen and Pembrolizumab in Hormone Receptor Expressing Advanced Breast Cancer",TERMINATED,2015-05-04,2019-06-08,2020-07-07,INTERVENTIONAL,PHASE2,38.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Neoplasms,Tamoxifen|Vorinostat|Pembrolizumab,DRUG,2,5,18 Years,,ALL,False,"University of California, San Francisco",OTHER,2,1,United States
NCT02078661,Safety and Efficacy of PG101 for Dry Eye Syndrome,"A Single Center, Randomized, Double-Masked, Placebo Controlled Study Evaluating the Safety and Efficacy of 0.25% PG101 and 1.0% PG101 in Subjects With Dry Eye Syndrome",COMPLETED,2013-12,2014-01,2014-03-05,INTERVENTIONAL,PHASE1|PHASE2,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dry Eye Syndrome,PG101,DRUG,1,1,18 Years,,ALL,False,"Rhodes Pharmaceuticals, L.P.",INDUSTRY,1,1,United States
NCT01293461,Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes,"A Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration in Patients With Type 1 Diabetes Mellitus",COMPLETED,2011-04,2012-10,2013-03-01,INTERVENTIONAL,PHASE1|PHASE2,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 1 Diabetes|Diabetes Mellitus|Peripheral Diabetic Neuropathy,CBX129801|Placebo,DRUG,2,4,18 Years,65 Years,ALL,False,Cebix Incorporated,INDUSTRY,0,8,United States
NCT01262586,Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.,Pilot Study to Assess the Difference in Glycemic Profiles Between Vildagliptin and Glimepiride Using Continuous Glucose Monitoring Device,COMPLETED,2010-11,2011-03,2016-11-18,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,Vildagliptin|Glimepiride,DRUG,1,1,18 Years,70 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,1,Germany
NCT03442673,Chemotherapy and G-CSF for Mobilization,A Randomized Phase II Trial Comparing Stem Cell Mobilization With Chemotherapy and Cytokine (G-CSF) Versus Cytokine (G-CSF) Alone in Myeloma Patients (MOCCCA-trial).,COMPLETED,2018-09-17,2024-05-01,2025-03-28,INTERVENTIONAL,PHASE2,137.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Vinorelbine|Gemcitabine|G-CSF,DRUG,1,9,18 Years,,ALL,False,"Insel Gruppe AG, University Hospital Bern",OTHER,0,1,Switzerland
NCT01652469,Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.,A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor,COMPLETED,2012-08,2015-12,2022-08-24,INTERVENTIONAL,PHASE3,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Erlotinib|Docetaxel,DRUG,1,4,18 Years,,ALL,False,ETOP IBCSG Partners Foundation,NETWORK,1,32,Spain|Denmark|Italy|Belgium|United Kingdom|Ireland|Hungary|Austria|Israel|Netherlands|Switzerland|Greece
NCT02607683,Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags),"A Phase 2b/3, Multicenter, Dose-ranging, Randomized, Double-masked, Placebo-controlled Study of XAF5 Ointment for Reduction of Lower Lid Steatoblepharon",COMPLETED,2016-01-01,2016-10-31,2017-11-08,INTERVENTIONAL,PHASE2|PHASE3,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Steatoblepharon,XAF5 (concentration A: 0.1%)|XAF5 (concentration B: 0.035%)|Matching placebo,DRUG,1,0,40 Years,70 Years,ALL,False,"Topokine Therapeutics, Inc.",INDUSTRY,0,6,United States
NCT04574583,"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta ""Trap""/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)","Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta ""Trap""/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)",COMPLETED,2020-11-24,2023-05-19,2025-02-03,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Metastatic Cancer|Solid Tumors,SX-682|M7824|MVA-BN-CV301|recombinant fowlpox viral (FPV)-CV301,DRUG|BIOLOGICAL,5,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States
NCT05430854,Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study,An Open-Label Extension Study To Evaluate The Long- Term Safety And Tolerability Of Daxdilimab (Hzn-7734) In Subjects With Systemic Lupus Erythematosus,TERMINATED,2022-06-01,2023-10-31,2024-09-19,INTERVENTIONAL,PHASE2,155.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Systemic Lupus Erythematosus,Daxdilimab,BIOLOGICAL,3,3,18 Years,72 Years,ALL,False,Amgen,INDUSTRY,0,52,Spain|United States|Argentina|Taiwan|Poland|Serbia|Greece|Mexico|India
NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)","A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea",COMPLETED,2012-05-16,2015-03-20,2019-07-23,INTERVENTIONAL,PHASE3,606.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Clostridium Difficile Infection,Surotomycin|Vancomycin|Placebo,DRUG,4,10,18 Years,90 Years,ALL,False,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",INDUSTRY,0,0,
NCT02606266,Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance,Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance,TERMINATED,2017-07-11,2018-12-11,2019-11-18,INTERVENTIONAL,PHASE2|PHASE3,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Congenital Cytomegalovirus (CMV),Valganciclovir,DRUG,1,3,6 Months,12 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France
NCT04315051,A Trial of Safety/Efficacy of Test Article in Patients With Interdigital T. Pedis,"Clinical Trial Protocol DBI-204 Double-Blind, Randomized, Placebo Controlled Trial of the Safety and Efficacy of DBI-001 Gel in Patients With Interdigital Tinea Pedis",TERMINATED,2019-09-12,2020-06-30,2021-06-18,INTERVENTIONAL,PHASE2,39.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Interdigital Tinea Pedis,Cohort 1 J. Lividum|Placebo Gel,DRUG|OTHER,1,0,18 Years,,ALL,True,"DermBiont, Inc.",INDUSTRY,0,1,Dominican Republic
NCT03715829,A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects,"A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO",COMPLETED,2018-11-26,2021-02-05,2022-03-25,INTERVENTIONAL,PHASE2,366.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Active Non-segmental Vitiligo,PF-06651600|PF-06651600|PF-06651600|PF-06651600|PF-06651600|placebo|PF06700841|narrow-band UVB phototherapy,DRUG|DEVICE,9,24,18 Years,65 Years,ALL,False,Pfizer,INDUSTRY,0,92,Canada|United States|Australia|Belgium|Italy|Japan|Spain|South Korea|Taiwan|Germany
NCT01688037,NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder",COMPLETED,2012-09,2013-10,2017-11-08,INTERVENTIONAL,PHASE2,109.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Tardive Dyskinesia,NBI-98854|NBI-98854|Placebo,DRUG,1,2,18 Years,85 Years,ALL,False,Neurocrine Biosciences,INDUSTRY,0,51,Puerto Rico|United States
NCT04643639,Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis,An Open-label Randomized Controlled Experimental Endotoxemia Study on the Effects of the Cytokine-adsorber CytoSorb on the Development of Immunoparalysis in Humans,COMPLETED,2020-09-16,2022-10-19,2022-12-22,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Sepsis|Immune Deficiency|Hemoperfusion|Blood Purification,CytoSorb hemoperfusion,DEVICE,1,10,18 Years,35 Years,MALE,True,Radboud University Medical Center,OTHER,1,1,Netherlands
NCT03900377,Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma,"A Multicenter, Open-label, Phase I/II Study to Investigate the Safety and Tolerability of SyB L-0501RI (Bendamustine Hydrochloride for Injection) Administered As an Intravenous (IV) Rapid Infusion Over 10 Minutes",COMPLETED,2019-04-01,2021-02-26,2023-11-24,INTERVENTIONAL,PHASE1|PHASE2,37.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Lymphoma, B-cell, Diffuse",SyB L-0501RI,DRUG,6,7,20 Years,79 Years,ALL,False,SymBio Pharmaceuticals,INDUSTRY,0,14,Japan
NCT03215277,A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis,"A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis",COMPLETED,2017-10-04,2020-05-25,2023-07-27,INTERVENTIONAL,PHASE2,76.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ankylosing Spondylitis,Bimekizumab|Certolizumab pegol|Placebo,DRUG|OTHER,4,2,18 Years,,ALL,False,UCB Biopharma SRL,INDUSTRY,0,34,United States|Russia|Poland|Germany|Netherlands|Greece|Czechia|Moldova
NCT02918877,Anesthetics to Prevent Lung Injury in Cardiac Surgery,Anesthetics to Prevent Lung Injury in Cardiac Surgery,COMPLETED,2017-06-09,2021-02-01,2021-05-05,INTERVENTIONAL,PHASE1|PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Inflammatory Lung Injury|Ischemia-Reperfusion Lung Injury|Postoperative Pulmonary Complications,Sevoflurane|Propofol,DRUG,1,6,18 Years,,ALL,False,Beth Israel Deaconess Medical Center,OTHER,0,1,United States
NCT01748877,"Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia","A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)",COMPLETED,2013-01,2014-06,2014-06-19,INTERVENTIONAL,PHASE2,188.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Post Herpetic Neuralgia,NXN-462|Placebo,DRUG,1,8,18 Years,,ALL,False,NeurAxon Inc.,INDUSTRY,0,25,Canada|United States
NCT05776875,Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC,Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC,TERMINATED,2023-06-07,2024-12-05,2025-01-15,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Carcinoma,Atezolizumab Injection|Bevacizumab|Transarterial chemoembolization,DRUG|COMBINATION_PRODUCT,1,5,18 Years,,ALL,False,Yale University,OTHER,1,1,United States
NCT01971775,Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer,Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer: Conventional Monopolar Electrosurgery vs. Ultrasonically Activated Shear(UAS),COMPLETED,2011-08,,2013-10-29,INTERVENTIONAL,PHASE3,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Gastric Cancer,Ultrasonically activated Shears|Conventional Monopolar Electrocautery,DEVICE,2,5,20 Years,75 Years,ALL,False,Seoul National University Hospital,OTHER,1,1,South Korea
NCT04998201,Study of ARO-APOC3 in Adults With Mixed Dyslipidemia,"A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia",COMPLETED,2021-09-28,2023-08-14,2025-10-03,INTERVENTIONAL,PHASE2,353.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Mixed Dyslipidemia,ARO-APOC3|Placebo,DRUG,1,17,18 Years,,ALL,False,Arrowhead Pharmaceuticals,INDUSTRY,0,30,Canada|United States|Australia|Hungary|Poland|New Zealand
NCT03640481,Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy,"A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)",TERMINATED,2018-10-11,2023-12-11,2024-12-12,INTERVENTIONAL,PHASE2,159.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Graft-versus-host-disease,Belumosudil (KD025),DRUG,1,15,12 Years,,ALL,True,"Kadmon, a Sanofi Company",INDUSTRY,0,35,United States
NCT01294319,Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men,Evaluation of Cortisol Resistance in Young Sedentary and Endurance-trained Men and Elderly Sedentary Men,COMPLETED,2011-01-24,2016-08-10,2024-07-15,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Cortisol Resistance|Negative Feedback|ACTH|Mineralcorticoid|Glucocorticoid,Mifepristone|Placebo|Spironolactone|Combined|Dexamethasone,DRUG,1,1,18 Years,80 Years,MALE,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,0,1,United States
NCT07141446,Evaluation of Efficacy of Neem (Azadirachta Indica) Versus Triamcinolone Acetonide in the Treatment of Oral Lichen Planus.,Evaluation of Efficacy of Neem (Azadirachta Indica) Versus Triamcinolone Acetonide in the Treatment of Oral Lichen Planus: A Randomized Controlled Trial.,COMPLETED,2023-02-05,2024-02-28,2025-09-03,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Oral Lichen Planus,Neem gel|Triamcinolone Acetonide,DRUG,3,1,20 Years,85 Years,ALL,False,Goa Dental College,OTHER_GOV,0,1,India
NCT01795742,Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer,Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer in the Treatment of Mild to Moderate Asthma in El Salvador,COMPLETED,2012-08,2012-10,2013-02-21,INTERVENTIONAL,PHASE2,110.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Asthma,Human-Powered Nebulizer,DEVICE,1,1,6 Years,65 Years,ALL,False,Marquette University,OTHER,0,1,El Salvador
NCT04235686,8 Week Multi-site Study of MYDAYIS® for Bipolar Depression,An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS&#174; (D-amphetamine / L-amphetamine) for Bipolar Depression,COMPLETED,2020-07-17,2025-07-25,2025-08-12,INTERVENTIONAL,PHASE2,74.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Bipolar Depression,Mydayis Extended-Release Capsule|Placebo,DRUG,1,12,18 Years,55 Years,ALL,False,Mayo Clinic,OTHER,1,2,United States
NCT03538054,Dextromethorphan in Fibromyalgia,Dextromethorphan in Fibromyalgia,COMPLETED,2018-06-26,2020-03-18,2022-08-26,INTERVENTIONAL,PHASE2,27.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,OTHER,SINGLE,Fibromyalgia,Dextromethorphan|Placebo,DRUG,1,2,23 Years,65 Years,FEMALE,False,University of Alabama at Birmingham,OTHER,0,1,United States
NCT02088541,Selinexor (KPT-330) in Older Patients With Relapsed AML,"A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation",COMPLETED,2014-03,2018-01-08,2023-01-26,INTERVENTIONAL,PHASE2,317.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myeloid Leukemia (AML),Selinexor|Hydroxyurea|Ara-C,DRUG,1,11,60 Years,,ALL,False,Karyopharm Therapeutics Inc,INDUSTRY,0,78,Canada|Denmark|United States|Italy|Spain|United Kingdom|France|Poland|Germany|Israel|Netherlands
NCT02443805,Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR,"A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis",COMPLETED,2015-09-29,2018-06-25,2019-10-14,INTERVENTIONAL,PHASE3,1607.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Rhinitis, Allergic, Perennial|House Dust Mite Allergy",300 IR|Placebo,BIOLOGICAL,1,2,12 Years,65 Years,ALL,False,Stallergenes Greer,INDUSTRY,0,2,United States|France
NCT02306694,Prospective Biomarkers of Bone Metabolism in Hemophilia A,Prospective Biomarkers of Bone Metabolism in Hemophilia A,COMPLETED,2014-12,2018-04-16,2020-04-01,INTERVENTIONAL,PHASE3,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hemophilia|Bone Disease,Advate,DRUG,4,0,16 Years,85 Years,MALE,False,Oregon Health and Science University,OTHER,1,1,United States
NCT01451866,Comparison Between Classic Leg-press Training and Complex Leg-press Training on a Dynamic Leg-press,Comparison of a Classic Leg-press Training Compared to a Complex Training on a Dynamic Leg-press With Visual Feed-back. Pilot-study,COMPLETED,2011-09,2011-11,2014-11-25,INTERVENTIONAL,PHASE2|PHASE3,34.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Healthy,resistance training|complex resistance training,OTHER,1,3,18 Years,65 Years,ALL,True,University of Applied Sciences of Western Switzerland,OTHER,0,1,Switzerland
NCT02434822,A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic,Safety and Immunogenicity of Two Doses of Oral Cholera Vaccine (ShancholTM) in Subjects Aged 1 Year and Older in Dominican Republic,COMPLETED,2015-04,2016-07,2018-03-26,INTERVENTIONAL,PHASE3,336.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Cholera,Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell,BIOLOGICAL,2,1,1 Year,,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,1,Dominican Republic
NCT00379522,Vasopressin in Traumatic Hemorrhagic Shock Study,"A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin Versus Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS-study)",COMPLETED,2010-07,2014-10,2014-11-05,INTERVENTIONAL,PHASE2|PHASE3,64.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Shock|Hypovolemia|Hemorrhagic Shock,Vasopressin|Saline placebo,DRUG,1,3,18 Years,,ALL,False,Volker Wenzel,OTHER,0,14,Germany|Austria
NCT02319031,"Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis","Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4)",COMPLETED,2015-02,2015-12,2017-01-27,INTERVENTIONAL,PHASE3,53.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatitis C,Daclatasvir|Sofosbuvir|Ribavirin,DRUG,1,2,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,10,Australia|France
NCT01268202,Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis,Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis,COMPLETED,2010-12-17,2019-04-18,2019-06-13,INTERVENTIONAL,PHASE2,61.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fibrosis,Pravastatin,DRUG,1,2,18 Years,,ALL,False,"Gustave Roussy, Cancer Campus, Grand Paris",OTHER,1,3,France
NCT03898102,Zinc Supplement in Regorafenib Treated mCRC Patient,Zinc Supplement in Metastatic Colorectal Cancer Patients Receiving Regorafenib: Phase II Prospective Randomized Trial,COMPLETED,2016-03,2019-03,2019-04-01,INTERVENTIONAL,PHASE2,65.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Colorectal Cancer Metastatic,Regorafenib|Zinc gluconate supplement,DRUG|DIETARY_SUPPLEMENT,1,8,20 Years,,ALL,False,Chang Gung Memorial Hospital,OTHER,0,0,
NCT02677545,Ticagrelor Versus Clopidogrel in Carotid Artery Stenting,Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A Randomised Multi-centre Phase II Trial Comparing Ticagrelor Versus Clopidogrel With Outcome Assessment on MRI (PRECISE-MRI),COMPLETED,2016-12,2022-04-28,2022-06-28,INTERVENTIONAL,PHASE2,210.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Carotid Artery Stenosis,Ticagrelor|Clopidogrel|Aspirin,DRUG,1,4,40 Years,,ALL,False,"University Hospital, Basel, Switzerland",OTHER,0,15,Italy|Belgium|United Kingdom|Switzerland|Germany|Netherlands
NCT02342795,Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation,Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation,COMPLETED,2015-06,2018-07,2018-09-07,INTERVENTIONAL,PHASE1|PHASE2,520.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Nontherapeutic,e-cigarette|cigarette substitute,OTHER,1,2,21 Years,65 Years,ALL,True,Virginia Commonwealth University,OTHER,3,2,United States
NCT01734239,A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018),"A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population",COMPLETED,2013-06-03,2013-10-22,2018-10-30,INTERVENTIONAL,PHASE3,102.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Pneumococcal Disease,Pneumovax™ 23,BIOLOGICAL,5,0,2 Years,,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,0,
NCT03448939,A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea,"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea",COMPLETED,2018-06-18,2019-05-24,2021-12-14,INTERVENTIONAL,PHASE3,361.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Papulopustular Rosacea,S5G4T-1|S5G4T-2,DRUG,2,1,18 Years,,ALL,False,"Sol-Gel Technologies, Ltd.",INDUSTRY,0,1,United States
NCT02223039,A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis,"Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of AbGn-168H Administered by Intravenous Infusion to Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Double-blind, Placebo-controlled)",COMPLETED,2014-05,2015-02,2016-04-14,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Moderate to Severe Chronic Plaque Psoriasis,AbGn-168H|Placebo,BIOLOGICAL,1,7,18 Years,75 Years,ALL,False,AbGenomics B.V Taiwan Branch,INDUSTRY,0,15,United States
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,"A Prospective, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Pilot Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery",COMPLETED,2010-07,2015-08,2017-03-22,INTERVENTIONAL,PHASE3,49.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Gastric Bypass|Parathyroid Hormone,Paricalcitol|Cholecalciferol|Placebo,DRUG,1,8,18 Years,100 Years,ALL,True,"Kerstyn C. Zalesin, M.D.",OTHER,1,1,United States
NCT03845075,"48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)","A 24-week Phase 2, Double-blind, Randomized, Placebo- Controlled, Single-center Safety and Efficacy Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO), and With a 24-week Open-label Extension, in Total 48 Weeks",COMPLETED,2019-02-25,2020-10-16,2024-02-13,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypothalamic Injury-induced Obesity (HIO),Tesofensine/Metoprolol|Placebo,DRUG,9,17,18 Years,75 Years,ALL,False,Saniona,INDUSTRY,0,1,Denmark
NCT01626495,Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma,CHP 959 - A Phase I/IIA Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant Or Refractory CD19+ Leukemia and Lymphoma,COMPLETED,2011-08-17,2019-07-11,2020-03-23,INTERVENTIONAL,PHASE1|PHASE2,73.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,B Cell Leukemia|B Cell Lymphoma,CART-19,BIOLOGICAL,1,3,1 Year,24 Years,ALL,False,University of Pennsylvania,OTHER,0,1,United States
NCT04412057,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury",COMPLETED,2020-07-17,2021-01-19,2022-03-24,INTERVENTIONAL,PHASE2,88.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,COVID-19 Pneumonia|Acute Lung Injury|ARDS,CERC-002|Placebo,DRUG,1,1,18 Years,,ALL,False,"Aevi Genomic Medicine, LLC, a Cerecor company",INDUSTRY,0,11,United States
NCT04678557,"A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus","An Open-Label Phase 1/2 Study to Evaluate the Safety, Engraftment, and Efficacy of VC-01™Combination Product in Subjects With Type 1 Diabetes Mellitus [T1DM]",TERMINATED,2019-06-25,2021-11-19,2023-10-18,INTERVENTIONAL,PHASE1|PHASE2,31.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,OTHER,NONE,Type 1 Diabetes,VC-01 Combination Product,COMBINATION_PRODUCT,2,0,18 Years,65 Years,ALL,False,ViaCyte,INDUSTRY,0,4,United States
NCT02660112,(+) Epicatechin to Treat Friedreich's Ataxia,"A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia",COMPLETED,2016-09,2018-12-30,2019-12-05,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Friedreich's Ataxia,(+)-Epicatechin,DRUG,2,0,10 Years,50 Years,ALL,False,Ralitza Gavrilova,OTHER,1,1,United States
NCT01629381,Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy,Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy: a Randomized Double-blind Trial (ERIKA Study),COMPLETED,2012-05,2014-03,2021-05-21,INTERVENTIONAL,PHASE2,500.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Venous Thromboembolism|Haemorrhage,Rivaroxaban|placebo,DRUG,2,2,18 Years,,ALL,False,University of Padova,OTHER,0,9,Italy
NCT01453881,Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation,Randomized Clinical Trials to Compare Asthma Control Efficacy of the Fine-particle Combination Formoterol/Beclomethasone by pMDI Administered With and Without Spacer.,COMPLETED,2011-04,2013-06,2015-03-31,INTERVENTIONAL,PHASE3,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Asthma,Spacer|Comparator,DEVICE,1,1,18 Years,65 Years,ALL,False,Universidade Federal de Pernambuco,OTHER,1,1,Brazil
NCT04828161,"A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19","A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 - The ""EMPATHY"" Trial",TERMINATED,2021-05-10,2022-01-27,2026-01-27,INTERVENTIONAL,PHASE2|PHASE3,407.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19,ensovibep|Placebo,DRUG,2,16,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,1,48,United States|Hungary|South Africa|Netherlands|India
NCT03070886,Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel,COMPLETED,2017-04-05,2025-10-31,2026-01-14,INTERVENTIONAL,PHASE2|PHASE3,612.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Stage I Prostate Adenocarcinoma AJCC v7|Stage II Prostate Adenocarcinoma AJCC v7|Stage III Prostate Adenocarcinoma AJCC v7,Bicalutamide|Degarelix|Docetaxel|External Beam Radiation Therapy|Flutamide|Goserelin|Goserelin Acetate|Laboratory Biomarker Analysis|Leuprolide|Leuprolide Acetate|Nilutamide,RADIATION|DRUG|OTHER,2,6,18 Years,,MALE,False,NRG Oncology,OTHER,1,313,Canada|United States|Puerto Rico
NCT01967173,Best African American Response to Asthma Drugs,Best African American Response to Asthma Drugs,COMPLETED,2014-02,2017-07-01,2018-11-15,INTERVENTIONAL,PHASE3,574.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Asthma,Flovent Diskus® 100 mcg|Flovent Diskus® 250 mcg|Flovent Diskus® 500 mcg|Advair Diskus® 100/50 mcg|Advair Diskus® 250/50 mcg,DRUG,1,0,5 Years,,ALL,False,Milton S. Hershey Medical Center,OTHER,1,28,United States
NCT01531673,Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation,"A Phase 2, Multicenter, Double-Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",COMPLETED,2012-02,2014-03,2018-04-13,INTERVENTIONAL,PHASE2,194.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cystic Fibrosis,VX-661|Ivacaftor|Placebo matched to VX-661|Placebo matched to ivacaftor,DRUG,4,14,12 Years,,ALL,False,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,36,Canada|United States|Germany|United Kingdom
NCT02730169,Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism,"A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism",COMPLETED,2016-05-12,2018-05-19,2022-09-14,INTERVENTIONAL,PHASE2,271.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypogonadotropic Hypogonadism,BGS649|Placebo,DRUG,1,7,18 Years,65 Years,MALE,False,Mereo BioPharma,INDUSTRY,0,63,Spain|United States|Italy|United Kingdom
NCT02491983,"Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer","A Randomized, Multicenter, Open-label, Phase II Trial to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With HER2 Negative, ER+ Metastatic Breast Cancer",COMPLETED,2015-08,2020-01,2024-12-09,INTERVENTIONAL,PHASE2,486.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Breast Cancer,Palbociclib|Fulvestrant|Letrozole,DRUG,1,5,18 Years,,FEMALE,False,MedSIR,OTHER,0,48,Spain|Italy|United Kingdom|Russia|France|Germany|Czechia
NCT02802254,Increasing Risk Perception of Physical Activity Using Patient-targeted Feedback.,Increasing Risk Perception of Physical Activity Using Patient-targeted Feedback: Randomized Controlled Trial.,COMPLETED,2016-08,2017-06,2022-08-09,INTERVENTIONAL,PHASE2|PHASE3,121.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Hypertension|Coronary Disease|Cardiac Diseases,Patient-targeted individual physical-activity-feedback|Pedometer,DEVICE|BEHAVIORAL,1,10,18 Years,75 Years,ALL,False,Universitätsklinikum Hamburg-Eppendorf,OTHER,0,2,Germany
NCT01433354,"Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)",An Open-label Study to Evaluate the Long-term Safety and Tolerability of AFQ056 in Adolescent Patients With Fragile X Syndrome,TERMINATED,2011-11,2014-09,2016-03-24,INTERVENTIONAL,PHASE2|PHASE3,119.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fragile X Syndrome,AFQ056,DRUG,1,0,12 Years,18 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,28,Spain|Denmark|United States|Australia|Belgium|Italy|United Kingdom|France|Germany|Israel|Netherlands|Switzerland|Sweden
NCT02263105,Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas,Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas: A Single-arm Prospective Phase II Clinical Study,COMPLETED,2014-10,2018-06,2018-07-17,INTERVENTIONAL,PHASE2,67.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,High-grade Gliomas,CDDP|Temozolomide,DRUG,1,1,18 Years,75 Years,ALL,False,Huashan Hospital,OTHER,0,1,China
NCT03541005,Evaluation of Obex® in Overweight and Obesity,Efficacy and Safety of the Obex® Nutritional Supplement in Overweight and Obese Subjects: Phase III.,COMPLETED,2018-10-01,2021-07-03,2021-10-21,INTERVENTIONAL,PHASE3,160.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Overweight and Obesity,Obex|Placebo,DIETARY_SUPPLEMENT,3,13,20 Years,65 Years,ALL,False,Catalysis SL,INDUSTRY,0,1,Cuba
NCT01085266,An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease,HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease,TERMINATED,2010-02,,2016-10-12,INTERVENTIONAL,PHASE3,362.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Huntington Disease,Dimebon (latrepirdine),DRUG,0,0,30 Years,,ALL,False,"Medivation, Inc.",INDUSTRY,1,0,
NCT04579666,MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)",TERMINATED,2020-09-30,2023-07-13,2025-04-24,INTERVENTIONAL,PHASE2,249.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Pegcetacoplan (APL-2)|Placebo,DRUG|OTHER,5,11,18 Years,,ALL,False,"Apellis Pharmaceuticals, Inc.",INDUSTRY,0,60,Japan|United States|Australia|Belgium|Italy|Spain|Ireland|Ukraine|United Kingdom|France|Poland|Germany|Netherlands|Czechia
NCT02314156,Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy,Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy,COMPLETED,2015-10,2021-05,2023-02-22,INTERVENTIONAL,PHASE2,67.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ductal Breast Carcinoma In Situ|Lobular Breast Carcinoma In Situ|Stage 0 Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer,Telapristone Acetate|Placebo|Telapristone Acetate|Placebo|Laboratory Biomarker Analysis|Questionnaire Administration,DRUG|OTHER,1,7,18 Years,,FEMALE,False,Northwestern University,OTHER,1,3,United States
NCT02154529,Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,TERMINATED,2014-05,2015-09-13,2022-04-27,INTERVENTIONAL,PHASE1|PHASE2,17.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,HER-2 Positive Breast Cancer|Metastatic Malignant Neoplasm to Brain,Tesevatinib|Trastuzumab,DRUG,2,5,18 Years,,FEMALE,False,"Kadmon Corporation, LLC",INDUSTRY,0,6,United States
NCT05280002,Adipose-tissue-derived Total-Stromal-cells (TOST) Therapy in Knee Osteoarthritis,Outcomes of Single Intra-articular Injection of Adipose-tissue-derived Total-Stromal-cells (TOST) Therapy in Knee Osteoarthritis,COMPLETED,2018-01-01,2021-12-31,2022-03-15,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Osteoarthritis Knees,Adipose Tissue derived Total-Stromal-Cells (TOST),BIOLOGICAL,3,0,40 Years,80 Years,ALL,False,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",OTHER,1,1,Bangladesh
NCT06083753,Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 as an Adjunctive Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2023-11-06,2025-08-04,2025-10-23,INTERVENTIONAL,PHASE2,182.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Relapsing Remitting Multiple Sclerosis,PIPE-307 Dose A|PIPE-307 Dose B|Placebo,DRUG,2,8,18 Years,50 Years,ALL,False,Contineum Therapeutics,INDUSTRY,0,21,United States
NCT02392637,"Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers","A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers",COMPLETED,2015-04-02,2020-08-13,2022-02-02,INTERVENTIONAL,PHASE2,62.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stage III Intrahepatic Cholangiocarcinoma AJCC v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7|Stage IVB Gallbladder Cancer AJCC v7|Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma,Cisplatin|Gemcitabine Hydrochloride|Laboratory Biomarker Analysis|Nab-paclitaxel,DRUG|OTHER,1,2,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,3,United States
NCT02927145,"A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate","A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/AS01",COMPLETED,2016-10-17,2019-06-27,2022-02-18,INTERVENTIONAL,PHASE1|PHASE2,88.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Malaria,RH5.1/ ASO1,BIOLOGICAL,3,3,18 Years,45 Years,ALL,True,University of Oxford,OTHER,0,2,United Kingdom
NCT05297045,A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Oral RGT001-075 in Adult Patients With Uncontrollable Type 2 Diabetes Mellitus on Metformin Therapy",TERMINATED,2022-03-29,2023-05-30,2023-11-18,INTERVENTIONAL,PHASE2,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,RGT001-075|Placebo,DRUG|OTHER,1,37,18 Years,75 Years,ALL,False,Regor Pharmaceuticals Inc.,INDUSTRY,0,1,United States
NCT04625972,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19",COMPLETED,2020-12-02,2022-07-25,2023-11-21,INTERVENTIONAL,PHASE3,1131.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,COVID-19,AZD7442|Placebo,DRUG,2,6,18 Years,120 Years,ALL,False,AstraZeneca,INDUSTRY,1,57,United States|United Kingdom
NCT04480372,SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II,"Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts",COMPLETED,2021-03-17,2024-04-03,2024-07-01,INTERVENTIONAL,PHASE2,68.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Malignant Pleural Mesothelioma|Non-small Cell Lung Cancer,Gemcitabine|Atezolizumab,DRUG,2,12,18 Years,,ALL,False,Swiss Cancer Institute,OTHER,0,12,Switzerland
NCT04451772,A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State,"A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)",COMPLETED,2020-07-27,2024-01-03,2025-01-14,INTERVENTIONAL,PHASE2,185.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Systemic Lupus Erythematosus (SLE),Elsubrutinib|Placebo for Elsubrutinib|Upadacitinib|Placebo for Upadacitinib,DRUG,1,4,18 Years,65 Years,ALL,False,AbbVie,INDUSTRY,0,87,Japan|United States|China|Australia|Colombia|Italy|Puerto Rico|South Korea|Spain|Argentina|United Kingdom|Hungary|Taiwan|Poland|Germany|New Zealand|Mexico|Bulgaria
NCT02258295,Hyaluronate Injection for Lateral Epicondylitis,Hyaluronate Injection for Lateral Epicondylitis: A Double-blind Randomized Controlled Trial,COMPLETED,2017-01-18,2019-09-01,2020-04-24,INTERVENTIONAL,PHASE3,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Tennis Elbow,Intragel|Saline,DRUG,1,2,18 Years,80 Years,ALL,False,Shaare Zedek Medical Center,OTHER,0,1,Israel
NCT01908595,Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis,"An Open-label, Multi-center, Long-term Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis",COMPLETED,2013-08,2015-05,2015-09-02,INTERVENTIONAL,PHASE3,480.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Psoriasis,M518101,DRUG,1,0,18 Years,,ALL,False,Maruho North America Inc.,INDUSTRY,0,31,United States
NCT05174039,"An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease","An Open-label Safety, Pharmacokinetic, and Efficacy Study of the Combination of Miglustat for the Treatment of CLN3 Disease in Patients 17 Years of Age and Older",COMPLETED,2022-03-10,2024-05-30,2025-09-09,INTERVENTIONAL,PHASE1|PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Batten Disease,Miglustat 100 milligrams (mg) Oral Capsule,DRUG,1,6,17 Years,,ALL,False,Beyond Batten Disease Foundation,OTHER,1,1,United States
NCT04399239,AuriNovo for Auricular Reconstruction,"A Multicenter, Single Arm, Prospective, Open-Label, Staged Study of the Safety and Efficacy of the AuriNovo Construct for Auricular Reconstruction in Subjects With Unilateral Microtia",TERMINATED,2021-08-09,2023-05-18,2024-03-04,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Microtia,AuriNovo,COMBINATION_PRODUCT,3,0,6 Years,25 Years,ALL,False,3DBio Therapeutics,INDUSTRY,0,2,United States
NCT05144139,A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above,"A Phase I/II Clinical Trial to Evaluate the Safety, Immunogenicity and Immune Persistence of COVID-19 mRNA Vaccine in Healthy People Aged 18 Years and Above.",COMPLETED,2021-12-03,2022-11-11,2022-12-28,INTERVENTIONAL,PHASE1|PHASE2,480.0,ACTUAL,RANDOMIZED,SEQUENTIAL,PREVENTION,DOUBLE,COVID-19 Pandemic,COVID-19 mRNA vaccine,BIOLOGICAL,3,3,18 Years,,ALL,True,Stemirna Therapeutics,INDUSTRY,0,1,Laos
NCT06060977,"A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants","A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants With 50% or Greater Scalp Hair Loss",COMPLETED,2023-09-25,2025-01-14,2025-04-30,INTERVENTIONAL,PHASE1|PHASE2,29.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Alopecia Areata (AA),IMG-007,DRUG,1,1,18 Years,65 Years,ALL,False,Inmagene LLC,INDUSTRY,0,17,Canada|United States
NCT04427501,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,"A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness",COMPLETED,2020-06-17,2023-02-21,2024-04-11,INTERVENTIONAL,PHASE2|PHASE3,3307.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,COVID-19,LY3819253|LY3832479|LY3853113|Placebo,DRUG,7,19,0 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,2,12,United States
NCT05157412,Role of Doxycycline in Chronic Rhinosinusitis With Nasal Polyps,Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps,COMPLETED,2021-07-01,2024-01-01,2024-08-13,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Nasal Polyps|Chronic Rhinosinusitis With Nasal Polyps,Doxycycline 100 mg Oral Tablet|Prednisolone 20 mg,DRUG,2,2,18 Years,80 Years,ALL,False,Assiut University,OTHER,0,1,Egypt
NCT02274766,Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia,ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study),COMPLETED,2014-10,2016-03-10,2018-01-10,INTERVENTIONAL,PHASE3,77.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dyskinesia|Levodopa-Induced Dyskinesia (LID)|Parkinson's Disease (PD),ADS-5102|Placebo,DRUG|OTHER,1,1,30 Years,85 Years,ALL,False,"Adamas Pharmaceuticals, Inc.",INDUSTRY,0,51,Spain|United States|France|Germany|Austria
NCT02793622,Prevention of Malaria in HIV-uninfected Pregnant Women and Infants,Prevention of Malaria in HIV-uninfected Pregnant Women and Infants,COMPLETED,2016-09,2018-12-04,2021-04-14,INTERVENTIONAL,PHASE3,782.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Malaria,Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy,DRUG,3,11,16 Years,,FEMALE,True,"University of California, San Francisco",OTHER,2,1,Uganda
NCT01165229,"Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older","Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older",COMPLETED,2010-08-02,2015-07-24,2020-04-27,INTERVENTIONAL,PHASE3,14819.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Herpes Zoster|Herpes Zoster Vaccine,Herpes Zoster Vaccine GSK1437173A|Placebo,BIOLOGICAL,3,27,70 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,0,213,Canada|United States|Australia|Italy|Japan|Mexico|Spain|Hong Kong|Finland|South Korea|France|United Kingdom|Taiwan|Germany|Czechia|Sweden|Estonia|Brazil
NCT04101331,Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides,A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT),COMPLETED,2019-11-13,2024-01-11,2024-11-05,INTERVENTIONAL,PHASE2,108.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Peripheral T Cell Lymphoma|Transformed Mycosis Fungoides,AFM13,DRUG,1,16,18 Years,,ALL,False,Affimed GmbH,INDUSTRY,0,69,Spain|United States|Australia|Italy|South Korea|Russia|France|Poland|Germany|Turkey (Türkiye)
NCT01566331,Safe Delivery Using a Belt on the Belly of Pregnant Woman,Safe Natural Delivery by Using a New Inflatable Ergonomic Three Chambers Belt,COMPLETED,2011-01,2011-03,2016-12-12,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,SINGLE,Other Obstetric Trauma - Delivered,Baby-guardTM,DEVICE,1,0,23 Years,42 Years,FEMALE,True,University of Padova,OTHER,1,1,Italy
NCT01662037,Bosentan Therapy in Children With Functional Single Ventricle,Bosentan Therapy for High Risk Staged Fontan Procedure in Children With Functional Single Ventricle,COMPLETED,2010-01,2012-06,2012-08-10,INTERVENTIONAL,PHASE2,34.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Congenital Heart Defects|Functional Single Ventricle,Bosentan,DRUG,1,2,4 Months,18 Years,ALL,False,Shanghai Jiao Tong University School of Medicine,OTHER,0,1,China
NCT02366637,An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease,"A Randomized, Double-blind, Placebo-controlled 2-way Crossover Study To Evaluate The Efficacy, Safety And Tolerability Of Pf-03715455 Administered Twice Daily By Inhalation For 4 Weeks In Subjects With Moderate To Severe Chronic Obstructive Pulmonary Disease (Copd)",TERMINATED,2015-01,2015-05,2016-07-06,INTERVENTIONAL,PHASE2,13.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Pulmonary Disease, Chronic Obstructive",Placebo|PF-03715455,DRUG,1,5,40 Years,80 Years,ALL,False,Pfizer,INDUSTRY,0,5,United Kingdom
NCT01541345,Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2,"A Phase III, Randomized, Controlled Clinical Trial of Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2",COMPLETED,2011-02,2019-06-04,2021-12-02,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Missing Teeth,Autogenous bone graft|InductOs|Augmentation surgery,PROCEDURE|DRUG|DEVICE,1,3,20 Years,75 Years,ALL,False,University of Zurich,OTHER,0,2,Switzerland|Austria
NCT03343145,"A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients","A Randomized, Open-label, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy",COMPLETED,2017-01-12,2019-07-29,2020-12-28,INTERVENTIONAL,PHASE3,143.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Breast Cancer,Leucostim 5µg/kg/day|Neupogen 5µg/kg/day,BIOLOGICAL,1,3,18 Years,70 Years,FEMALE,False,"Dong-A ST Co., Ltd.",INDUSTRY,0,1,Indonesia
NCT04571645,Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination With Standard Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",TERMINATED,2021-04-30,2022-05-16,2024-04-15,INTERVENTIONAL,PHASE3,9.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Myeloid Leukemia,Dociparstat|Control,DRUG|OTHER,1,0,18 Years,,ALL,False,Jazz Pharmaceuticals,INDUSTRY,0,14,United States
NCT02518672,Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC),Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.,TERMINATED,2015-10,2016-11,2017-10-04,INTERVENTIONAL,PHASE2,11.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Cystic Fibrosis,MAG-DHA|Placebo,DIETARY_SUPPLEMENT,1,10,18 Years,,ALL,False,SCF Pharma,INDUSTRY,2,1,Canada
NCT01175395,20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD),An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD,COMPLETED,2010-09,2013-01,2014-10-20,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Age-Related Macular Degeneration|Choroidal Neovascularization,IBI-20089/Lucentis,DRUG,1,1,55 Years,,ALL,False,University of Illinois at Chicago,OTHER,1,1,United States
NCT05512377,"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours",COMPLETED,2022-12-13,2025-09-25,2026-01-21,INTERVENTIONAL,PHASE2,99.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Neoplasms|Solid Tumors|Biliary Tract Cancer|Lung Neoplasms|Bladder Cancer,brigimadlin,DRUG,1,10,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,60,Japan|United States|Australia|Belgium|Spain|United Kingdom|South Korea|France|Taiwan|Thailand|Saudi Arabia|Austria|Germany|South Africa|Switzerland|Singapore
NCT01721577,Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas,"Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas",TERMINATED,2012-12,2015-12,2023-05-22,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Anaplastic Ependymoma,AXL1717,DRUG,2,6,18 Years,,ALL,False,Rush University Medical Center,OTHER,1,1,United States
NCT02901275,Enhancing Medication-based Analgesia in Humans,Using Dronabinol to Enhance the Analgesic Effect of Hydromorphone in Humans,COMPLETED,2016-12,2020-03-23,2023-11-07,INTERVENTIONAL,PHASE2,29.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,TRIPLE,"Pain|Cannabis|Opioid Use, Unspecified",Within-subject test of blinded study medications,DRUG,3,0,18 Years,75 Years,ALL,True,Johns Hopkins University,OTHER,0,1,United States
NCT02555657,Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119),COMPLETED,2015-10-13,2020-11-10,2021-12-10,INTERVENTIONAL,PHASE3,622.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Triple Negative Breast Cancer,pembrolizumab|capecitabine|eribulin|gemcitabine|vinorelbine,DRUG|BIOLOGICAL,3,14,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,
NCT01569581,"A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children","A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children",COMPLETED,2012-03,2013-03,2023-10-11,INTERVENTIONAL,PHASE3,12000.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,The Efficacy of Inactivated EV71 Vaccine (KMB17) Against HFMD in Chinese Children and Infants,100U/0.5ml in 6-11 months old infants|100U/0.5ml in 12-23 months old infants|100U/0.5ml in 24-35 months old children|100U/0.5ml in 36-71 months old children,BIOLOGICAL,3,2,6 Months,71 Months,ALL,True,"Institute of Medical Biology, Chinese Academy of Medical Sciences",OTHER,1,1,China
NCT05190419,Study to Assess the Efficacy and Safety of Orismilast in Psoriasis,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate-to-Severe Plaque-Type Psoriasis",COMPLETED,2021-12-30,2022-12-20,2024-04-16,INTERVENTIONAL,PHASE2,202.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis|Skin Diseases,Orismilast modified release tablets|Placebo,DRUG,1,11,18 Years,,ALL,False,UNION therapeutics,INDUSTRY,0,34,Poland|Germany|United States|United Kingdom
NCT02206230,Trial of Hypofractionated Radiation Therapy for Glioblastoma,A Randomized Controlled Trial of Conventional Versus Hypofractionated Radiation Therapy With Temozolomide for Patients With Newly Diagnosed Glioblastoma,COMPLETED,2014-09-25,2023-02-14,2024-01-31,INTERVENTIONAL,PHASE2,133.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Glioblastoma,Hypofractionated radiation therapy|Standard radiation therapy,RADIATION,1,3,18 Years,70 Years,ALL,False,AHS Cancer Control Alberta,OTHER,1,1,Canada
NCT03128528,Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure,"Randomized, Double-blind, Placebo Controlled, Parallel-group, Prospective Clinical Study to Analyse the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure",COMPLETED,2017-07-01,2020-04-30,2020-09-28,INTERVENTIONAL,PHASE2,84.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Heart Failure,Empagliflozin 10mg|Placebo Oral Tablet,DRUG,1,13,18 Years,75 Years,ALL,False,University of Erlangen-Nürnberg Medical School,OTHER,0,1,Germany
NCT01210365,Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema,Safety and Efficacy of the Combination of Furosemide 40 mg + Amiloride Hydrochloride 10 mg in the Reduction of Edema of Cardiac Origin in Patients With Congestive Heart Failure Functional Class II (NYHA),TERMINATED,2011-01-01,2013-03,2022-06-03,INTERVENTIONAL,PHASE3,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Congestive Heart Failure,Diurisa®|Lasix ®,DRUG,1,0,18 Years,,ALL,False,Eurofarma Laboratorios S.A.,INDUSTRY,0,4,Brazil
NCT01190228,Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV,"Assessment of the Memory Immune Response, Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV and Long-Term Follow-Up",COMPLETED,2010-08-25,2015-10-12,2022-03-28,INTERVENTIONAL,PHASE3,454.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Japanese Encephalitis|Varicella,JE-CV Vaccine|Varicella Vaccine,BIOLOGICAL,9,0,36 Months,42 Months,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,1,Philippines
NCT01144702,Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum,"Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Uncomplicated Malaria by Plasmodium Falciparum, Juruá Valley, State of Acre, Brazil, 2009.",COMPLETED,2010-11,2014-07,2015-05-19,INTERVENTIONAL,PHASE2|PHASE3,163.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Falciparum Malaria,artesunate & mefloquine combination,DRUG,1,1,6 Months,70 Years,ALL,False,Oswaldo Cruz Foundation,OTHER,3,2,Brazil
NCT02449902,TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy,"A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TX-12-004-HR in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (VVA)",COMPLETED,2013-07,2013-09,2015-12-14,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Menopause|Vulvovaginal Atrophy|Painful Intercourse|Dyspareunia,Estradiol|placebo,DRUG,10,0,40 Years,75 Years,FEMALE,False,TherapeuticsMD,INDUSTRY,0,1,United States
NCT03635437,Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes,"A Phase I/II, 3-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on Beta-Cell Regeneration in Type 1-diabetes Patients",COMPLETED,2018-09-05,2022-09-27,2022-11-02,INTERVENTIONAL,PHASE1|PHASE2,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 1 Diabetes Mellitus,Gamma-Aminobutyric Acid (GABA)|Alprazolam,DRUG,1,12,18 Years,50 Years,ALL,False,Per-Ola Carlsson,OTHER,1,1,Sweden
NCT03428945,Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus,Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D),TERMINATED,2018-08-15,2022-10-31,2024-04-09,INTERVENTIONAL,PHASE2,273.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Type1 Diabetes Mellitus,Hydroxychloroquine|Placebo,DRUG,1,0,3 Years,,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,1,51,Canada|United States|Australia|Italy|United Kingdom|Sweden
NCT02535195,Effect of Ginger Supplement on Non-alcoholic Fatty Liver,,COMPLETED,2013-03,2015-08,2015-08-28,INTERVENTIONAL,PHASE2|PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Non-alcoholic Fatty Liver Disease,Ginger supplement|Placebo (starch),DIETARY_SUPPLEMENT,2,1,18 Years,70 Years,ALL,True,Dr Azita Hekmatdoost,OTHER,0,0,
NCT04682639,A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis",COMPLETED,2020-12-15,2023-06-30,2024-05-06,INTERVENTIONAL,PHASE2,108.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Eosinophilic Esophagitis,Etrasimod|Placebo|Etrasimod,DRUG,1,4,18 Years,65 Years,ALL,False,Pfizer,INDUSTRY,1,256,Canada|United States|Australia|Belgium|Spain|Germany|Netherlands|Switzerland
NCT01134575,CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL),"Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of Rituximab",COMPLETED,2010-06-04,2018-04-18,2024-07-16,INTERVENTIONAL,PHASE2,90.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Acute Lymphoblastic Leukemia,CMC-544 (Inotuzumab Ozogamycin)|Rituximab,DRUG,1,0,16 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT01538875,Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy,Hydralazine vs. Labetalol for the Management of Hypertensive Crisis in Patients With Hypertensive Disorders of Pregnancy. A Randomized Controlled Trial.,COMPLETED,2012-07,2013-05,2013-05-17,INTERVENTIONAL,PHASE3,261.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hypertension, Pregnancy Induced",Hydralazine|Labetalol,DRUG,1,2,,,FEMALE,False,"Saint Thomas Hospital, Panama",OTHER,0,1,Panama
NCT05875701,Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines,A Phase 3 Study to Evaluate the Immunogenicity and Safety of Novavax COVID-19 Vaccine(s) as Second or Subsequent Booster After mRNA Vaccines in Individuals 18 to 49 Years of Age,COMPLETED,2023-03-28,2023-11-11,2025-06-26,INTERVENTIONAL,PHASE3,147.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,COVID-19,NVX-CoV2373|SARS-CoV-2 rS antigen/Matrix-M Adjuvant,BIOLOGICAL,1,10,18 Years,49 Years,ALL,True,Novavax,INDUSTRY,0,5,United States
NCT05427812,Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma,"A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma",TERMINATED,2022-09-27,2024-11-19,2025-01-17,INTERVENTIONAL,PHASE1|PHASE2,29.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Relapsed/Refractory Multiple Myeloma,ISB 1442 SC injection escalating doses|ISB 1442 SC injection at RP2D,DRUG,3,14,18 Years,,ALL,False,Ichnos Sciences SA,INDUSTRY,0,15,United States|Australia|India
NCT02907619,An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF-06252616 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY",TERMINATED,2016-10-13,2018-11-22,2020-11-23,INTERVENTIONAL,PHASE2,59.0,ACTUAL,,,TREATMENT,NONE,Duchenne Muscular Dystrophy,PF-06252616,BIOLOGICAL,28,22,6 Years,18 Years,MALE,False,Pfizer,INDUSTRY,0,47,Canada|United States|Italy|Japan|United Kingdom
NCT03630419,Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients,Determining if a Personalized Mito Food Plan Diet and Cellular Repair Therapy Based on Individual Physiological and Cellular Comprehensive Body Assessments in Patients With Alzheimer's Disease Decreases Inflammation and Oxidative Stress,COMPLETED,2018-02-10,2018-07-28,2018-10-02,INTERVENTIONAL,PHASE1|PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Mild Cognitive Impairment|Alzheimer Disease,Mito-Food Plan|Cellular Repair Therapy,DIETARY_SUPPLEMENT|OTHER,3,1,55 Years,90 Years,ALL,True,"Perseverance Research Center, LLC",OTHER,1,1,United States
NCT01471730,The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery,"The ZEroPLASmaTrial (ZEPLAST): a Randomized, Controlled Trial on Transfusion Avoidance in High Transfusion-risk Cardiac Surgery Patients",COMPLETED,2011-11,2014-12,2015-03-31,INTERVENTIONAL,PHASE3,119.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Heart Disease,Fibrinogen|Saline solution|Prothrombin complex,DRUG,1,3,18 Years,,ALL,False,IRCCS Policlinico S. Donato,OTHER,1,1,Italy
NCT03320330,"Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors","A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors",COMPLETED,2018-01-31,2024-06-30,2024-07-15,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Refractory Malignant Solid Neoplasm|Refractory Osteosarcoma,Laboratory Biomarker Analysis|Pepinemab|Pharmacological Study,OTHER|BIOLOGICAL,9,3,12 Months,30 Years,ALL,False,Children's Oncology Group,NETWORK,1,24,United States
NCT01416428,Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies,"Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies",TERMINATED,2011-10-15,2019-08-12,2022-11-08,INTERVENTIONAL,PHASE1|PHASE2,210.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma|Waldenstrom Macroglobulinemia,oprozomib,DRUG,1,17,18 Years,,ALL,False,Amgen,INDUSTRY,0,19,United States
NCT01350128,PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),"A Randomized, Double-Blind, Chronic Dosing (7 Days), Three-Period, Six-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Four Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Atrovent® HFA Inhalation Aerosol (Open-Label) as An Active Control",COMPLETED,2011-05-01,2011-10-01,2018-06-20,INTERVENTIONAL,PHASE2,103.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Chronic Obstructive Pulmonary Disease,PT001 MDI|Ipratropium Bromide HFA Inhalation Aerosol|Placebo MDI,DRUG|OTHER,1,8,40 Years,80 Years,ALL,False,"Pearl Therapeutics, Inc.",INDUSTRY,0,8,United States
NCT05151328,Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Plecanatide in the Treatment of Functional Constipation in Chinese Patients for up to 12 Weeks",COMPLETED,2022-03-18,2023-10-26,2024-07-11,INTERVENTIONAL,PHASE3,648.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,QUADRUPLE,Functional Constipation,Plecanatide,DRUG,1,13,18 Years,,ALL,False,"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.",INDUSTRY,0,1,China
NCT01266928,Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study,,COMPLETED,2011-01,2011-11,2012-02-07,INTERVENTIONAL,PHASE3,244.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Preterm Premature Rupture of Membranes,vitamine C and E,DRUG,1,1,18 Years,40 Years,FEMALE,True,Erzincan Military Hospital,OTHER,0,1,Turkey (Türkiye)
NCT05003700,Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma,"Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma：a Prospective, Single-arm，Phase II Trial.",COMPLETED,2021-08-12,2024-07-04,2024-11-05,INTERVENTIONAL,PHASE2,39.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma,Hepatic arterial infusion chemotherapy|Lenvatinib|Camrelizumab,PROCEDURE|DRUG,1,7,18 Years,75 Years,ALL,False,"Nanfang Hospital, Southern Medical University",OTHER,0,1,China
NCT03328507,A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects,A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects,COMPLETED,2017-11-09,2019-11-12,2023-10-24,INTERVENTIONAL,PHASE2,121.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Colonoscopy,BLI4900|PEG Control,DRUG,1,0,18 Years,85 Years,ALL,False,Braintree Laboratories,INDUSTRY,0,4,United States
NCT02445807,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,"A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days",COMPLETED,2015-12,2016-07,2018-05-15,INTERVENTIONAL,PHASE3,265.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Stable Plaque Psoriasis,DFD06-Cream|Vehicle Cream,DRUG,1,2,18 Years,,ALL,False,"Promius Pharma, LLC",INDUSTRY,0,30,United States
NCT01878292,Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder,"A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder",COMPLETED,2013-07-11,2016-10-05,2019-12-24,INTERVENTIONAL,PHASE3,529.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Major Depressive Disorder,Placebo|Vilazodone|Vilazodone,DRUG,1,1,12 Years,17 Years,ALL,False,Forest Laboratories,INDUSTRY,0,52,United States
NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab,"A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod",COMPLETED,2020-07-14,2025-03-11,2025-11-12,INTERVENTIONAL,PHASE3,562.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsing Multiple Sclerosis,Ofatumumab,BIOLOGICAL,1,1,18 Years,60 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,123,Canada|United States|Spain|Russia|Lebanon|Hungary|Slovenia|Saudi Arabia|Italy|Australia|Austria|Estonia|Norway|United Kingdom|Slovakia|Argentina|Poland|Germany|Switzerland|Czechia|Latvia|Bulgaria|Belgium|Portugal|Turkey (Türkiye)|Greece|Mexico
NCT02338700,Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient,Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Prostate Carcinoma Patient,COMPLETED,2015-01,2015-08,2015-09-10,INTERVENTIONAL,PHASE1|PHASE2,20.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostatic Neoplasms,MV|standard treatment,OTHER|BIOLOGICAL,1,2,18 Years,80 Years,ALL,False,"Fuda Cancer Hospital, Guangzhou",OTHER,0,1,China
NCT01887600,Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis,"A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis",COMPLETED,2013-09-03,2017-11-01,2024-11-14,INTERVENTIONAL,PHASE3,594.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Anemia in Chronic Kidney Disease in Non-dialysis Patients,Roxadustat|Placebo,DRUG,2,51,18 Years,,ALL,False,Astellas Pharma Europe B.V.,INDUSTRY,1,138,Spain|Guatemala|Ukraine|Russia|Hungary|Italy|Dominican Republic|Estonia|Georgia|Romania|Belarus|United Kingdom|Poland|South Africa|Peru|Serbia|Panama|Bulgaria|Colombia|Belgium|Turkey (Türkiye)|Greece
NCT03626636,A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration,"A Randomized Controlled, Double-Masked, Crossover Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration",COMPLETED,2017-08-01,2019-04-04,2020-07-08,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Dry Age-related Macular Degeneration,Risuteganib|Sham,DRUG|OTHER,1,0,50 Years,85 Years,ALL,False,"Allegro Ophthalmics, LLC",INDUSTRY,0,7,United States
NCT05137236,A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters,"A Phase 2A, Randomized, Stratified, Observer-Blind Study to Evaluate the Immunogenicity and Safety of mRNA-1283 Vaccine Boosters for SARS-CoV-2",COMPLETED,2021-12-06,2023-03-23,2025-07-17,INTERVENTIONAL,PHASE2,540.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,SARS-CoV-2,mRNA-1283|mRNA-1283.211|mRNA-1273|mRNA-1283.529,BIOLOGICAL,9,10,18 Years,,ALL,True,"ModernaTX, Inc.",INDUSTRY,0,17,United States
NCT01793636,A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer,"An Open Label, Randomised Phase II Study, Comparing AZD2014 Versus Everolimus With Advanced Metastatic Renal Cancer and Progression on VEGF Targeted Therapy",TERMINATED,2013-02,2015-11,2014-06-24,INTERVENTIONAL,PHASE2,49.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Clear Cell Renal Carcinoma,AZD2014|Everolimus,DRUG,1,1,18 Years,,ALL,False,Queen Mary University of London,OTHER,2,9,United Kingdom
NCT05108766,A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis,"A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis",COMPLETED,2020-12-17,2022-07-08,2023-04-12,INTERVENTIONAL,PHASE3,220.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plaque Psoriasis,Tildrakizumab 100 mg|Placebo,DRUG,1,3,18 Years,70 Years,ALL,False,"Shenzhen Kangzhe Pharmaceutical Co., Ltd.",INDUSTRY,0,1,China
NCT02597322,Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN),"An Open-label, Non-randomized, Multicenter, Two Stage Designed Phase II Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)",COMPLETED,2012-02,2017-06,2025-04-06,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,cT2a N0NxM0 Renal Tumor,AXITINIB,DRUG,1,5,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,1,France
NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,Phase 2 Study of Androgen Deprivation Therapy (ADT) Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,TERMINATED,2015-11,2017-09-14,2018-11-28,INTERVENTIONAL,PHASE2,19.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostatic Neoplasms,Doxorubicin|Ketoconazole|Docetaxel|Estramustine|Degarelix,DRUG,1,16,18 Years,,MALE,False,"The University of Texas Health Science Center, Houston",OTHER,0,1,United States
NCT05856331,Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema,"Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema",COMPLETED,2023-10-12,2025-08-06,2025-08-11,INTERVENTIONAL,PHASE2,99.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alpha 1-Antitrypsin Deficiency|Emphysema,SAR447537|Zemaira,DRUG,1,10,18 Years,80 Years,ALL,False,Sanofi,INDUSTRY,0,65,Spain|Denmark|United States|Australia|United Kingdom|Poland|Sweden|New Zealand
NCT03595553,Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection,"A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)",COMPLETED,2019-01-28,2021-11-17,2023-03-03,INTERVENTIONAL,PHASE3,759.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Clostridioides Difficile Infection,Ridinilazole|Vancomycin,DRUG,1,7,18 Years,,ALL,False,Summit Therapeutics,INDUSTRY,0,149,Romania|Canada|United States|Australia|Spain|South Korea|Argentina|Russia|Hungary|Poland|New Zealand|Greece|Brazil|Bulgaria
NCT01732445,Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis,"A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia",COMPLETED,2013-04,2017-08-10,2017-10-18,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Anemia|Primary Myelofibrosis|Secondary Myelofibrosis,ruxolitinib phosphate|danazol|quality-of-life assessment|questionnaire administration,DRUG|OTHER,1,2,18 Years,,ALL,False,Mayo Clinic,OTHER,1,2,United States
NCT03740737,Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1),"A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology",COMPLETED,2018-10-26,2020-11-11,2024-01-18,INTERVENTIONAL,PHASE3,579.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Infertility,Follitropin delta|Placebo,DRUG|OTHER,1,68,18 Years,34 Years,FEMALE,False,Ferring Pharmaceuticals,INDUSTRY,0,23,United States
